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ABSTRACT

The development of schizophrenia is thought to involve an interaction of genetic
susceptibility and environmental factors. In particular, immune insults have been
suggested as relevant environmental impacts, with evidence of cytokine alterations in
schizophrenia patients and an emerging role for cytokines in the brain. Neuregulin 1
(Nrg1) represents one potential candidate vulnerability gene and although murine and
human studies indicate the potential for a Nrg1 mutation to influence immune function,
the response to a direct immune stimulus has not been studied. The aim of the present
study was to determine if a mutation in the Nrg1 gene altered sensitivity to an immune
challenge by changing the peripheral cytokine response and corresponding cytokine
levels in the brain.
The Nrg1 heterozygous transmembrane domain mutant (Nrg1 Het) mice and wild typelike (WT) littermates were subject to an immune stimulus in the form of B16F0
melanoma cells which established a chronic immune response over 9 days. Plasma
levels of 32 peripheral cytokines were measured using a multiplexed flow cytometry
assay. Additional measures of the peripheral immune response were analysed using
flow cytometry while tumour makers for immune infiltration and angiogenesis were
measured using qPCR and immuno-staining. Based on alterations in the peripheral
immune system, interleukin 6 (IL-6) and granulocyte colony stimulating factor (G-CSF)
were studied in the prefrontal cortex and the hippocampus, brain regions highly
implicated in schizophrenia. Protein and mRNA expression levels for IL-6, IL-6Rα and
gp130 receptor, as well as G-CSF and G-CSFR were measured using Western blot, flow
cytometry and qPCR methods. In an additional exploratory study, qPCR was used to

Peta Snikeris

ii

measure mRNA expression of a number of pathway molecules involved in PI3K/Akt
and Jak/Stat signalling, both candidates to integrate neuronal and peripheral immune
function.
The immune challenged Nrg1 Het mice showed a threefold elevation in IL-6 while GCSF was double when compared with immune challenged WT mice (chapter 2). WT
mice subject to the immune stimulus showed an increase in IL-5 and KC demonstrating
that an immune response was generated. There were no differences in circulating
immune cells or tumour specific factors.
Following the confirmation of alteration in the periphery, the cytokines IL-6 and GCSF, as well as their obligate signalling receptors were investigated in the brain
(chapters 3 and 4). IL-6 was reduced in the prefrontal cortex of immune challenged
Nrg1 mice compared with unchallenged Nrg1 mice. Additionally, IL-6Rα was increased
in the same brain region when Nrg1 immune stimulated mice were compared to
immune stimulated WT mice. Soluble gp130 was lower in the hippocampus of the Nrg1
Het compared to WT controls, and was even further reduced in both groups with an
immune stimulus. The hippocampus also displayed alterations in G-CSF where WT
mice demonstrated an increase in G-CSF compared to their unchallenged littermates.
Further, Nrg1 mice revealed lower levels of G-CSF compared to the immune challenged
WT animals.
In the final exploratory study, two pathways highly implicated in both neuronal function
in schizophrenia as well as in the immune system, were considered: the PI3K/Akt
pathway and the Jak/Stat pathway (chapter 5). The PFC showed increases in Akt1 and
SOCS3 based on Nrg1 genotype, while ErbB2 and Pten were increased by the genotype
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x immune interaction. The hippocampus, showed a decrease in Jak1 mRNA as a result
of genotype plus immune insult. These alterations suggest a central role for PI3K/Akt
signalling.
Together these data demonstrate strong cross talk between the immune system and the
brain. The elevated IL-6 plasma level found in the Nrg1 Het mice was consistent with
increased levels of IL-6 found in several studies on schizophrenia patients, as well as in
humans carrying a Nrg1 mutation. While G-CSF has not been directly studied, a
peripheral role is implicated in schizophrenia in relation to side effects caused by antipsychotic medications. The implications of reduced IL-6 and GCSF as found in the
brain are yet to be understood, however these results confirm a dysfunction of cytokines
in the brain of Nrg1 Het mice. Although the detected alterations in the studied signalling
pathways should be considered carefully due to study limitations; a potential
dysregulation of the PI3K/Akt pathway is indicated. It remains to be determined
whether these changes

have neuromodulatory functions and

can influence

schizophrenia-relevant neurotransmission and behaviour. This study demonstrated,
however, that peripheral cytokines and brain cytokines are perturbed when a Nrg1
mutation is combined with a direct peripheral immune stimulus, similar to previous
reports in humans, in a plausibly schizophrenia-relevant manner.
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A demonstration of neuroimmune interactions between the candidate
schizophrenia vulnerability gene Neuregulin 1, and peripheral and central
cytokine levels: focus on IL-6 and G-CSF

CHAPTER ONE

Introduction and literature review

Peta Snikeris
University of Wollongong

1.1

Introduction

Schizophrenia is a chronic and devastating psychiatric disorder. It is generally accepted
that the illness is a neurodevelopmental disorder and that symptoms result from aberrant
neurotransmission, with genetic vulnerability highly implicated in the disorder (Tandon
et al., 2008a). While the symptoms of schizophrenia are well characterised, the genetic
alterations, developmental underpinnings, symptom causation and possible coexistence
with other diseases remain incompletely understood.
Presently, support is increasing for links between the aetiology of schizophrenia and a
persistent malfunctioning of the immune system (Patterson, 2009). Epidemiological
studies showed that schizophrenia patients have a lower incidence of a subset of
cancers, rheumatoid arthritis and type II diabetes, diseases related to dysfunction of the
immune system (Catts et al., 2008; Leucht et al., 2007). Accordingly, altered levels of
several cytokines were shown in the blood and cerebrospinal fluid of schizophrenia
patients (Miller et al., 2011; Potvin et al., 2008). Remarkably, the Schizophrenia
Working Group of the Psychiatric Genomics Consortium (2014) demonstrated in their
recent genome wide association study that several genes found to be associated with a
schizophrenia diagnosis were enriched in immune loci. These results underline previous
epidemiological findings linking schizophrenia and the immune system and add support
for the hypothesis that combinations of genetic and immune-relevant environmental
insults lead to the manifestation of schizophrenia (Tsuang, 2000).
Indeed, Ibi et al (2010) demonstrated that maternal immune activation, when combined
with a Disrupted in Schizophrenia 1 (DISC1) genetic mutation, resulted in altered
cytokine levels and a schizophrenia-like phenotype in adult murine offspring. While
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Desbonnet et al (2012) showed that a genetic mutation in the schizophrenia
susceptibility gene Nrg1 altered the immune response to stress in adult mice. In humans,
Marballi et al (2010) demonstrated differing levels of cytokines in first degree relatives
of schizophrenia patients who carried a schizophrenia relevant gene mutation compared
to those relatives not carrying the mutation. However, whether a genetic vulnerability to
schizophrenia would result in an altered response to a direct immune stimulus in early
adulthood has not been studied. As a result, this thesis will examine if a mutation in a
single schizophrenia candidate vulnerability gene can alter the response to a direct
immune challenge in young adult mice.

1.2

Literature review

1.2.1

Schizophrenia

Schizophrenia is a chronic and devastating psychiatric disorder that affects around 1%
of the population worldwide; it is associated with a great burden to patients, carers and
health systems (Rossler et al., 2005). The disease is characterized by a number of
symptoms that are classified as positive, negative and cognitive with the onset of
symptoms generally during adolescence or early adulthood (Hafner, 1998; Miyamoto et
al., 2003; Tandon et al., 2009; van der Werf et al., 2014). Studies investigating
anatomical and physiological changes in brains of schizophrenia patients reveal altered
cytoarchitecture, enlarged ventricles and reductions in cortical grey matter (Harrison,
2008; Keshavan et al., 2008; Tandon et al., 2008b). Although the underlying aetiology
remains unknown, it is widely acknowledged that the symptoms of schizophrenia result
from abnormalities in neurotransmission, particularly in the dopaminergic and
glutamatergic, but also the gamma amino butyric acid (GABA)-ergic and serotonergic
systems (Berretta et al., 2009; Harrison, 1999; Lang et al., 2007; Murray, 2002; Stone et
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al., 2007). These changes do not appear to deteriorate following symptom onset and are
therefore thought to result from abnormal development, resulting in the commonly
accepted hypothesis of schizophrenia as a neurodevelopmental disorder (Harrison,
2008; Miyamoto et al., 2003; Tandon et al., 2008b). The disease, however, presents as a
heterogeneous disorder with the underlying factors of its development, the causal
factors of symptoms, and the possible coexistence with other diseases still to be
resolved.
1.2.2

The genetic basis of schizophrenia

The most consistent risk factor for schizophrenia development is an inherited genetic
predisposition (Tandon et al., 2008a). Adoption studies in particular have shown that a
family history of schizophrenia is the most significant risk factor in developing the
illness (Schultz et al., 2007). Monozygotic twins have a 40-50% concordance rate for
schizophrenia and the risks of developing the disease are increased 10 fold in first
degree relatives of schizophrenia patients (Weiser et al., 2005). In subsequent
population studies, several susceptibility genes have been identified, including
Neuregulin 1 (Nrg1), V-erb-a erythroblastic leukaemia viral oncogene homolog 4
(ErbB4), V-akt murine thymoma viral oncogene homolog 1 (Akt1), dystrobrevinbinding protein 1 (Dysbindin), Catechol-O-methyl transferase (COMT), and Disruptedin-Schizophrenia 1 (DISC1) (Harrison and Weinberger, 2005; Norton et al., 2006;
Singh et al., 2014; Stone et al., 2007). From this diverse array of candidate genes, the
Nrg1 gene and its gene products were shown as attractive candidates for further study
(Esper et al., 2006; Schmitt et al., 2008).
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1.2.3

Neuregulin 1

Nrg1 belongs to a family of growth factors with four individually identified genes
(Nrg1-4). The Nrg1 gene encodes six types of proteins with different signalling
properties (Mei and Xiong, 2008). All six Nrg1 type proteins (I-VI) contain an
intracellular cytoplasmic tail or intracellular domain, a transmembrane domain and an
extracellular epidermal growth factor like domain. These six Nrg1 type proteins can be
further processed into at least 31 known isoforms. Most of the Nrg1 isoforms are
synthesized as a pro-neuregulin transmembrane precursor that undergoes further
proteolytic processing, principally at the cell surface (Kalinowski et al., 2010). Nrg1 has
been identified in range of different tissue types, including nervous, cardiac, lung and
normal as well as cancerous breast tissues (Finigan et al., 2013; Holmes et al., 1992;
Lemmens et al., 2007; Mei and Xiong, 2008). The full functional implications of
mutations on the Nrg1 gene continue to be investigated.
Nrg1 signalling occurs by stimulation of the family of erythroblastic leukaemia viral
oncogenes (ErbB) tyrosine kinase receptors, ErbB2, -3 and -4. The ErbB4 receptor is
the only one of these receptors that can interact with the Nrg1 ligand and produce
signalling when in the homodimeric conformation. ErbB3 is able to bind the Nrg1
ligand, but does not transmit a signal unless it has formed a heterodimer, preferably
with the ErbB2 receptor. ErbB2 on the other hand has no intrinsic ability to bind Nrg1,
but when acting in concert with ErbB3 or ErbB4, it can be activated by ligand binding
to its heterodimeric partner. Here, the ErbB4 homodimers were found to signal with
weaker potency, than if a heterodimer is formed with ErbB2 (Yarden and Sliwkowski,
2001a). Nrg1 and its signalling through the ErbB receptors have been shown essential
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for both neuronal and cardiac development, as mice deficient in Nrg1, ErbB2, -3 or -4
are not viable (Yarden and Sliwkowski, 2001a).
In addition to the canonical signalling pathway, a lesser studied non-canonical, or
backward signalling pathway has been demonstrated for Nrg1. This back-signalling
pathway occurs when pro-Nrg1, acting as a receptor, binds ErbB4 which stimulates
gamma-secretase cleavage of the Nrg1 intracellular domain (Dejaegere et al., 2008;
Talmage, 2008). The intracellular domain translocates to the nucleus where it has been
shown to effect a number of functions including: inhibition of NMDA toxicity-induced
apoptosis, the regulation of PSD-95 transcription and an increase in surface expression
of nAChR-alpha7, where the intracellular domain of Nrg1 type III is cleaved (Bao et al.,
2003, 2004; Buonanno, 2010; Zhang et al., 2008). Although further study is required to
fully elucidate the mechanisms for Nrg1 back-signalling and the functional
consequences of this pathway, it is possible that this back-signalling could play a role in
the Nrg1 induced changes in the brain and the peripheral immune system.

a)

Neuregulin 1 in the brain

As a growth factor in the central nervous system (CNS), Nrg1 has been shown to be
critically involved in neurogenesis, neuronal survival, neuronal migration and synaptic
plasticity (Mei and Xiong, 2008). Upon binding to its ErbB receptors in the brain,
forward signalling triggers various intracellular signalling pathways, including the
phosphatidylinositol-3 kinase-protein kinase B (PI3K/PKB, also known as PI3K/Akt)
and Janus kinase/signal transducers and activators of transcription (Jak/Stat) signalling
(Banerjee et al., 2010; Liu and Kern, 2002). Nrg1 signalling was additionally shown to
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directly influence GABAergic, glutamatergic and dopaminergic neurotransmission
(Buonanno, 2010; Kwon et al., 2008). It is proposed that this direct interaction occurs
because the location of the primary Nrg1 receptor, ErbB4 is on GABAergic
interneurons and is in close proximity to glutamatergic N-methyl-D-aspartate receptors
(NMDA-R) (Neddens and Buonanno, 2010; Neddens et al., 2011). These functions of
Nrg1 represent a potential link between Nrg1 dysfunction and the major
neurotransmitter theories of schizophrenia (Buonanno, 2010; Collier and Li, 2003;
Harrison and Weinberger, 2005; Neddens et al., 2009; Stone et al., 2007).
b)

Neuregulin 1 in schizophrenia

Stefansson et al (2002) first identified Nrg1 as a promising schizophrenia candidate
gene in a genome wide association study in an Icelandic population. Subsequent genetic
and mRNA expression studies have confirmed that alterations of the Nrg1 system are
associated with this illness in a range of populations, (Alaerts et al., 2009; Law et al.,
2006; Stefansson et al., 2004), as well as in a meta-analysis (Munafò et al., 2006) and
systematic review (Agim et al., 2013). In addition altered levels of Nrg1 and its receptor
ErbB4 gene transcripts and proteins were demonstrated in the brain in schizophrenia
patients (Barakat et al., 2010; Bertram et al., 2007; Chong et al., 2008; Kang et al.,
2012; Law et al., 2007)
In post-mortem brain studies, Barakat et al (2010) found a decrease in Nrg1 C-terminal
fragments in the frontal cortex (Brodmann’s area 6), consistent with the finding of
Bertram et al (2007) where Nrg1 (isoform alpha) was decreased in the white matter in
the PFC in patients. Chong et al (2008) demonstrated that Nrg1 (53kDa protein) and the
full length ErbB4 protein were increased in the cytoplasmic fraction of PFC patient
samples, while cleaved ErbB4 products were decreased in the same fractions. Further,
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Marballi et al (2012) found no change in the full length membrane bound Nrg1 protein
in the prefrontal cortex or the hippocampus of schizophrenia patients while an increase
in the extracellular cleavage product of Nrg1 was seen in the prefrontal cortex with no
change in the hippocampus. Marballi (2012) also demonstrated a decrease in a 50kDa
Nrg1 fragment in both the prefrontal cortex and the hippocampus which the authors
speculate is an intracellular cleavage product. Overall Marballi (2012) suggests that
altered Nrg1 may be cleavage specific in schizophrenia patients. These findings clearly
show alterations in Nrg1 exist in patients, however they do appear conflicting.
Also a meta-analysis suggested the evidence for Nrg1 as a candidate gene for
schizophrenia vulnerability to be inconclusive (Gong et al., 2009). The presented
inconsistencies however, have previously been attributed to population differences in
allelic and haplotype frequencies (Gardner et al., 2006; Harrison and Law, 2006), and
support for the involvement of Nrg1 in schizophrenia risk remains (Gatt et al., 2015;
Greenwood et al., 2012; Weickert et al., 2012). The mechanisms by which Nrg1 confers
an increased risk to develop schizophrenia symptoms, however, remain inadequately
understood (Mei and Xiong, 2008; Stefansson et al., 2004; Weickert et al., 2012).
c)

Neuregulin 1 animal models

Based on the initial findings, genetic animal models with mutations of the Nrg1 gene
were developed and have underlined the relevance of Nrg1 to schizophrenia
vulnerability. These models include heterozygous mutations in the transmembrane
domain region (Duffy et al., 2008, 2010; Karl et al., 2007), type I/II (Deakin et al.,
2009, 2011) and type III (Chen et al., 2008) Nrg1. These mutant mice show different,
but overlapping phenotypes, with previous work showing that heterozygous Nrg1
transmembrane domain (Nrg1 Het) mutant mice exhibit an inborn vulnerability to
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develop behavioural abnormalities resembling schizophrenia. These behavioural
abnormalities include hyper locomotion, deficits in sensorimotor gating and object
recognition (Duffy et al., 2008, 2010; Karl et al., 2007; O’Tuathaigh et al., 2008;
Stefansson et al., 2002). Further, mice exposed to excess Nrg1 in the neonatal period, or
those constitutively overexpressing Nrg1 were shown to have several behavioural
impairments, further confirming the potential involvement of Nrg1 in schizophrenia
pathology (Abe et al., 2011; Kato et al., 2010; Mouri et al., 2013).
There is some criticism of the model in the literature, based on the inconsistent human
gene studies and evidence that the timing and significance of behavioural abnormalities
in mutant mice has been shown to be protocol specific and in some cases is not
consistent (van den Buuse et al., 2009; Karl et al., 2011). The mouse model utilised in
the present study are the Nrg1 Het mutant mice (target allele: Nrg1tm2Zhou), which
have been described previously (Stefansson et al., 2002). This model was established to
represent individuals at genetic risk for the development of schizophrenia characteristics
(Karl et al., 2007). Whereas some phenotypes of the Nrg1 Het mice are very consistent,
others were rather observed with secondary challenges, emphasising their state as a
vulnerability model (Boucher et al., 2007a; Karl et al., 2011; Long et al., 2012, 2013).
While studies on Nrg1 and other susceptibility genes have increased our knowledge of
schizophrenia development, they have clearly demonstrated that genetic alterations are
also not the singular cause of the disease. Population based studies of patients and nonaffected family members have demonstrated that having a genetic alteration in any of
the candidate susceptibility genes does not confer schizophrenia, only a vulnerability to
developing the illness. Further, no single genetic polymorphism, or consistent
combination of polymorphisms, exists in all patients (Esper et al., 2006; Schizophrenia
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Working Group of the Psychiatric Genomics Consortium, 2014). This apparent failure
of genetics to explain the cause of the disease, has led to increasing acceptance that
interactions between susceptibility genes and the environment, such as foetal stress,
obstetric complications and immune insults, are most likely to result in the development
of schizophrenia (Tsuang, 2000; Tsuang et al., 2001).
1.2.4

Environmental risk factors: Focus on the immune system and cytokines

A wide variety of environmental risk factors have been established in the aetiology of
schizophrenia (Tandon et al., 2008b). Interestingly, many of these environmental
stimuli directly or indirectly influence the immune system (Aubert, 2008; Meyer et al.,
2008a). Specifically, infections and induced inflammation have been identified to play a
role in schizophrenia development in studies of humans and in animal models (Meyer et
al., 2008a; Muller and Schwarz, 2008; Tandon et al., 2008b). With cytokines being
well-established as critical messengers of inflammation, a whole variety of cytokines
and their receptors have shown variations in schizophrenia patients (detailed below in
section 1.2.4e) and reviewed in meta-analyses by (Miller et al., 2011; Potvin et al.,
2008). Patterson (2009), points out that many of these changes are present in both the
peripheral blood and the cerebrospinal fluid, supporting a novel role for cytokines as
neuromodulators.
a)

The innate and adaptive immune system

The peripheral immune system is primarily a defence system evolved for: surveillance
of tissues; recognition of damage caused by injury and invading pathogens; as well as
cancer surveillance. The immune system generates a vast range of cells and molecules
capable of differentiating and eliminating a seemingly endless number of pathogens in a
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series of complex yet controlled responses. Additionally, elements of the immune
system participate in ongoing tissue remodelling in response to continuously changing
environmental demands. The immune system is divided into two components: the
innate immune system, which is considered less specific and is the first line of defence;
and the adaptive immune system, which is capable of recognising and specifically
eliminating selected foreign antigens (Yirmiya and Goshen, 2011).
The innate immune system provides first line cellular and humoral defences against
invading pathogens. When activated, the innate immune system initiates an
inflammatory response, involving the rapid recruitment of innate immune cells,
particularly macrophages and neutrophils. These cells phagocytose pathogens and
produce a number of cytokines and chemokines that activate associated immune and
tissue repair processes (Jones and Thomsen, 2013; Weismann and Binder, 2012;
Yirmiya and Goshen, 2011). In contrast, the adaptive immune system recognises and
subsequently remembers specific antigens. This enables the adaptive immune system to
mount a stronger and more rapid response each time a specific antigen is encountered
(Jones and Thomsen, 2013). Antigens are presented to T cells to activate a cellular
immune response, with T cells activating B cells to produce antibodies for a humoral
response. The T cells are generally divided into two main subsets: the T helper (TH) and
T cytotoxic (TC) cells, although a third subset of T regulatory cells is also considered.
The TH and TC lymphocytes are classified dependent on surface molecules (cluster of
differentiation or CD): CD4+ cells generally function as TH cells while CD8+ cells
generally function as TC cells. It is the CD4+ TH lymphocytes that secrete the majority
of cytokines in response to antigenic activation and thus determine the direction of the
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immune response (Jones and Thomsen, 2013; Weismann and Binder, 2012; Yirmiya
and Goshen, 2011).
The TH cells are often further classified based on cytokine secretion as either TH type 1
(TH1) or TH type 2 (TH2) cells. TH1 cells characteristically produce cytokines such as
interleukin (IL)-2, tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ).
TH2 cells produce mainly cytokines such as IL-4, IL-6 and IL-10 (Müller et al., 2009).
The TH1 cells promote a cell-mediated immune response directed against intracellular
pathogens, while the TH2 cells promote B cell maturation and an antibody-based,
humoral response directed against extracellular pathogens (Müller et al., 2009). Each
cell-type cytokine profile promotes their specific immune type response while
suppressing the alternative creating the so called ‘polarized’ immune response which is
considered to be unbalanced in schizophrenia patients (Müller et al., 2009).
b)

Cytokines

Cytokines are low molecular weight secreted proteins that exert a wide variety of effects
on immune and other cells to regulate the duration and intensity of an immune response.
One cytokine can have varied function, and redundancy across cytokines is common.
Cytokines generally act locally and are therefore often only found in low levels in
circulation. Single cells will respond to the local milieu of cytokines and it is the
balance of different cytokines that affect the ultimate response (Simpson et al., 1997).
Cytokines exert their effects by binding to specific membrane bound receptors located
on a wide variety of cell types, as well as binding soluble receptors. These soluble
receptors can act as either inhibitors (e.g. soluble IL-2 receptor or sIL-2R) or enhancers
(e.g. soluble IL-6 receptor or sIL-6R) of activity. Further, endogenous antagonists exist,
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which compete with cytokines for receptor binding such as the IL-1 receptor antagonist
(IL-1RA) (Miller et al., 2011).
Terminology can further separate cytokines into pro- and anti- inflammatory types, as
well as hematopoietic cytokines. The separation of cytokines into pro- and antiinflammatory however, does not reflect the immune-type cells that produce these
cytokines. Pro-inflammatory cytokines such as TNFα and IL-6 belong to the type-1 and
type-2 immune response respectively, yet IL-4 and IL-10, considered antiinflammatory, both belong to the type-2 immune response. While the hematopoietic
cytokines, such as granulocyte-colony stimulating factor (G-CSF), stimulate the
differentiation of hematologic progenitor cells into specific lineages of leukocytes or
erythrocytes, however, G-CSF can also play a role in promoting the type-2 cytokine
response (Xiao et al., 2007). With multiple roles and redundancies, many cytokines can
play both pro- and anti-inflammatory roles in response to the cytokine milieu around
them (Cavaillon, 2001).
In essence the cytokine network appears to be as complex as the immune system itself,
perhaps akin to the complexity of the neurotransmitter networks in the brain. For this
reason, the initial investigation of peripheral cytokines in the Nrg1 Het mouse model in
this study was not limited to only those cytokines previously implicated in
schizophrenia or those considered the major pro- and anti- inflammatory cytokines. A
deliberately wide range of cytokines was included in the initial measurements with
subsequent studies in the CNS narrowed by the results.
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c)

Cytokines as neuromodulators

Traditionally, cytokines have been viewed as modulators of peripheral immunity,
regulating the duration and intensity of the immune response. They were not considered
directly involved in normal brain function (Szelenyi and Vizi, 2007). However, our
understanding of the role of cytokines in normal brain development and function is
increasing swiftly (Jones and Thomsen, 2013). Cytokines are shown to be involved in
normal neurodevelopment, synaptic function, neuroprotection, neurotoxicity, and to
interact with other neuroendocrine and neuropeptide systems (Boulanger and Shatz,
2004; Boulanger et al., 2001; Schmitz and Chew, 2008; Yirmiya and Goshen, 2011).
Cytokines also play a central role in the modulation of not only basic behaviours but
also complex cognitive tasks (McAfoose and Baune, 2009); the underlying
mechanisms, however, are yet to be resolved.
Cytokines produced in the periphery can penetrate the blood brain barrier, not just in
pathological states that result in a leaky blood brain barrier, but also under basal
conditions. Several mechanisms have been identified that allow this transition of
peripheral cytokines into the brain, including active transport mechanisms and saturable
transporters (Miller et al., 2009; Szelenyi and Vizi, 2007; Vollmer-Conna et al., 2004).
More intriguing are increasing reports that not only peripheral blood cells, but also brain
cells, including neurons, microglia and astrocytes, have the potential of de novo
synthesis of cytokines. This is not only in response to infections or immunogenic
agents, but also in response to antipsychotic drugs, including clozapine (Paterson et al.,
2006; Sugino et al., 2009). In addition, cells of the CNS also express cytokine receptors
(McAfoose and Baune, 2009; Na and Kim, 2007; Szelenyi and Vizi, 2007; Tohmi et al.,
2007).
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d)

Cytokines in brain dysfunction and disease

Changes in cytokine levels in both blood and brain have been shown to interfere with
neurodevelopment, and the detrimental effect of perinatal infections is well established
(Meyer et al., 2008a). Throughout childhood and adolescence, however, synaptogenesis,
synaptic pruning and myelination continue and are prone to be influenced by
inflammatory stimuli (de Graaf-Peters and Hadders-Algra, 2006). Not surprisingly,
brain cytokines were found to be dysregulated in psychopathologies like depression,
Alzheimer’s disease, and, schizophrenia (Fruntes and Limosin, 2008; McAfoose and
Baune, 2009; Potvin et al., 2008). With neurons and glial cells responsive to cytokines
(Miller et al., 2009), this provides the basis for the translation of peripheral
inflammatory changes, such as those observed in schizophrenia patients, into
dysregulation of brain function, with cytokines in the role of neuromodulators.
Additional indications are that the complex interactions between the brain and the
immune system may similarly be impaired in schizophrenia (Muller and Schwarz, 2008;
Strous and Shoenfeld, 2006).
e)

Cytokines in schizophrenia

Further to the role of cytokines in normal brain function, they have also been implicated
in the symptomatology of schizophrenia (Fruntes and Limosin, 2008; McAfoose and
Baune, 2009; Meyer et al., 2008a, 2008b; Potvin et al., 2008). Indeed, although the data
basis is still scattered and inconclusive, recent studies clearly demonstrate that adult
schizophrenia patients’ display an imbalance in cytokine levels in both the CNS and the
periphery (Patterson, 2009; Potvin et al., 2008). Together these findings raise the
possibility that immune dysfunction, through a cytokine imbalance, is a primary or
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secondary persistent state in the CNS and the peripheral immune system of
schizophrenia sufferers (Patterson, 2009).
There have been numerous studies on cytokine levels in adult schizophrenia patients,
uncovering a multitude of differences in different cytokines and soluble cytokine
receptors. Several cytokines have been investigated in adult schizophrenia patients,
uncovering alterations in IL-1, IL-1RA, IL-2, sIL-2R, IL-4, IL-6, sIL-6R, IL-8, IL-10,
IL-12, IL-17 and IL-18 along with changes in TNFα, and IFNγ (Borovcanin et al.,
2012; Müller, 2008; Muller and Schwarz, 2008; Nawa and Takei, 2006; Patterson,
2009; Potvin et al., 2008; Strous and Shoenfeld, 2006). A meta-analysis published by
Potvin et al (2008) noted robust increases in in vivo serum levels of IL-1RA, sIL-2R and
IL-6, while a decrease in in vitro IL-2 production was found in subjects with
schizophrenia. These cytokine alterations are consistent with the theory of a blunted
type 1 and over-active type 2 immune response, the data however remain conflicted,
with other studies suggesting an enhanced type 1 response with no evidence of type 2
involvement (Miller et al., 2011; Müller et al., 2009).
This conflict may arise from differences in experimental methods. Firstly, studies have
reported cytokines variously in circulating peripheral blood, cerebrospinal fluid, or as in
vitro cytokine production following stimulation. Additionally, patient populations have
been differentially selected, with samples taken from patients with first episode
psychoses (medication naïve), recently withdrawn from medication (medication free),
or stably medicated. Moreover, medication free or stably medicated patient samples
were drawn from either chronic suffers or those suffering an acute relapse of symptoms.
Interestingly, several studies demonstrated that altered cytokine levels were correlated
with symptom severity, antipsychotic use or medication resistance in patients (Bresee
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and Rapaport, 2009; Kim et al., 2004; Mahendran and Chan, 2004; Na and Kim, 2007;
Singh et al., 2009; Zhang et al., 2002, 2009). Further, antipsychotic drugs have been
shown to act directly on cytokine levels, however different medications result in
different cytokine effects (McAllister et al., 1995; Xu et al., 1994).
A more recent meta-analysis by Miller et al (2011) included 40 studies conducted since
2005 and delineated patients into acutely relapsed and first-episode psychosis patients.
The meta-analysis found that IL-1β, IL-6 and transforming growth factor (TGF-β) were
increased similarly in both patient categories and were normalised with antipsychotic
treatment. Interestingly IL-6 was the same in stably medicated outpatients compared
with controls. IL-12, IFNγ, TNFα and sIL-2R were also found elevated in acute
exacerbations of symptoms however, these did not normalise with treatment. Miller et
al (2011) note several limiting factors in the studies used for the meta-analysis,
particularly the lack of controls for confounding factors including body mass index and
smoking.
1.2.5

The inflammatory hypothesis of schizophrenia

In the last decade, the inflammatory hypothesis of schizophrenia has re-gained much
attention (Coelho et al., 2008; Miller et al., 2011; Müller and Schwarz, 2007; Potvin et
al., 2008). This hypothesis advocates cytokines as important intermediaries for crosstalk between the immune system and the brain by modulating central neurotransmitter
systems (Müller and Schwarz, 2007). As previously noted, peri-natal neurodevelopment
can be severely affected by changes in blood and brain cytokine levels (Meyer et al.,
2008a). With continued neuronal development through childhood, adolescence and into
adulthood, CNS growth and function remains prone to cytokine influence (de GraafPeters and Hadders-Algra, 2006). Indeed, recent epidemiological data stated that
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infections in adolescence also confer increased risk for schizophrenia development,
more so when combined with a genetic predisposition (Dalman et al., 2008; Hickie et
al., 2009). While there are limited studies demonstrating common mechanisms between
neuronal and immune function, and few that attempt to directly link schizophrenia
pathophysiology with altered immune function in a schizophrenia relevant model, these
immunologically significant findings in schizophrenia patients make their existence and
relevance highly likely.
1.2.6

Modelling an immune challenge in the Nrg1 mutant mouse model

Support for peripheral immune system alterations in schizophrenia patients are
demonstrated in several epidemiological studies. These show that schizophrenia patients
have altered incidence of certain types of cancer, rheumatoid arthritis and type II
diabetes, illnesses related to a dysfunction of the inflammatory response (Ajdacic-Gross
et al., 2014) and reviewed in (Catts et al., 2008; Leucht et al., 2007). Indeed, current
treatments employed for metastatic melanoma include high-dose administration of
recombinant cytokines such as IL-2, confirming the importance of a role for cytokines
and the immune system in treating cancer (Aziz et al., 2009; Dutcher, 2002). IL-2 is
also considered as a either mono- or adjunct therapy in a range of other solid tumours
(Grande et al., 2006). Use of recombinant IL-2 has been linked to transient depression,
hallucinations and delusions in cancer patients (Denicoff et al., 1987; McAllister et al.,
1995). Further, mice treated with cytokines such as IL-2, IL-1β and IFNγ have
demonstrated behavioural changes consistent with murine models of schizophrenia,
including increased anxiety, anhedonia, cognitive deficits and hyper locomotion (Myint
et al., 2009). These data raise the possibility of a common mechanism in the
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pathophysiology of schizophrenia and an altered immune system, resulting in reduced
incidences of immune mediated diseases, such as melanoma.
The C57Bl/6-specific B16F0 melanoma cells are a well-established tool to study
melanoma growth and its effects on the immune system in mice (Overwijk and Restifo,
2000). Using these melanoma cells as an immune challenge in the Nrg1 mutant mouse
model for schizophrenia will allow characterisation of differences in changes in
cytokine levels following an immune stimulus based on the schizophrenia-relevant
genotype compared to controls.
1.2.7

Brain regions: the prefrontal cortex and the hippocampus

Post-mortem studies from schizophrenia patients have consistently revealed structural
and functional alterations in different brain regions, with particular focus on the
prefrontal cortex (PFC) and the hippocampus (Harrison, 2000). Normal functioning of
the PFC includes cognitive planning and working memory, functions that are disrupted
in schizophrenia (Conklin et al., 2005). Neuroimaging studies have confirmed decreased
activation of, and reduced blood flow to, the PFC in patients performing a specific
working memory task (Carter et al., 1998). In addition, patients display a reduction in
grey matter volume, confirming structural anomalies in the PFC (Breier et al., 1992;
Harms et al., 2010). Additionally, cognitive functioning, learning and memory are
normal functions of the hippocampus, which are disordered in schizophrenia patients.
The anomalies found in the hippocampus in schizophrenia have been the subject of a
number of detailed reviews (Harrison, 2004; Preston et al., 2005; Tseng et al., 2009). In
brief, the hippocampus displays reduced volume, altered synaptic connections and
neurotransmitter receptor changes in schizophrenia (Harrison, 2004). Impairments in
declarative and recognition memory combined with reduced hippocampal activation
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have also been demonstrated (Preston et al., 2005). Neonatal hippocampal lesions in
mice result in adolescent neurochemical changes and behavioural changes relevant to
schizophrenia, including deficits in social interaction and hyper locomotion, paired with
disrupted neurotransmission (Tseng et al., 2009). Based on these findings, brain based
investigations in the present studies focused on the PFC and hippocampus in Nrg1 Het
animals and controls.

1.3

Hypothesis and significance of the study

It has been noted by Tsuang (2000) that a genotype x environment interaction can be
considered from two viewpoints: environmental factors may influence gene expression;
or the genetic phenotype may result in altered sensitivity to environmental factors. We
hypothesized that an immune system challenge, in the form of melanoma, would result
in a different immune response both in the periphery and in the brain in Nrg1 Het mice
when compared with wild type-like (WT) litter mates suggesting that the genetic
phenotype will alter sensitivity to the immune stimulus.
Two main questions were formulated in order to investigate this hypothesis:
1) Does a Nrg1 mutant mouse model demonstrate an altered peripheral immune
response, specifically in the cytokine profile (Chapter 2)?
2) Are the peripheral cytokine alterations reflected in the brain (Chapters 3 and 4)?
A further exploratory question was investigated to gain a preliminary understanding of
possible signalling pathway involvement in the differences discovered.
3) Are there any changes evident in gene expression in the signalling pathways common
to Nrg1 and the altered cytokines found in the brain (Chapter 5)?
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With the existing literature demonstrating a clear role for a genetic phenotype in the
aetiology of schizophrenia and clear evidence for cytokine alterations in schizophrenia
patients, it is remarkable that studies on whether such genetic mutations result in
changes of the immune response remain limited. Despite recent increases in the number
of publications on these topics, whether such changes are in fact interdependent is an
important gap in psychopathological research that needs to be addressed to potentially
allow the development of new approaches for novel prevention and treatment strategies.
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A demonstration of neuroimmune interactions between the

candidate schizophrenia vulnerability gene Neuregulin 1, and
peripheral and central cytokine levels: focus on IL-6 and G-CSF

CHAPTER TWO

Tumour growth and peripheral immunology

Peta Snikeris
University of Wollongong

2.1

Tumour growth and peripheral immunology

Previous epidemiological studies have demonstrated a reduction in the lifetime
incidence of melanoma in schizophrenia patients (Catts et al., 2008; Goldacre et al.,
2005; Mortensen, 1994). Generally, the progression of melanoma is considered to result
from the inability of the immune system to either recognise or mediate clearance of the
tumour cells (von Boehmer, 2005; Goldsby et al., 2002), with current treatments
including administration of recombinant cytokines (see 1.2.6). Whereas the effect of
melanoma cells on the immune system is well described (Fan et al., 2009; Fang et al.,
2008; Hensley et al., 1998; Kakinuma and Hwang, 2006; Li et al., 2009a; Overwijk and
Schluns, 2009; Wang et al., 2009a) little is known about the effect of melanoma on
cytokine levels in schizophrenia patients or those with a Nrg1 gene mutation.
2.1.1

Neuregulin 1 in tumour development and the peripheral immune system

The Nrg1 gene encodes six proteins with different signalling properties using the ErbB
receptors for signalling (see 1.2.3). While Nrg1 and the ErbB receptors are shown to
have an important role in nervous system development, they have also been implicated
in peripheral tumour development. Both Nrg1 and the ErbB receptors have shown
relevance as predictive indicators for some forms of cancer and have been investigated
as possible biomarkers and potential therapeutics (Saxena and Dwivedi, 2012;
Seshacharyulu et al., 2012; Yarden and Sliwkowski, 2001a). Nrg1 has been specifically
implicated in the formation of new blood vessels in tumour tissue, a process tightly
regulated under normal conditions but dysregulated during solid tumour growth and
metastasis (Hanahan and Folkman, 1996; Nakano et al., 2004). This is in line with the
critical role Nrg1 plays in cardiac development and function (reviewed in Wadugu and
Kühn, 2012) demonstrated in the Nrg1 homozygous transmembrane domain knockout
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mice, which display embryonically lethal cardiac insufficiencies (Stefansson et al.,
2002). The main focus of these peripheral cancer studies, however, has been on the role
of Nrg1 in the cancer tissue itself. Little is known about the potential for a broader Nrg1
role in the overall immune response.
Very little was found in the literature on the direct effect of Nrg1 on the peripheral
immune system. Two studies on pain modulation in the spinal cord and nerve root
propose Nrg1 as a cytokine (Lacroix-Fralish, 2008; LaCroix-Fralish et al., 2008).
However these studies are not directly relevant to the potential role for Nrg1 in the
peripheral response and the justification for the use of the term cytokine in relation to
Nrg1 in these experiments is minimal. Of the limited studies indicating a peripheral
immune impact resulting from a Nrg1 mutation, Desbonnet et al (2012) demonstrated
immune changes in the Nrg1 Het mice following a chronic stress paradigm. Chronic
stress has been previously shown to release a complex milieu of cytokines. The main
interaction Desbonnet et al (2012) found between Nrg1 and chronic stress was an
increase in IFNγ which is considered a TH1 type cytokine, involved in the T cell
mediated immune activation, suggesting the Nrg1 mutation has more potential to result
in an altered cell mediated immune response.
These findings demonstrate that an interaction between a Nrg1 mutation and the
peripheral cytokine response is highly likely to exist, and that this interaction may result
in a skewed ratio of TH1: TH2 cytokine production. Understanding the peripheral
cytokine response to a direct immune stimulus in Nrg1 Het mice will provide insight
into the balance of cytokines produced and further our understanding of any potential
imbalance in the polarized immune response in schizophrenia patients as discussed by
Müller et al (2009).
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2.1.2

Inducing and measuring the peripheral response

The aim of the following study was therefore to determine whether the Nrg1 Het mice
demonstrated an altered peripheral immune response. The peripheral response was
measured by investigating the basic tumour parameters, circulating immune cells and
cytokines in response to the stimulus.
Nrg1 Het mice have been used as a model to study characteristics similar to individuals
at genetic risk for the development of schizophrenia (Karl et al., 2007) as previously
discussed (1.2.3c). In particular Nrg1 Het mice have been used as a vulnerability model;
allowing exploration of the genetic risk combined with environmental risk factors
(Boucher et al., 2007a; Karl et al., 2011; Long et al., 2012, 2013). In this study an
immune stimulus was combined with the genetic risk to investigate peripheral
responses.
Considering the epidemiological data demonstrating alteration in cancer incidence in
schizophrenia patients (reviewed in Catts et al., 2008; Leucht et al., 2007), the B16F0
melanoma was chosen to model an immune stimulus (1.2.6). In brief, B16F0 tumours
have been demonstrated to induce a low level innate and systemic immune response in
normal mice and have been used previously to investigate tumour immune responses. In
the present project the Nrg1 Het mice were challenged with a sufficiently
immunologically compatible (syngeneic) melanoma so as to avoid complete tumour
rejection while inducing the necessary immune response (Fan et al., 2009; Fang et al.,
2008; Hensley et al., 1998; Kakinuma and Hwang, 2006; Li et al., 2009a; Overwijk and
Schluns, 2009; Wang et al., 2009a). This provided a baseline for measurement of
potentially altered responses in the Nrg1 Het mice, including circulating immune cells
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from both the innate and systemic immune compartments and cytokine levels following
tumour induction.
The use of the syngeneic B16F0 melanoma model not only provided the opportunity to
measure the innate and adaptive immune responses to such a stimulus, but also to
determine if the Nrg1 Het transmembrane mutation provided any inherent improvement
or detriment in immune surveillance, suppression or progression. Therefore tumour
growth was monitored and the size of the resulting solid tumour was measured after
excision. In addition, the basic markers of angiogenesis and infiltration markers for
neutrophils and macrophages were measured in the excised tumour. Since Nrg1 has
been shown to increase the expression of vascular endothelial growth factor (VEGF)
and measures of vascular formation (angiogenesis) can be used as a measurement of
tumour aggressiveness, VEGF expression in the tumours was measured. Significant
inflammation has also been observed at tumour sites, with infiltration by innate immune
cells a hallmark of this inflammation (Hanahan and Folkman, 1996; Nakano et al.,
2004; Xiong et al., 2001). Neutrophils are one of the first cell types recruited to the
tumour microenvironment, with macrophages shown to be the most abundant over time.
A strong infiltration by these two cells types has been correlated with tumour growth
inhibition, although both cell types have also been implicated in promoting tumour
growth and angiogenesis in some circumstances, therefore expression of markers for
both cell types was measured in the tumours (Bröcker et al., 1988; Fridlender and
Albelda, 2012; Navarini-Meury and Conrad, 2009; van Ravenswaay Claasen et al.,
1992; Torisu et al., 2000).
Schizophrenia patients have variously demonstrated increases, decreases and no change
in each of the main immune cell types although the results have been conflicting over
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time (reviewed in Rothermundt et al., 2001). Immune cells derive from either the
myeloid or lymphoid lineage. The two main myeloid derived cell types are the
monocytes and the granulocytes, with neutrophils the most abundant of the circulating
granulocytes. B cells and T cells are produced by the lymphoid precursors with
additional cell subsets developing depending on location and activation status. T cells
further develop into a number of additional cell types; the most well described being the
TH and TC cells (Kondo et al., 2003; Laiosa et al., 2006). We determined the levels of
each of macrophages, neutrophils, B cells and TH and TC cells as a basic measure of
systemic immune activation; however detailed investigation into the activation status or
functional subtypes were beyond the scope of this project.
Similar to the immune cell types, cytokines have also demonstrated a variety of changes
in schizophrenia (see 1.2.4e) with several changes demonstrated to be consistent across
meta-analyses (Miller et al., 2011; Potvin et al., 2008). Despite the findings in the
Potvin et al (2008) and Miller et al (2011) meta-analyses that indicate IL-1β, IL-1RA,
IL-2, sIL-2R, IL-6, IL-12, TGF-β, TNFα and IFNγ have been consistently found altered
in patients, a debate remains as to whether there are other cytokines that will yet prove
to be consistently changed and biologically relevant, thus a wide panel of cytokines was
investigated.
2.1.3

Summary

With peripheral immune system changes associated with schizophrenia along with links
to Nrg1 as a schizophrenia vulnerability gene and no evidence to date of direct Nrg1
involvement in the peripheral immune system, this study aimed to determine if the
combination of gene and immune stimulus presented an aberrant peripheral immune
response. As melanoma has been negatively associated with schizophrenia and the
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B16F0 cell line demonstrated to induce an immune response in the mouse strain used,
this was used as the immune stimulus. In order to determine if the peripheral immune
response was perturbed several markers were investigated, this included: tumour size,
angiogenesis and possible infiltration of macrophages and neutrophils into the tumours
were measured; circulating levels of the major immune cell compartments of both the
innate and adaptive immune response, as well as plasma cytokine levels.
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2.2

Methods

2.2.1

Animal housing and breeding

All animals were housed in the animal facilities of the University of Wollongong under
standard temperature controlled (20°C ± 2) conditions consisting of a 12:12 hour lightdark cycle with lights on at 0700 hrs. Animals had ad libitum access to standard lab
chow and water. Breeding was performed by mating one WT female C57Bl/6 mouse
with one Nrg1 Het male mouse. Thereafter, animals were separated, with each female
assigned to a white plastic cage (50 x 20 cm) provided with additional nesting material.
The day of birth was defined as post-natal day 0. The generation of the Nrg1 Het mice
(target allele: Nrg1tm2Zhou) has been described previously (Stefansson et al., 2002).
Male offspring were separated from their dams on post-natal day 28. Animals were
housed under standard conditions with two mice of corresponding genotype per cage
matched by weight. Standard cage enrichment was provided (including sawdust,
bedding material and a PVC tube). Experimental animals were 8-9 week old, male Nrg1
Het and WT control littermates. Female offspring were transferred to other experimental
protocols. Euthanasia of animals was performed using the CO2 slow infusion method.
All experiments were approved by and performed in accordance with the guidelines of
the Animal Ethics Committee of the University of Wollongong (Breeding protocol
AE10/03, experimental protocol AE09/17). Procedures complied with the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes, which
conforms to International Guiding Principles for Biomedical Research Involving
Animals. All efforts were made to minimise animal numbers and suffering.
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2.2.2

Genotyping and weaning

Mice were ear marked for individual identification and genotyping with the ear tissue
obtained during the ear marking process used for genotyping at the age of 3 weeks. The
genotyping was performed using a commercially available genotyping kit (REDExtractN-Amp PCR kit, Sigma, St. Louis, MO, USA) followed by a PCR which allowed for
the simultaneous detection of the wild type and/or mutated allele. In brief, a pre-mixed
preparation of Extraction Solution and Tissue Preparation Solution (4:1) was added to
each tissue sample, vortexed and incubated for 10min at RT. Tissue was then incubated
at 95°C for 3min before addition of Neutralization Solution B and maintained at 4°C
until use. PCR amplification was conducted per manufacturers’ instructions by adding
16µl of master mix (10µl of REDExtract-N-Amp PCR reaction mix, 1µl each of
forward and reverse primers (8µM) (Table 2.2-1) plus 5µl RNase/DNase free H2O per
sample) to 4µl tissue extract in thin-walled PCR tubes. DNA was amplified using an
Eppendorf, Mastercycler Pro S thermo cycler.
Amplified DNA was loaded directly onto a 1% agarose gel with SYBR green and run
for 30min at 95V with a DNA ladder (DirectLoad PCR 100bp Low Ladder, Sigma) as
well as Nrg1 mutation positive and negative controls. DNA was visualised with UV
light on a GelDoc 212 Pro using Molecular Imaging Standard Edition (v5.0.2.30)
software (Carestream, Rochester, NY, USA).
Table 2.2-1 Primer sequences used for Genotyping
Target
Nrg1 WT Trinity
Nrg1 Neo173

Sequence
F: GGG CGC CCT GTT CCA CCA CA
R:CCT CCG CTT CTG GAA AGG GGT GA
F: ATG AAC TGC AGG ACG AGG CA
R:GCC ACA GTC GAT GAA TCC AG

Primers supplied by Invitrogen, Carlsbad, CA, USA
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2.2.3

B16F0 melanoma model

An in vivo murine melanoma model was used. Established from a spontaneously
occurring C57Bl/6 melanoma, the B16F0 murine melanoma cells are a well-established
in vivo model for challenging the immune system (Nakamura et al., 2002; Nicolson et
al., 1978; Overwijk and Restifo, 2000). The B16F0 cell line were a kind gift from Dr
Andrew Katsifis (ANSTO, Sydney, NSW, AU) and were originally purchased from the
American Type Culture Collection (ATCC). All chemicals and reagents for B16F0 cell
culture were obtained from Invitrogen (Carlsbad, CA, USA) unless otherwise stated.
The B16F0 adherent melanoma cell line was cultured in vitro using RPMI 1640
medium (Sigma) supplemented with 10% Foetal Calf Serum and 200µM L-glutamine/
penicillin/ streptomycin in a 37°C, 5% CO2 incubator. Culture medium was replaced
every three days and cells passaged using trypsin (0.05%) at 70-80% confluent to a 1:10
dilution. Cells were harvested (passage 7-9) for injection using trypsin (0.05%) and
resuspended in sterile dPBS (without Ca2+ and Mg2+). In brief, excess media was
removed, cells were rinsed with 2ml trypsin, followed by incubation in fresh 2ml
trypsin at 37°C, 5% CO2 until all cells had detached from the flask. 25ml supplemented
media (passaging) or dPBS (injections) was added to dilute trypsin and the entire
contents of the flask transferred to a sterile 50ml conical tube. After 5min centrifugation
at 500 x g, supernatant was removed and pellet resuspended in 2ml supplement media
(passaging) or dPBS (injections). For passaging, the resuspended pellet was then diluted
1:10 in sterile cell culture flasks. For injections, a small aliquot was removed for cell
counting, using trypan blue, a haemocytometer and a light microscope (40x
magnification). The final pellet was resuspended at 3x106 cells per 1ml of PBS (3x105
cells per 0.1ml injection). Cells were maintained in a sterile tube on ice during
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injections and mixed to ensure cells were adequately dispersed before charging each
syringe.
Cells were injected subcutaneously into the shaved left flank of animals at 8 weeks of
age (3x105 cells per 0.1ml injection per mouse) using a sterile insulin syringe (0.5ml)
charged with 0.1ml of cell suspension solution. A total of 8 Nrg1 Het and 12 WT
animals received tumour injections. Tumours were not visible until day 8 post injection
at the earliest (where the day of injection = day 0). Mice were euthanized by CO2 on
day 9 post melanoma injection. One WT mouse did not display a tumour when
euthanized and was excluded from all further analysis.
2.2.4

Tissue collection

a)

Whole blood, plasma and spleen

Blood was sampled by cardiac puncture into 1.3ml micro tubes with EDTA (Sarstedt,
Nümbrecht, Germany) supplemented with 10µl aprotinin (Sigma). Whole blood was
gently mixed by inverting the tube and then placed on ice. For flow cytometry, whole
blood was added to 10ml ice cold flow cytometry buffer and placed on ice (see 2.2.5a)
for flow cytometry protocol following blood collection). To obtain plasma, samples
were centrifuged for 10min at 4oC at 18000 x g, a minimum of 30min after collection,
Plasma samples were frozen and stored at -20oC until further analysis.
The spleen was collected following cardiac puncture and snap frozen in liquid nitrogen
before storage at -80oC. Spleens were thawed before being weighed.
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b)

Tumour tissue

The volume of primary tumours was determined post excision using vernier callipers.
Tumour size was measured by (a) longest length (mm) and (b) its perpendicular width
(mm), and volume was reported as ½(length × width2) (mm3) (Kostourou et al., 2013;
Li et al., 2004). Following excision tumours were snap frozen in liquid nitrogen before
storage at -80oC.
2.2.5

Cellular analysis

a)

Flow cytometry

Following blood collection, whole blood was added to 10ml of ice cold flow cytometry
buffer (Table 2.2-2) and placed on ice. Cells were centrifuged 5min, 300 x g at 4°C and
supernatant discarded. The pellet was resuspended in 2.5ml red cell lysis buffer (Table
2.2-2) and incubated for 10min on ice. Cells were then washed twice by centrifugation
at 300 x g for 5min at 4oC, discarding supernatant and resuspending in 10ml flow
cytometry buffer. Following final wash cells were resuspended in 1ml flow cytometry
buffer. A cell count was conducted using trypan blue and a haemocytometer to
determine viable cell number. Using a 96 well plate, 1,000,000 viable cells were
distributed per well and appropriate antibody added. Cells were incubated for 30min in
the dark, on ice using 0.5µg antibody per sample. The antibodies (Table 2.2-3) were
added in the following staining combinations:
•

Stain 1: F4/80, B220, Ly6G, CD3

•

Stain 2: CD8, B220, CD3, CD4

Titrations were performed to confirm 0.5µg antibody per sample well was appropriate.
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Cells were washed twice by centrifugation at 300 x g for 3min at 4oC, discarding
supernatant and resuspending in 200µl flow cytometry buffer. Samples were then
transferred to 1.2ml Micro Titer Tubes (QSP, Petaluma, CA, USA) before acquisition
using BD LSRII (BD Biosciences, San Jose, CA, USA) running FACSDiva software
(v3.3, BD Biosciences). FlowJo v7.2.5 software (TreeStar Inc., OR, USA) was used for
analysis of results, gating details are provided below.
Table 2.2-2: Solutions and Buffers
Buffers/ Solutions
Flow cytometry
buffer
Red blood cell lysis
buffer

Solution A

Solution B

Solution C
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Components
1 x PBS
0.5% Bovine Serum Albumin (BSA)
0.05 mM NaN3
Final 1x concentration buffer is made up immediately before
use and consists of 7 parts dH20, 2 parts Solution A, 0.5 part
Solution B, and 0.5 part Solution C (v/v). Where solutions
A, B and C are as described below:
35g NH4Cl
1.85g KCl
1.5g Na2HPO4.H2O
0.12g KH2PO4
5g Glucose
0.05g Phenol Red
1 litre dH2O
2.1g MgCl2
0.7g MgSO4
1.7g CaCl2
500ml dH2O
11.25g NaHCO3
500ml dH2O
Solutions A, B and C were autoclaved and stored at 4°C
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Table 2.2-3: Antibodies used for flow cytometry
Specificity
Rat anti-mouse F4/80
Rat anti-mouse CD45R/B220
Rat anti-mouse Ly6G
Hamster anti-mouse CD3e
Hamster anti-mouse CD3e
Rat anti-mouse CD8a
Rat anti-mouse CD4

Label
Alexa 488
PerCp Cy5.5
PE-Cy7
APC
PE-Cy7
FITC
APC-H7

Amount/ sample (µg)
0.5
0.5
0.5
0.5
0.5
0.5
0.5

All antibodies from: BD Biosciences, San Jose, CA, USA except F4/80 (Alexa 488) from: eBiosciences
Inc.,

Total leukocytes were separated from cell debris using forward and side scatter plots.
Individual cell types were then determined using selective gating. The circulating
monocyte/ macrophage population is presented as a percentage of total leukocytes
identified firstly using forward and side scatter to select for size and inclusions (to
remove granulocyte populations) and then by anti-F4/80 positive, anti-Ly6G
(Lymphocyte antigen 6 complex, locus G; also known as GR1) negative fluorescence
(Campisano et al., 2013; Holt et al., 2008). Neutrophils are represented by anti-Ly6G
positive cells also following forward and side scatter section for granulocyte
populations (Buonocore et al., 2008; Campisano et al., 2013). Total T and B cells are
represented as a percentage of total lymphocytes. The lymphocyte population is selected
from the forward and side scatter plot with total B cells represented by the anti-B220
positive lymphocyte population (Allman and Pillai, 2008; Ellis et al., 2001). Total T
cells are represented by the anti-CD3 positive population, a pan T cell marker, with total
T cell population further delineated into anti-CD4 positive (TH cells) and anti-CD8
positive (TC cell) populations, presented as a percentage of total T cells (see for example
Figure 2.2-1) (Aniansson Zdolsek et al., 1999).
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Figure 2.2-1 Example gating plot
A representative flow cytometry plot of total lymphocytes with anti-CD4 labelled
(CD4+) cells on the X-axis and anti-CD8 labelled (CD8+) cells on the Y-axis after
gating.

b)

Immunohistochemistry

Frozen tumours were sectioned to 7µm thickness using a cryostat at -20°C and mounted
on polylysine slides in series. Sections were stored at -80°C until staining.
For immunofluorescent staining, sections were fixed in -20oC acetone for 5min
followed by 5min wash in PBS to remove all acetone and prevent crystallization. The
PBS wash was then repeated for 2min. A PAP pen was used to draw around sections
then the sections were incubated with IF block for 10min (Table 2.2-4). Sections were
drained (not rinsed) before addition of primary antibody in IF blocking solution. The
sections were incubated with primary antibodies in blocking solution at RT for 90min in
a damp chamber. Slides were washed in TNT wash (Table 2.2-5), followed by 10mM
Tris, pH 7.4. Sections were then incubated with secondary antibody in IF blocking
solution for 30min at RT. The slides were washed in TNT wash buffer followed by
10mM Tris, pH 7.4 as before. Nuclei were counterstained with 1g/ml Hoechst 33342
(Sigma) for 1min and sections were covered with fluorescent mounting medium (Dako,
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North America) and a coverslip with before being stored in the dark at 4°C until
imaging.
Table 2.2-4 IF block
0.1M
0.15M
2%
2%
Distilled water
Final Volume

Tris, pH 7.4
NaCl
Normal goat serum*
normal horse serum*

5ml of 1M
7.5ml of 1M
1ml
1ml
35.5ml
50ml

*Hyclone, Logan, UT

Table 2.2-5 TNT wash
0.1M
0.15M
0.05%
Distilled water
Final Volume

Tris, pH 7.4
NaCl
Tween 20

5ml of 1M
7.5ml of 1M
25µl
35.5ml
50ml

Rat anti-mouse CD31 (PECAM-1; clone 390) antibody was used for detection of
vasculature (2.5µg/ml; eBiosciences) followed by Alexa Fluor 594-conjugated goat
anti-rat IgG (4µg/ml; Invitrogen, Carlsbad, CA) (Varney et al., 2005). For analysis of
immunofluorescence, each field was imaged at 400x magnification by multichannel
fluorescence microscopy for antibody staining of the cell surface marker CD31 and
Hoechst 33342 nuclear stain. Images were acquired using the Nikon TE2000-E
microscope (Nikon, Japan), running ImagePro-Plus software (MediaCybernetics,
Rockville, MD, USA). The relative frequency of blood vessels was determined by
averaging the number of positive staining vessels in 3-5 non-consecutive microscope
fields from tumour sections in randomly selected Nrg1 (n=4) and WT (n=4) tumours.
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2.2.6

Protein analysis

a)

Luminex

Luminex is a multiplex assay which allows several analytes to be measured
simultaneously in small sample volumes. This assay has shown good correlation with
the more traditional ELISA assay method for cytokine measurement (see (Elshal and
McCoy, 2006) for a detailed comparison). Plasma samples were analysed in duplex
using a pre-mixed 32-plex mouse cytokine/chemokine 96 well plate assay kit
(MILLIPLEX®Map, Millipore, Billerica, MA, USA) This kit contained the cytokines:
IL-6, G-CSF, IL-12p40, IL-5, IL-13, platelet-derived growth factor-inducible protein
KC (KC), monocyte chemoattractant protein-1 (MCP-1), eosinophil chemotactic protein
(Eotaxin), IL-1α, interferon-gamma-inducible protein 10 (IP-10), leukaemia inhibitory
factor (LIF), Cytokine LIX (LIX), monokine induced by interferon-gamma (MIG),
regulated upon activation, normal T cell expressed and secreted (RANTES),
macrophage inflammatory protein 1-alpha (MIP-1α), macrophage inflammatory protein
1-beta (MIP-1β), macrophage-colony stimulating factor (M-CSF), IL-12p70, VEGF,
TNFα, granulocyte macrophage-colony stimulating factor (GM-CSF), IFNγ, IL-1β, IL2, IL-3, IL-4, IL-7, IL-10, IL-15, IL-17 and macrophage inflammatory protein 2 (MIP2) and was performed in accordance with the manufacturers’ protocol. Note that KC,
MIP-2 and LIX are murine functional homologues of human IL-8 (Hol et al., 2010).
Undiluted plasma samples were used, as optimisation steps conducted prior to
experimentation showed the best results were achieved without pre-dilution (data not
shown). In brief, wash buffer was used to pre-wet the filters in a 96 well assay plate by
10min incubation with agitation at RT before removal of buffer. All removal of reagents
was performed by vacuum. All vacuum steps were followed by blotting the bottom of
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the plate to remove excess reagents. All preparation steps were completed at RT.
Standards, controls and samples were loaded into 96 well plates, with samples randomly
allocated to ensure even distribution of groups across the plate. Matrix solution was
then added to standard and control wells followed by the addition of assay buffer and
pre-mixed cytokine assay beads to all wells per manufacturer’s instruction (Millipore,
Billerica, MA, USA). All wells contained sample (or standard/ control) at the ratio of 1
part sample to 2 parts reagents. The plate was sealed and incubated overnight at 4°C
with agitation. The following day, reagents were removed and wells washed twice with
wash buffer. Detection antibodies were added into each well and incubated in sealed
plate for 1 hour with agitation at RT. Following incubation, Streptavidin-PE was added
to the detection antibodies and incubated for 30min, with agitation, at RT. All reagents
were then removed by vacuum followed by two washes and final resuspension in 150µl
of Luminex xMap sheath fluid (Luminex Corporation, Austin, TX, USA) by 5min
agitation at RT on plate shaker. The plate was run on a Luminex 100™ System using
xPONENT® 3.1 Software (Luminex Corporation). Data output was analysed using
MasterPlex® QT: Multiplex Quantitative Analysis Curve-Fitting Software (Hitachi
Solutions America Ltd, South San Francisco, CA, USA).
2.2.7

Tumour gene expression analysis

a)

RNA extraction

RNA extraction was performed using the QIAshredder to homogenise tumour tissue and
the RNeasy Plus Mini Kit to isolate mRNA (Qiagen, Valencia, CA, USA). The kits
were used as per manufacturer’s instructions. In brief, up to 700µl of lysate was add to
each QIAshredder spin column, placed into an RNase free collection tube and
centrifuged a maximum micro centrifuge speed for 2min. As the lysate passes through
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the column it is homogenised. Extraction of mRNA was performed as a series of buffer
additions and column centrifugation exactly per manufacturer’s instructions, including a
step to eliminate genomic DNA. Extracted RNA was eluted into 30-50µl of RNase free
water. RNA concentration and quality was quantified using the NanoDrop (Thermo
Scientific, NanoDrop 2000c) and accepted for use with: A260/280 ratio > 1.8 and
A230/260 ratio > 2.0. Additional purification of extracted RNA was performed where
required using ethanol precipitation as follows. Cold isopropanol was added to the RNA
solution in equal volumes. Then 1/10 volume ammonium acetate (7.5M, pH 5.2,
adjusted using glacial acetic acid) was added before vortexing and incubation at -20°C
for 1 hr. Samples were centrifuged for 10min (12,000 x g, 4°C) and the supernatant
discarded. Pellet was washed in 800µl cold ethanol (70%) and dislodged by inverting
tubes 5 times followed by centrifugation for 5min (14,000 x g, 4°C). The wash steps
were then repeated and supernatant discarded. An additional centrifugation step was
performed (5min, 14,000 x g, 4°C) followed by removal of supernatant and RNA pellets
were air dried. The dried pellet was resuspended in 20-30µl RNase free water before
quantification on the NanoDrop as described above. A selection of 4 Nrg1 Het and 4
WT tumour samples was used. This selection was chosen based on the 4 best quality
mRNA samples as determined by the NanoDrop A260/280 and A230/260 ratios.
b)

cDNA synthesis

Taqman individual gene expression assays (Applied Biosystems) were used to measure
relative mRNA levels in the B16F0 melanomas of Nrg1 mutant and WT mice.
Following RNA extraction (2.2.7a), the QuantiTect Probe RT-PCR Kit (Qiagen) was
used per manufacturers’ instructions to synthesize cDNA and measure relative mRNA
levels using a one-step RT-qPCR approach. In brief, an appropriate volume containing
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57ng of isolated template RNA for each sample was added to 5µl 2x QuantiTect Probe
RT master mix, 0.4µM primer (forward and reverse), 0.1µM probe and 0.1µl of
QuantiTect RT mix per sample, with RNase-free water added to make a total sample
reaction mix of 10µl. All preparation steps were completed on ice to avoid premature
synthesis of cDNA.
Individual taqman primer/probes assays were purchased off the shelf from Applied
Biosystems for: VEGF (marker of angiogenesis); CD68, CD163, and Arg1 (markers of
macrophages) (Ellyard et al., 2010; Sullivan and Brekken, 2010; Varney et al., 2005);
the cytokines G-CSF, IL-6 and normalised against Beta actin (Shi et al., 2011) as
detailed in Table 2.2-6. The neutrophil marker Ly6G was custom made following the
sequence in the publication of Sasmono et al (2007) with a forward primer of TGG
ACT CTC ACA GAA GCA AAG and reverse primer GCA GAG GTC TTC CTT GCA
ACA for a sequence product length of 128bp. The relevant probe was developed by
Applied Biosystems to match the sequences above. All sequences for Ly6G (primers
and probes) were checked using NCBI nucleotide blast data base with only 1 predicted
result returned for the sequence used.
Table 2.2-6 Individual Taqman primer/probe assays
Gene Name
Vascular endothelial growth factor A
CD68 antigen
CD163 antigen
Arginase, liver
Colony stimulating factor 3 (granulocyte)
Interleukin 6
Actin, beta

Assay ID
Mm01281449_m1
Mm03047340_m1
Mm00474091_m1
Mm00475988_m1
Mm00438334_m1
Mm00446190_m1
Mm00607939_s1

Note: Applied Biosystems primer/probe sequences are commercial in confidence and sequences are not
provided.
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RT-qPCR was performed on a LightCycler 480 II (Roche) with the cycling conditions
detailed in Table 2.2-7. Fluorescent data collection performed at the combined
annealing/ extension step.
Table 2.2-7 Thermal cycling parameters: Taqman tumour tissue
Step
Reverse Transcription
PCR initial heat activation
Denaturation
Combined Annealing/ extension

Temperature (°C)
50
95
94
60

Time (min:sec)
20:00
15:00
0:15
1:00

Cycles
1
1
45

Results are presented as fold change in expression levels (Livak and Schmittgen, 2001;
Schmittgen and Livak, 2008) with untreated WT expression levels normalised to 1 ±
SEM with other values presented as comparison fold change.
2.2.8

Statistics

After confirming normal distribution with the Kolmogorov-Smirnov test, body weight
was analysed using a 2 (genotype) x 2 (immune challenge) x 2 (initial vs final) with
repeated measures on initial vs final weight ANOVA, post-hoc paired samples t-tests
were used to compare initial and final weight in each group. Tumour size was analysed
using 2-tailed independent samples t-test. All other parameters were analysed using a 2way ANOVA (factors: genotype x immune challenge), using 2-tailed independent
samples t-tests to further explore group differences. Due to the exploratory nature of
these studies, all p-values are presented as uncorrected p-values. Data are presented as
mean ± SEM. Significance was set at p<0.05.
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2.3

Results

2.3.1

Body weight and spleen mass unchanged in response to immune
stimulus

All animals were weighed immediately prior to injection with B16F0 melanoma cells
and again before sacrifice. A difference was seen between initial and final body weight
within groups, (F1,31=144.119, p<0.001), and paired sample t-tests confirmed body
weight increased in all groups (p<0.01) with an average body weight gain of 9%
overall. There were no other differences within or between groups in initial or final
body weight with no effect of genotype, immune challenge or any interaction between
the two (Table 2.3-1).
Spleens were removed and weighed; a 2-way ANOVA revealed no difference in spleen
weight between groups as a result of genotype or treatment. In addition, there was no
genotype x treatment interaction (Table 2.3-1).
Table 2.3-1: Mean body weight (g) and spleen weight (mg)
Control

Immune challenged

WT

Nrg1 Het

WT

Nrg1 Het

Initial body weight

21.5 ± 0.3

21.3 ± 0.5

20.4 ± 0.4

21.0 ± 0.4

Final body weight

23.1 ± 0.3

23.3 ± 0.4

22.7 ± 0.4

23.0 ± 0.2

Body weight gain

1.6 ± 0.1

1.8 ± 0.2

2.3 ± 0.3

2.0 ± 0.2

Spleen Weight (mg)

64.5 ± 3.0

72.0 ± 4.6

69.2 ± 3.1

72.0 ± 3.6

Body Weight (g)

Male Nrg1 Het mutant mice and WT littermates injected with subcutaneous B16F0
melanoma or saline vehicle.
The data represent mean ± SEM, IBW: initial body weight, FBW: final body weight, BWG: body weight
gain, n=8-11 per group

Peta Snikeris

43

2.3.2

Tumour growth, size and angiogenesis not influenced by genotype

Tumours for both Nrg1 Het and their WT littermates were visible on day 8 or 9 post
injection. Figure 2.3-1 shows a representative tumour in-situ (A) (day 9 post injection)
and following excision (B). There was no difference in tumour volume when measured
with vernier callipers after excision with WT tumours 58.7± 27.9mm3 and Nrg1
tumours 86.4± 30.0mm3 (p>0.05, independent samples t-tests).

A

B

Figure 2.3-1: B16F0 Melanoma Growth.
Representative image of tumour growth in both Nrg1 Het and WT mice 9 days post
injection (A) in-situ and (B) post excision. There was no difference in tumour size
between genotypes.
The level of vascular infiltration into the B16F0 melanomas was measured in Nrg1 Het
as compared to WT. Measurement was by immunofluorescent staining of CD31 to
visualise vasculature and mRNA expression levels of VEGF. No difference was found
in the number of vessels shown by immunofluorescence (Figure 2.3-2). In addition,
there was no difference in the mRNA expression levels of the marker of angiogenesis
(VEGF), in the B16F0 melanoma tissue following 9 days of in vivo tumour growth in
Nrg1 Het and WT mice. VEGF mRNA expression in Nrg1 Het animal was 0.8 ±0.14
(mean fold change ± SEM, n=4 per group).
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CD31

100 µm

Hoechst

100 µm
Figure 2.3-2: Representative B16F0 vasculature.

This image is representative of vascularisation in both Nrg1 Het and WT mice.
Tumours were excised 9 days post injection (A) CD31 immunofluorescent staining for
vascular endothelium and (B) Hoechst immunofluorescent staining for cell nuclei.
There was no difference in the number of vessels visualised (n=4 per group).
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2.3.3

Tumour macrophage and neutrophil population

The level of macrophage and neutrophil populations in the B16F0 melanomas was
investigated by mRNA expression levels within the tumour tissue. The macrophage
markers CD68, CD163 and Arg1 (Ellyard et al., 2010; Sullivan and Brekken, 2010;
Varney et al., 2005) and the neutrophil marker Ly6G were measured (Sasmono et al.,
2007). In addition, the mRNA expression level of the cytokines IL-6 and G-CSF (shown
to have elevated protein levels in the plasma of Nrg1 Het animals subject to a
melanoma, see Figure 2.3-3) were measured. There were no differences in the mRNA
expression levels of CD68, CD163, Arg1, IL-6, Ly6G or G-CSF in Nrg1 tumours when
compared to those from WT littermates (Table 2.3-2)
Table 2.3-2: mRNA expression levels for markers of macrophage and neutrophil
infiltration in tumours
Marker
Macrophages

Neutrophils

WT

Nrg1 Het

CD68

1.00 ± 0.06

0.91 ± 0.07

CD163

1.00 ± 0.48

0.88 ± 0.43

Arg1

1.00 ± 0.25

0.69 ± 0.08

IL-6

1.00 ± 0.49

1.04 ± 0.34

Ly6G

1.00 ± 0.06

1.41 ± 0.23

G-CSF

1.00 ± 0.23

1.07 ± 0.06

As measured in the B16F0 melanomas following 9 days of in vivo tumour growth in
Nrg1 Het and WT mice.
The data represent mean fold change ± SEM, n=4 per group, except G-CSF where n=3 per group. WT
expression levels normalised to 1 and fold change for Nrg1 Het calculated as a comparison.

2.3.4

Peripheral circulating immune cells unchanged in both Nrg1 Het and
WT mice with or without the immune stimulus

Immune cells of the innate and adaptive immune response were measured in the
peripheral blood. Monocyte/macrophages and neutrophils are presented as a percentage
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of total leukocytes. Total T cells are presented as a percentage of total lymphocytes and
CD4+ or CD8+ T cells are a percentage of total T cells. B cells are presented as a
percentage of total lymphocytes (see 2.2.5a) for details of gating). No differences were
found in any of the immune cell compartments measured using 2-way ANOVA
(factors: genotype x immune challenge), additionally, no differences were shown with
further analysis using 2-tailed independent samples t-test to compare groups (p>0.05)
(Table 2.3-3).
Table 2.3-3: Peripheral circulating immune cells in male Nrg1 Het mice compared to
WT littermates, with or without a B16F0 melanoma immune challenge
Control

Immune challenged

WT

Nrg1 Het

WT

Nrg1 Het

% Monocyte/Macrophagea

24.6 ± 3.0

27.3 ± 3.2

27.5 ± 1.5

24.8 ± 3.6

% Neutrophila

14.6 ± 3.7

7.1 ± 2.1

17.1 ± 8.0

21.2 ± 9.7

% Total T cellsb

29.6 ± 1.3

31.9 ± 2.1

32.7 ± 4.4

30.7 ± 2.1

c

52.5 ± 1.7

52.2 ± 1.1

50.1 ± 2.1

49.8 ± 3.0

% CD8+ T cellsc

39.7 ± 1.8

39.6 ± 1.4

40.9 ± 3.2

38.3 ± 0.8

32.1 ± 4.7

35.4 ± 3.5

31.9 ± 1.7

32.7 ± 4.1

% CD4+ T cells
% B cellsb

The data represent mean % ± SEM, a) percentage of total leukocytes, b) percentage of total lymphocytes,
c) percentage of total T cells, n=4 per group

2.3.5

Plasma cytokine profile alterations found based on genotype and/or
immune stimulation

Thirty-two different cytokines were measured in the plasma to investigate the peripheral
cytokine profile with or without the melanoma challenge. Twelve of the cytokines
tested provided data while twenty were close to or below the detection limit using the
Luminex multiplex assay (Table 2.3-4).
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Table 2.3-4: Cytokine/ Chemokine 32-plex Luminex kit list
Cytokine/ Chemokine
IL-6
G-CSF
IL-5
KC
MCP-1
IL-13
Eotaxin
IL-1α
IP-10
LIX
MIG
M-CSF
IL-12p40
IL-12p70
RANTES
MIP-1β
VEGF
GM-CSF
TNFα
IFNγ
IL-1β
IL-2
IL-3
IL-4
IL-7
IL-9
IL-10
IL-15
IL-17
MIP-1α
MIP-2
LIF
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Figure 2.3-3A
Figure 2.3-3B
Figure 2.3-4
Figure 2.3-4
Figure 2.3-5
Figure 2.3-5
Table 2.3-5
Table 2.3-5
Table 2.3-5
Table 2.3-5
Table 2.3-5
Close to detection limit – data not shown
Close to detection limit – data not shown
Close to detection limit – data not shown
Close to detection limit – data not shown
Close to detection limit – data not shown
Close to detection limit – data not shown
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
Below the limit of detection
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a)

Interleukin 6 levels higher in the Nrg1 Het mice with a tumour load

Plasma IL-6 showed a genotype x treatment interaction (F1,31=4.472, p=0.043, 2-way
ANOVA) as well as a main effect of genotype (F1,31=8.58, p=0.006, 2-way ANOVA)
and treatment (F1,31=16.96, p<0.001, 2-way ANOVA) (Figure 2.3-3 A). Unchallenged
WT mice had plasma IL-6 levels of 2.6±1.4 pg/µl. Plasma levels of IL-6 were higher in
Nrg1 Het mice (20.6±3.2 pg/µl) subject to the immune challenge compared to
unchallenged Nrg1 Het (4.7±1.6 pg/µl, p=0.001, independent samples t-test) and
challenged WT controls (7.8±2.8 pg/µl, p=0.008, independent samples t-test).
b)

Granulocyte-colony stimulating factor higher in the Nrg1 Het mice with
an immune stimulus

Plasma G-CSF demonstrated a treatment effect (: F1,31=4.40, p=0.044, 2-way ANOVA)
while the main effect of genotype and the genotype x treatment effect displayed a trend
(F1,31=3.71, p=0.06, F1,31=3.103, p=0.088 respectively, 2-way ANOVA). Plasma G-CSF
was higher in the Nrg1 Het immune challenged mice (659±78 pg/µl) when compared to
challenged WT (371±86 pg/µl, p=0.029, independent samples t-test) and the Nrg1 Het
unchallenged mice (357±84 pg/µl, p=0.020, independent samples t-test). WT
unchallenged mice had a plasma G-CSF level of 344.6±38.8 pg/µl (Figure 2.3-3 B).
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Figure 2.3-3: Plasma IL-6 and G-CSF levels in unchallenged and immune challenged
Nrg1 Het mice compared to WT.
Immune challenged Nrg1 Het animals had higher levels of IL-6 and G-CSF when
compared with Nrg1 Het unchallenged mice, as well as when compared with WT
immune challenged animals. Plasma levels of (A) IL-6 and (B) G-CSF (pg/ml)
measured using multiplex bead based Luminex assay in WT and Nrg1 Het mice injected
subcutaneously with either B16F0 subcutaneous melanoma (3x105 cells in 0.1ml) or
PBS control (0.1ml). Plasma was collected 9 days after melanoma injection, n = 8-11
animals per group (independent samples t-test, *p<0.05, **p<0.01).
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c)

Interleukin 5 and KC higher in WT animals with an immune challenge

IL-5 and KC (a murine homolog of human IL-8) plasma levels demonstrated a main
effect of treatment (IL-5: F1,31=6.10, p=0.019, KC: F1,31=6.89, p=0.013, 2-way
ANOVA). A higher level of both IL-5 and KC was seen in the WT immune challenged
mice (IL-5: 16.4±1.8 pg/µl, KC: 218.3±40.9 pg/µl) compared to the WT unchallenged
mice (IL-5: 9.4±2.3 pg/µl, KC: 96.9±17.3 pg/µl) (IL-5: p=0.026; KC: p=0.017,
independent samples t-test; Figure 2.3-4). The Nrg1 Het unchallenged mice had
10.1±0.8 pg/µl plasma IL-5 and 133.4±58.9 pg/µl plasma KC while the Nrg1 Het
immune challenged mice had 15.5±4.2 pg/µl plasma IL-5 and 241.0±44.5 pg/µl plasma
KC, although no difference was determined using independent samples t-tests.
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Figure 2.3-4: Plasma IL-5 and KC levels in unchallenged and immune challenged Nrg1
Het mice compared to WT.
The immune challenge increased average plasma levels of IL-5 and KC regardless of
genotype (2-way ANOVA main effect of treatment, significance not shown on figure,
refer to text 2.3.5c) Plasma IL-5 and KC levels were different in WT unchallenged and
WT immune challenged mice. Plasma levels of (A) IL-5 and (B) KC (pg/ml) measured
using multiplex bead based Luminex assay in WT and Nrg1 Het mice injected
subcutaneously with either B16F0 subcutaneous melanoma (3x105 cells in 0.1ml) or
PBS control (0.1ml). Plasma was collected 9 days after melanoma injection, n = 8-11
animals per group (independent samples t-test, p<0.05).
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d)

Interleukin 13 shows a genotype x treatment interaction and MCP-1
demonstrated a main effect of treatment

Further a genotype x treatment interaction was found in plasma IL-13 (F1,31=4.779,
p=0.036), and a main effect of treatment on plasma MCP-1 (F1,31=4.21, p=0.049).
Further analysis of IL-13 and MCP-1 showed no differences between the four
experimental groups (independent samples t-test) (Figure 2.3-5). The WT unchallenged
mice had 121.9±21.3 pg/µl plasma IL-13 and 26.8±8.8 pg/µl plasma MCP-1 while the
WT immune challenged mice had 191.3±28.1 pg/µl plasma IL-13 and 60.0±15.9 pg/µl
plasma MCP-1. The Nrg1 Het unchallenged mice had 203.4±47.2 pg/µl plasma IL-13
and 35.1±11.8 pg/µl plasma MCP-1 while the Nrg1 immune challenged mice had
135.3±21.7 pg/µl plasma IL-13 and 60.1±15.5 pg/µl plasma MCP-1. All additional
independent samples t-tests to analyse these data between the 4 groups revealed no
differences based on genotype alone when comparing cytokines in the Nrg1 Het and
WT. Additionally, no differences were found in the plasma levels of the remaining
detectable cytokines: Eotaxin, IL-1α, IP10, LIX, and MIG (Table 2.3-5).
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Figure 2.3-5: Plasma MCP-1 and IL-13 levels in unchallenged and immune challenged
Nrg1 Het mice compared to WT.
No difference was found in plasma MCP-1 or IL-13 between experimental groups using
independent samples t-tests, despite significant 2-way ANOVA findings. Plasma levels
of (A) MCP-1 and (B) IL-13 (pg/ml) measured using multiplex bead based Luminex
assay in WT and Nrg1 Het mice injected subcutaneously with either B16F0
subcutaneous melanoma (3x105 cells in 0.1ml) or PBS control (0.1ml). Plasma was
collected 9 days after melanoma injection, n = 8-11 animals per group (independent
samples t-test, p>0.05).
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Table 2.3-5: Unchanged plasma cytokine levels (pg/ml) in male Nrg1 mutant mice and
their WT littermates.
Control
Immune challenged
WT

Nrg1 Het

WT

Nrg1 Het

482.4 ± 38.3

486.9 ± 41.3

541.3 ± 59.4

525.0 ± 37.3

IL-1α

46.3 ± 3.8

53.3 ± 21.3

48.9 ± 8.9

109.7 ± 33.7

IP-10

23.5 ± 10.2

53.4 ± 17.1

56.0 ± 25.1

68.4 ± 21.1

LIX

954.9 ± 456.8

1202.4 ± 770.7

876.9 ± 211.7

979.1 ± 172.6

MIG

292.4 ± 48.9

302.5 ± 56.3

284.5 ± 43.9

267.8 ± 33.7

Eotaxin

The data represent mean (pg/ml) ± SEM, n=8-11 per group
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2.4

Discussion

This is the first experimental report to demonstrate a peripheral cytokine alteration in
the Nrg1 Het mouse model in response to a direct immune challenge. It was previously
shown that a Nrg1 Het mutation in mice resulted in altered cytokine production in
response to stress (Desbonnet et al., 2012), however the peripheral immune response to
a direct immune system stimulant was unknown. In response to the melanoma immune
challenge we found differences in IL-6 and G-CSF levels in the Nrg1 Het mice.
2.4.1

Interleukin-6 levels were higher in WT immune challenged animals with
further elevated levels in Nrg1 Het immune stimulated mice

The levels of circulating IL-6 seen in in the Nrg1 Het immune challenged mice were 4
times those in unchallenged Nrg1 Het mice. The difference in the IL-6 levels in Nrg1
Het mice subject to the immune stimulus was 3 times that shown in the challenged WT
mice (Figure 2.3-3). The 2-way ANOVA results, demonstrating not only an interaction
between genotype and immune challenge (F1,31=4.472, p=0.043) but also a main effect
of genotype (F1,31=8.58, p=0.006), clearly show that the effect of the immune challenge
was much larger in the Nrg1 mice as compared to the WT mice. Previous studies have
shown higher circulating levels of IL-6 in melanoma patients (Hoejberg et al., 2012;
Vereecken et al., 2012; Yurkovetsky et al., 2007), schizophrenia patients (Na and Kim,
2007; Schmitt et al., 2005; Zhang et al., 2002) and higher levels of IL-6 in families
carrying a Nrg1 transmembrane domain mutation (Marballi et al., 2010). WT littermates
also demonstrated apparent higher levels of IL-6 in the challenged animals compared to
vehicle although this was not significant (Figure 2.3-3). With no difference in the Nrg1
Het IL-6 levels at baseline compared to unchallenged WT mice, the 3 fold higher levels
of IL-6 in the Nrg1 Het challenged animal compared with WT challenged littermates
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demonstrate for the first time that a direct peripheral immune stimulus on top of a Nrg1
mutant background produce a synergistic increase in IL-6 levels.
The higher levels of IL-6 found in this study are consistent with those of Desbonnet et
al (2012) who showed both the Nrg1 mutation and a chronic stress paradigm increased
IL-6 levels alone, with a more evident increase in IL-6 in the Nrg1 Het mice subjected
to chronic stress using cultured spleen cells. Similar levels of plasma IL-6 in the
unchallenged Nrg1 Het mice when compared to WT in this study appear inconsistent
with Desbonnet et al (2012), where baseline spleen IL-6 levels were higher in control
Nrg1 Het mice compared to WT. There are a number of possible explanations for this
apparent inconsistency of findings. Firstly, the mice in the Desbonnet study were
subject to a battery of behavioural tests before sacrifice, beside the chronic defeat
paradigm. Such behavioural tests, although considered standard testing, increase stress
levels in mice (Bailey and Crawley, 2009) and pre-conditioned stress has been shown to
increase IL-6 (Cheng et al., 2015). Secondly, the mice in the Desbonnet study were
older at sacrifice where age related increases in IL-6 have been seen in humans (Wei et
al., 1992). With a number of possible explanations for this inconsistency between
studies, the focus of the discussion is on the similar increase found following an
immune stimulus.
Desbonnet et al (2012) further demonstrated that the cytokine response in Nrg1 Het
animals was linked to the type of immune stimulus. The Nrg1 mutation had no
additional effect on a lipopolysaccharide (LPS)-induced (B cell stimulus) cytokine
release, including IL-6. These data suggest that a Nrg1 mutation does not inhibit the
TH2 cytokine response, which was enhanced by chronic stress but was not altered as a
consequence of Nrg1 mutation in response to LPS. A TH2 response promotes B cell
Peta Snikeris

57

maturation and an antibody-based, humoral response directed against extracellular
pathogens, therefore suggesting that a Nrg1 mutation would not inhibit the antibody
mediated anti-tumour response. The levels of IL-6 however were increased in Nrg1
mice subject to chronic stress when subjected to Concanavalin A stimulation (T cell
stimulus). Considering these data from Desbonnet el al (2012) and the current study
findings demonstrating an interaction between Nrg1 mutation and a peripheral immune
stimulus on IL-6 levels, a role for Nrg1 the peripheral cytokine response is evidenced.
The higher levels of IL-6 in Nrg1 Het challenged animals is also consistent with the
findings of Marballi et al (2010) where a similar Nrg1 transmembrane domain mutation
in humans results in peripheral immune alterations. Individuals from within 14 families
carrying the Nrg1 mutation demonstrated higher plasma levels of IL-6 than unaffected
individuals (Marballi et al., 2010). Further, an in vitro study on lymphoblastoid cell
lines derived from first degree relatives of individuals diagnosed with psychosis, but
having no signs of illness themselves, from these same 14 families, showed higher
levels of IL-6 secretion. Messenger RNA analysis of the same cell lines showed that the
expression of IL-6 was also increased (Marballi et al., 2010). These data are consistent
with the findings of the current study, particularly when considering that each of these
individuals could be expected to have undergone previous immune challenges, likely
suffering from some childhood and other illnesses throughout development. However,
this remains speculative with no information on medical background reported in the
study. This further raises the possibility that the alteration of IL-6 in the Nrg1 mutant
model may be a persistent state following one or more immune stimuli, as hypothesized
by Patterson (2009).
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IL-6 can act as a pro- or anti- inflammatory cytokine, displaying multiple functions
including involvement in the type-2 immune response, haematopoiesis and acute-phase
reactions. This allows for several interpretations of why the levels of IL-6 may be
elevated in the Nrg1 Het stimulated animals. IL-6 is perhaps best characterized for its
role in the maturation of B cells to antibody-producing cells (Hirano et al., 1986) yet no
change in the percentage of circulating B cells in this study suggest elevated IL-6 is not
affecting the B cell mediated immune response. However, although no change in B cell
percentage was seen in the current study, a closer inspection of the maturation stage of
B cells or measurement of anti-B16F0 antibody titers may elucidate differences.
Alternatively, the anti-inflammatory properties of IL-6 are mediated through inhibitory
effects on pro-inflammatory cytokines

like

reducing

TNFα activity whilst

simultaneously up-regulating anti-inflammatory proteins including the IL-1RA (Jones et
al., 2001). In this study, both TNFα and IL-1RA were below the level of detection so
determining if IL-6 is involved in an anti-inflammatory response requires further study.
The data presented in this study clearly demonstrate an alteration in the peripheral IL-6
response in Nrg1 Het mice that is consistent with existing literature. The possibility of
these elevated IL-6 levels contributing to a polarised type-2 T helper cell response
cannot be ruled out. While IL-6 is considered a type-2 cytokine (Müller et al., 2009),
without detailed measurement of B cell activation and additional TH2 cytokine levels
below the limits of detection, there is not enough evidence to determine whether higher
plasma IL-6 in immune stimulated Nrg1 Het mice is influencing a TH2 type response.
This also leaves the option of an anti-inflammatory role for these higher levels of IL-6.
Nonetheless, the higher levels of IL-6 seen in immune stimulated Nrg1 Het animals,
compared to both unchallenged Nrg1 Het and challenged WT mice, indicates a
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dysregulation of IL-6 in the Nrg1 animals and the finding that a Nrg1 mutation results
in elevated plasma IL-6 levels stands out as a robust finding.
2.4.2

Granulocyte-colony stimulating factor was elevated in Nrg1 Het
immune challenged mice only

The higher level of G-CSF in Nrg1 Het mice with melanoma is a novel finding. G-CSF
levels were 84% higher in Nrg1 Het immune challenged mice compared to Nrg1 Het
unchallenged mice while no change was seen in challenged WT littermates compared to
unchallenged WT controls (Figure 2.3-3). G-CSF stimulates differentiation and
proliferation of the progenitor cells of neutrophilic granulocytes, producing mature
neutrophils and stimulating release of mature neutrophils into circulation during
inflammation (Nagata and Fukunaga, 1991). G-CSF is also capable of blocking
apoptosis in cells of the myeloid lineage (monocytes and granulocytes) (Schneider et
al., 2005a). For these reasons it has been investigated and used as a treatment to increase
neutrophils in patients with neutropenia or following chemotherapy which has depleted
these cells from the bone marrow (Fukunaga et al., 1991; Schneider et al., 2005b).
G-CSF has been shown increased in the serum of patients with melanoma (Yurkovetsky
et al., 2007), however alterations in circulating levels of G-CSF have not previously
been associated with schizophrenia patients. This cytokine is rarely reported in the
schizophrenia literature excepting as a treatment for clozapine induced agranulocytosis.
G-CSF plasma levels do not seem to correlate with patients who will develop clozapine
induced agranulocytosis. Still, recombinant G-CSF is successfully used as an adjunct
therapy with clozapine treatment in these patients (Pollmächer et al., 1997; Schuld et al.,
2000). However, it remains unclear if G-CSF levels could be predictive of
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agranulocytosis in patients and whether the lack of association with schizophrenia is
because G-CSF is unchanged or because it has not been widely studied.
2.4.3

IL-6 and G-CSF may act together to influence the immune system

Concurrent increases in IL-6 and G-CSF have previously been demonstrated in tumour
studies, including a B16F1 melanoma model (Bharadwaj et al., 2007; Yan et al., 2013).
Yan et al (2013) found that IL-6 and G-CSF cooperated to inhibit neutrophil granule
release in the B16F1 model, therefore increasing the pro-tumour function of this cell
type. An additional study demonstrated that elevated levels of IL-6 and G-CSF, found in
pancreatic cancer, were able to suppress monocyte derived dendritic cells, a common
feature of this cancer type (Bharadwaj et al., 2007). Using a model of ischemia Gregory
et al (2010) further demonstrated that IL-6 and G-CSF together affect monocyte
signalling potential at the level of the bone marrow, resulting in impaired ability to revascularise following an ischemic event. Together these studies indicate that a
concomitant increase in both IL-6 and G-CSF can have varied effects on multiple
immune cell types, specifically those of the myeloid lineage. Therefore the higher levels
of plasma IL-6 and G-CSF (Figure 2.3-3), seen in the Nrg1 Het mice subject a
melanoma inoculation may be working together to alter the proliferation, maturation or
release of cells of the myeloid linage primed for specific action in the periphery.
2.4.4

Immune stimulus resulted in elevated IL-5 and KC in WT mice subject
to an immune stimulus

One measure of whether the melanoma model represents an adequate immune stimulus
is in the changes found in the WT mice subject to the immune challenge. IL-5 and KC
were 75% and 125% higher in the WT challenged animals compared to unchallenged
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WT mice respectively, and although the Nrg1 Het animals displayed a similar trend
(54% and 81%), this was not significantly different, most likely due to the high
variability in levels between animals (Figure 2.3-4). These results, combined with the 2way ANOVA showing a main effect of treatment (IL-5: F1,31=6.10, p=0.019, KC:
F1,31=6.89, p=0.013) suggests that these changes are representative of a normal immune
response. Consistent with these data, IL-5 and IL-8 have been shown increased in the
plasma of alternate tumour types in the existing literature (Benoy et al., 2004; Ikutani et
al., 2012; Lee et al., 2013; Pine et al., 2011), where IL-8 is the human homologue of KC
(Hol et al., 2010). Additionally, MCP-1 and IL-13 revealed differences in the ANOVA
analysis which were however, not confirmed as between group difference using
independent samples t-tests. The large standard error of the mean shown in each group
for these analytes has likely confounded the result and increased sample numbers or a
more specific assay would be required to determine any true alterations in these
cytokines. Notwithstanding these limitations, future studies may be indicated to
determine if the genotype x treatment ANOVA result represents a physiologically
relevant finding.
2.4.5

B16F0 melanoma demonstrated no differences based on genotype

With epidemiological studies demonstrating lower rates of melanoma in schizophrenia
patients (Goldacre et al., 2005; Mortensen, 1994), it was interesting to note no
difference in tumour size, angiogenesis markers or innate immune cell population
within the tumour. In this experimental protocol we used an isograft model where
immortalised cells from a spontaneously occurring tumour from the same genetic mouse
strain were introduced into experimental animals in high numbers. This is not truly
representative of how cancer establishes itself naturally in the body. Therefore, although
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this result indicates that there is no difference in the immune response to a large
inoculation of melanoma cells, it does not rule out the possibility of a Nrg1 mutation
exerting an altered genetic influence on spontaneous cancer growth. It remains to be
investigated if a less aggressive, slower growing tumour or a spontaneous tumour model
may allow any subtle differences in tumour growth or the immune response within the
tumour microenvironment to be elucidated over a longer time period which may be
more representative of the native tumour growth environment. In addition, different
techniques and a more detailed study of immune cell subtypes and locations within the
tumour microenvironment may find differences. This was, however, beyond the scope
of this study.
With no difference in circulating cytokine levels demonstrated between the Nrg1 Het
and WT mice without an immune stimulus the Nrg1 Het mutation did not appear to
result in any basal impact on the cytokine system in animals at this age. The melanoma
challenge was expected to alter some cytokines in both the WT and Nrg1 Het mice as a
mark of basic immune stimulation, although as a syngeneic tumour model, the
magnitude of changes was not be expected to be large. Both IL-5 and KC were higher in
the WT challenged animals, and although the Nrg1 Het challenged animals display a
similar trend, this was not statistically different (Figure 2.3-4). This was consistent with
the expectation that an immune challenge would have a basic impact on the immune
system in both genotypes.
2.4.6

Circulating immune cells displayed no differences in the main cell type
ratios

No difference was shown in body weight, spleen weight or the main cell types of the
immune system between experimental groups. Suggesting that use of this type of
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immune stimulus does not have a broader impact on the immune system, however given
that the measurements were taken at a single time point and a detailed analysis of the
immune cell subtypes and activation status; both circulating and in the tumour
microenvironment, were beyond the scope of this project, such alterations cannot be
discounted without further study. In addition, acute immune challenges, or direct
stimulation of different immune response pathways may elicit different result.
2.4.7

Conclusion

This study has demonstrated that the combination of a genetic mutation in the Nrg1
gene and a peripheral immune stimulus in the form of a melanoma resulted in an altered
cytokine response. This was seen in the elevated levels of IL-6 and G-CSF in the
periphery of Nrg1 Het mice when inoculated with B16F0 melanoma cells. The
combined elevation of these two cytokines is likely to result in an impact on cells of the
myeloid linage despite the lack of findings in this model (2.4.3). More detailed study of
monocyte/macrophage and neutrophil subsets in these mice would elucidate any
relevant differences. The present results are consistent with the human study on a group
of families with a similar Nrg1 mutation and a higher burden of psychosis diagnoses
than the general population (Marballi et al., 2010). This suggests that the Nrg1 Het mice
likely represent an appropriate model for further study into immune responses that may
be linked to similar human Nrg1 mutations and potentially schizophrenia pathogenesis.
The following chapters will focus on the response of IL-6, G-CSF and their respective
signalling receptors in the brain of Nrg1 Het and WT mice with or without the B16F0
melanoma stimulus.
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A demonstration of neuroimmune interactions between the candidate
schizophrenia vulnerability gene Neuregulin 1, and peripheral and central
cytokine levels: focus on IL-6 and G-CSF

CHAPTER THREE
Interleukin 6 in the brain

Peta Snikeris
University of Wollongong

3.1

Interleukin 6 in the brain

IL-6 has multiple roles in the peripheral immune system and is also involved in a range
of brain functions, with production of the cytokine shown in both peripheral and central
cell types. IL-6 has a well-established role in the acute phase hepatic response and
induction of fever as well as differentiation and growth of haematopoietic stem cells, T
cells and B cells (Rose-John et al., 2007). IL-6 is also shown to be important in the CNS
beyond the induction of fever. This includes neurogenesis, synaptic plasticity and
neurodegeneration; as relevant for emotionality, cognition and cognitive dysfunction
(McAfoose and Baune, 2009; Yirmiya and Goshen, 2011). Primary production of IL-6
in the periphery comes from T cells and macrophages whereas central production is
primarily from microglia (Norris and Benveniste, 1993; Sallmann et al., 2000; Straub,
2006; Van Wagoner et al., 1999). While Banks et al (1994) further demonstrated that
IL-6 produced in the periphery can cross the blood-brain barrier (BBB) under basal
conditions. The level of IL-6 in the brain is however, not totally reliant on microglia or
peripheral production and BBB permeation. Neurons and astrocytes are also shown to
produce IL-6 and express IL-6 receptors in several schizophrenia-relevant brain areas,
including the PFC and hippocampus (Gadient and Otten, 1994; Jüttler et al., 2002;
McAfoose and Baune, 2009; Ringheim et al., 1998; Straub, 2006). With elevated levels
of plasma IL-6 found in the Nrg1 Het mice subjected to melanoma (Figure 2.3-3), the
following study investigated whether a similar IL-6 alteration would be reflected in the
brain.
3.1.1 IL-6 and the IL-6 signalling partners
IL-6 is an approximately 21-30kDa glycoprotein, which also exists in multimeric forms,
most commonly dimers of 45-85kDa (Cayphas et al., 1987; Hirano et al., 1985; May et
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al., 1991). IL-6 signalling is mediated by two receptor proteins: I) the ligand binding IL6 receptor known as the IL-6 receptor alpha (IL-6Rα) chain, which has no intrinsic
signalling capabilities; and II) the signal transduction molecule glycoprotein 130
(gp130), also known as the IL-6 signal transducer or the IL-6 receptor β chain.
Expression of mRNA in the brain for both IL-6 and IL-6Rα have been demonstrated by
in-situ in a regionally distinct manner, particularly evident in the hippocampus,
hypothalamus, cortex and cerebellum (Gadient and Otten, 1994; Ringheim et al., 1998).
The gp130 receptor is widely distributed in the CNS, with the distribution overlapping
those areas reported to express IL-6 and the IL-6Rα (Vallières and Rivest, 1997).
a)

Interleukin 6 receptor alpha

IL-6Rα is an 80kDa protein, found in both membrane bound (mIL-6Rα) and soluble
(sIL-6Rα) form. The IL-6Rα does not activate intracellular signalling cascades in either
form. The mIL-6Rα is mainly expressed on activated B cells, resting T cells,
neutrophils, monocytes/macrophages and hepatocytes (Knupfer and Preiss, 2008; RoseJohn et al., 2007). The mIL-6Rα is also expressed on neurons and glial cells (Gadient
and Otten, 1994; Mathieu et al., 2010). Soluble IL-6Rα is produced endogenously in the
human brain which suggests that the actions of IL-6 are not restricted by the localisation
of mIL-6Rα in the CNS (Ringheim et al., 1998).
b)

The gp130 receptor

The mature gp130 protein is 130kDa and is required for IL-6 signalling to occur and
gp130 is a common signalling molecule for several cytokines in the IL-6 family. The
membrane bound form is widely distributed in the CNS (Ringheim et al., 1998;
Simpson et al., 1997) and the gp130 molecule also exists in soluble form (sgp130)
(Jostock et al., 2001; Rose-John et al., 2006).
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3.1.2 The classic IL-6 signalling pathway, the trans-signalling pathway, and
mediation by soluble receptors
The gp130 receptor protein does not directly bind IL-6 or IL-6Rα alone, but rather binds
IL-6 only when in a complex with mIL-6Rα or sIL-6Rα. (Rose-John et al., 2006; Taga
et al., 1989). In the classic signalling pathway (Figure 3.1-1A) IL-6 binds to mIL-6Rα
and subsequently to mgp130 to initiate intracellular signalling (Knupfer and Preiss,
2008; Rose-John et al., 2007). The IL-6/sIL-6Rα complex is able to bind mgp130 on
cells lacking mIL-6Rα to initiate signalling, this is called trans-signalling (Figure 3.11B). Further, the sgp130 molecule is able to bind the IL-6/sIL-6Rα complex to
selectively inhibit signalling by competing for membrane receptor binding (Figure 3.11C) (Jostock et al., 2001; Rose-John et al., 2006).
With IL-6 signalling events reliant on the availability of membrane bound or the soluble
forms of IL-6Rα and gp130 to either enhance or inhibit the final signalling product, the
relative concentrations of sIL-6Rα, sgp130 and IL-6 determine their physiological
effects (Scheller et al., 2011; Simpson et al., 1997). Therefore we have measured IL-6
as well as the total and soluble forms of IL-6Rα and gp130
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Figure 3.1-1: The IL-6 signalling complex: classic signalling, trans-signalling and
selective soluble gp130 inhibition of signalling.
IL-6 signalling requires IL-6, the IL-6Rα and gp130 to form a complex in order to
initiate intracellular signalling. Classic signalling occurs when IL-6 complexes with
mIL-6Rα which then binds the gp130 receptor, initiating signalling (A). Transsignalling occurs when IL-6 complexes with sIL-6Rα and binds to gp130 on cells with
no available mIL-6Rα to initiate signalling (B). A soluble form of gp130 exists but
cannot bind IL-6 directly and thus does not inhibit signalling when mIL-6Rα is present;
however the sgp130 can bind the IL-6/ sIL-6Rα complex and inhibit signalling on cells
where mIL-6Rα is not present (C). Figure adapted from (Kallen, 2002; Rose-John et al.,
2006; Scheller et al., 2011).
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3.1.3 Summary
With increased peripheral IL-6 correlated with worse symptomatology, antipsychotic
use and medication resistance (Na and Kim, 2007; Singh et al., 2009; Zhang et al.,
2002, 2009) and the importance of the neurotransmitter systems influenced by IL-6 in
the symptomatology of schizophrenia, the levels of IL-6 in the brain may play an
important role in this illness. Combined with the earlier finding of elevated levels of IL6 in the Nrg1 Het mice subjected to an immune stimulus, the hypothesis that levels of
IL-6 and its signalling molecules in the brain of these mice could also be altered is
strengthened.
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3.2

Methods

3.2.1

Animal housing and breeding

Described in chapter 2 (2.2.1).
3.2.2

Genotyping and weaning

Described in chapter 2 (2.2.2)
3.2.3

B16F0 melanoma model

Described in chapter 2 (2.2.3). Nrg1 Het n=8, WT n=11.
3.2.4

Collection and dissection of brain tissue

Brain tissue was sampled immediately following euthanasia and cardiac puncture and
fresh brains were dissected into PFC and hippocampi straight away. Mouse brains were
dissected according to the mouse brain atlas (Paxinos and Franklin, 2001). Briefly, the
prefrontal cortex was dissected using the olfactory bulbs, interhemispheric fissure and
the corpus callosum along with visible colour differences in brain region tissue as
landmarks. The hippocampus can be clearly identified as a subcortical structure. Once
the prefrontal cortex was removed, the cerebellum and brain stem was removed and
brains were sectioned in the mid-sagittal plane. The thalamus, septum and underlying
structures were removed, leaving the hippocampus clearly visible and distinguishable
for removal from the cortex. This method has been used previously (Filiou et al., 2011,
2012). Several practice dissections were made to establish landmarks and locate
structural components before experimental tissue was collected.
Samples were snap frozen in liquid nitrogen before storage at -80oC. Before
experimental use, dissected brain tissue was approximately halved with one half used
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for protein analysis and one half used for mRNA experiments. The brain tissue was
weighed and randomly allocated to either a protein or mRNA buffer solution for
homogenisation immediately following weighing.
It is important to note that much has been written about the potential limitations of using
CO2 as a method of euthanasia when studying the brain. Studies into the CO2 method
that specifically considering effects on the analytes measured in these experiments were
not found however the current consensus is that there are limited recommendations for
alternate methods of euthanasia and therefore the benefits outweigh the possible
limitations (Angus et al., 2008; Conlee et al., 2005; Hawkins et al., 2006).
3.2.5

Protein analysis

a)

Protein isolation and storage

Dissected mouse brain tissue was weighed and homogenised in 9 volumes ice-cold
buffer containing 100µl protease inhibitor cocktail (Sigma), 100µl 50mM βGlycerophosphate (Sigma) and 33.3µl 0.3M Phenylmethylsulfonyl fluoride (Sigma)
made up in 9.8ml NP40 cell lysis buffer (Invitrogen) and briefly vortexed.
Homogenised tissue was maintained on dry ice while total protein concentrations were
determined for each sample using the DC assay kit (BioRad, Hercules, CA, USA)
(3.2.5b). Due to the limited weight of samples allocated for protein analysis, PFC
samples were pooled, with 2 animals from each group randomly pooled together to
create 4 pooled total protein samples per group.
b)

Protein quantification

Samples were quantified using the DC protein assay (BioRad) following manufacturers’
instructions. In brief, a standard curve was determined using a BSA dilution of 0, 200,
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400, 600, 800, 1000, 1200µg/ml. Using a 96 well flat bottom plate standard and sample
tubes were mixed then 5µl was added per well. Next 25µl reagent A’ (where A’ = 20µl
of reagent S into each 1ml of reagent A) was added and mixed gently by agitating plate
by hand. Then 200µl reagent B was added and mixed gently by agitating plate by hand.
All steps were performed at RT. All bubbles were removed and the plate was incubated
for 15min at RT. Results were obtained from SpectraMax 384 Plus (Molecular Devices)
plate reader (750nm) using a linear standard curve. The amount of protein used per
experimental protocol is listed in the appropriate methods section.
c)

Western blot

Western blotting was used to determine relative differences in the protein levels of IL-6,
IL-6Rα and gp130 in the PFC and the hippocampus. A total of 5µg of total protein per
well was used for both the PFC and the hippocampus for the three antibodies tested.
The number of samples was 8 per group for the hippocampus and due to tissue
limitations previously noted, the PFC experiments were conducted on 4 pooled samples
per group (3.2.5a)3.2.5b). Each sample was tested in triplicate.
Protein samples were mixed with XT sample and reducing buffers (Bio-Rad), as per
manufacturers’ instructions. Samples were heated to 95°C for 5min then cooled on ice
and briefly centrifuged to collect condensation. Proteins were electrophoresed in precast 4-12% bis-tris gels (Bio-Rad) (200V for 50min); in 1x electrode running buffer
(XT-MOPS, BioRad). Precision Plus Protein™ WesternC™ Standards (2µl) were run
alongside samples. Samples were then transferred on to a polyvinylidene fluoride
(PVDF) membrane (Bio-Rad) (100V, 1 hour) using 1x transfer buffer (150ml 10x
Tris/Glycine buffer, 300ml methanol, 1050ml dH2O, used ice cold). The MemCode™
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Reversible Protein Stain Kit – for PVDF Membranes (Pierce Biotechnology, Rockford,
IL, USA) was performed to confirm transfer of protein.
Membranes were blocked with 5% BSA or skim milk powder (BioRad) in TBS-Tween
(0.01%) for 1h at RT, based on previous optimisation testing. Membranes were blotted
with primary antibody diluted in 0.5% BSA or skim milk in TBS-Tween at 4°C
overnight on an orbital shaker. Membranes were washed 3 times with TBS-Tween at
5min intervals at RT, with agitation. Samples were then incubated with the specific
secondary antibody diluted in 0.5% BSA or skim milk powder in TBS-Tween with
agitation for 1h at RT. Secondary antibody was washed 3 times with TBS-Tween at
5min intervals at RT, with agitation. Primary and secondary antibodies were used as
detailed in Table 3.2-1
Membranes were developed in Amersham ECL™ Western Blotting Detection Reagents
(GE HealthCare, Buckinghamshire, UK). The membranes were then exposed to Kodak
BioMax films (Sigma) for up to 10min or captured on CCD Camera (Carestream, Gel
Logic 2200 PRO) depending on strength of immunoreactive signals. Developed films
(X-ray film processor; AGFA, CP1000, AGFA Healthcare, Rydalmere, NSW,
Australia) were scanned using a GS-690 Imaging Densitometer (Bio-Rad) and
quantified with Molecular Imaging Standard Edition software (v5.0.2.30, Carestream).
CCD images were quantified using Molecular Imaging Standard Edition software
(v5.0.2.30). The net intensity for each band was determined. A mouse anti-actin
antibody was used as an internal standard (#MAB1501, 1/50000; Millipore) and each
band quantified was normalised to the respective net intensity of the actin band. Data
points were checked for triplicate outliers (standard deviation greater than 30% of the
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mean) and individual data points removed. Triplicates (or duplicates where outliers
were removed) were then averaged across the repeats.
Membranes were stripped of antibody using a buffer of Glycine (1.88g) plus SDS (15g)
made up to 1 litre using distilled water (pH 2.0). Blots were incubated at RT in 10ml
buffer for 15min with agitation (x2) before being washed in TBS-Tween for 10min at
RT, with agitation. Following stripping, membranes were re-blocked and re-blotted with
primary and secondary antibodies as described above. A maximum of 3 blots per
membrane were performed.
Table 3.2-1: Antibodies for IL-6 and associated receptor western blots, including
secondary antibody and buffer details
Primary Antibody

Secondary Antibody

Rabbit polyclonal anti-IL-6
(H-183): sc-7920a (1/500)
Goat polyclonal anti-mouse
IL-6Rα (#AF1830) b (1/500)
Goat anti-mouse gp130
(#AF468) b (1/500)
Mouse anti-mouse actinc
(1/50,000)

Goat-anti-rabbit IgG-HRPb
(1/2500)
Donkey-anti-goat IgG-HRPb
(1/2500)
Donkey-anti-goat IgG-HRPb
(1/2500)
Donkey-anti-mouse IgG-HRPb
(1/2500)

Blocking
Buffer
(5% in TSBT)
Skim Milk

Incubation
Buffer (0.5%
in TBST)
Skim Milk

BSA

BSA

BSA

BSA

a) Santa Cruz Biotechnology Inc, b) R&D Systems Inc, c) Millipore, figure in ( ) is dilution factor

Membranes were developed then exposed to Kodak BioMax films for 10min (IL-6, IL6Rα) or captured on CCD Camera (gp130). Developed films were scanned using a GS690 Imaging Densitometer and quantified with Molecular Imaging Standard Edition
software. CCD images were quantified using Molecular Imaging Standard Edition
software.
Due to the consistent failure of one sample and insufficient protein to repeat the sample
in triplicate, all western blot results in the PFC for the Nrg1 Het unchallenged groups
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are based on n=3, the other PFC groups remain n=4. For a representative blot image, see
Appendix B.
d)

Luminex

Several analytes were measured using cytometric bead assays and flow cytometry.
Brain samples were analysed using a custom duplex mouse cytokine 96 well plate assay
kit to investigate sIL-6Rα and sgp130 receptor (MILLIPLEX®Map, Millipore, Billerica,
MA, USA). The number of samples was 8-11 per group for the hippocampus and due to
tissue limitations previously noted, the PFC experiments were conducted on n=4 pooled
samples per group. The assay was performed in accordance with the manufacturers’
protocol. Brain samples were homogenised as described above (3.2.5a) with 80µg total
protein per well. Protocol was followed as described in chapter 2 (2.2.6a) with the
following assay specific steps: Standards, controls and samples were loaded into 96 well
plates, with samples pseudo-randomly allocated to ensure even distribution of groups
across the plate. Homogenising buffer was added to standard and control wells followed
by the addition of cytokine assay beads to detect sIL-6Rα and sgp130 receptor. On day
two detection antibodies were incubated with samples in sealed plate for 1 hour with
agitation at RT. Streptavidin-PE was added to the detection antibodies and incubated a
further 30min with agitation at RT. The assay was then run on the Luminex 100 and
analysed as previously described (2.2.6a). Where duplicate results were below the limit
of detection or did not reach required bead count, the respective sample was removed
from analysis resulting in a reduced number of samples for sIL-6Rα and sgp130 for
statistical analysis (details in results sections 3.3.3. and 3.3.5 respectively).
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3.2.6

Gene expression analysis

a)

RNA extraction

Brain tissue RNA extraction was performed using the UltraClean Tissue and Cells RNA
Isolation Kit (spin columns) following manufacturers’ instructions (Mo Bio
Laboratories Inc, CA, USA). In brief, tissue was homogenized using an RNase free
micro pestle in 600µl TR1 buffer plus Beta-Mercaptoethanol (10µl per 1ml TR1,
prepared immediately before use) in an RNase free tube, followed by passing through a
20 gauge RNase free needle at least 10 times. One volume (600µl) of solution TR2 was
added to the homogenate and mixed with a pipette. 600µl of the homogenate mix was
transferred to the spin filter in a fresh tube then centrifuged 1min at 10,000 x g. The
flow through was discarded and the above steps repeated with the second 600µl volume.
The spin filter was then washed with 500µl of solution TR3 by the same centrifugation
step and transferred to a fresh tube. A second wash was performed by adding 500µl
solution TR4 to spin column, centrifugation of 1min at 10,000 x g followed by
discarding flow through and repeating TR4 wash. Following second TR4 wash and
removal of flow through, the spin column membrane was dried by 2min centrifugation
at 13,000 x g. The spin column was then transferred to a new collection tube before 3050µl of RNase free water was added to column, incubated for 1min at RT then
centrifuged for 1min at 10,000 x g to elute isolated RNA. All steps were performed at
room temperature with final RNA solution stored at -80oC until use. RNA concentration
and quality was quantified using the NanoDrop (Thermo Scientific) and accepted for
use with: A260/280 ratio > 1.9 and A230/260 ratio > 2.0. Additional purification of
extracted RNA was performed where required using ethanol precipitation as described
in chapter 2 (2.2.7a).
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b)

cDNA synthesis

The RT2 First Strand Kit was used to make copy DNA (cDNA) from brain tissue
following the manufacturer’s instruction using 280ng RNA from the pooled PFC
samples, or 550ng RNA from hippocampus samples per reaction, total reaction volume
20µl (SA Biosciences, MD, USA). An initial genomic DNA elimination step was
performed using the included genomic DNA elimination mixture with up to 8µl isolated
RNA (for 280ng PFC RNA or 550ng hippocampal RNA), 2µl GE (a 5x gDNA
elimination buffer provided with kit) and RNase free water to a final volume of 10µl.
The contents were gently mixed with a pipette followed by brief centrifugation. The
mixture was then incubated at 42ºC for 5min then immediately chilled on ice for >1min.
To synthesise cDNA, 10µl of RT Cocktail per manufacturers’ instructions was added to
each 10µl genomic DNA elimination mixture and mixed gently but thoroughly with a
pipette. The mixture was then incubated at 42ºC for 15min followed by heating at 95ºC
for 5min to stop the reaction (Mastercycler Pro S, Eppendorf). Finally 91µl of RNase
free water was added to each reaction mix and the diluted product stored at -80oC until
further use. The resulting cDNA was used for determination of reference genes, the
PCR array plate and individual taqman assays performed on brain tissue.
c)

Determination of reference genes

Since brain tissue from the PFC and Hippocampi of Nrg1 mice treated with melanoma
had not, to our knowledge, previously been performed, we determined appropriate RTqPCR reference genes empirically. The geNorm Plus reference gene selection kit
(PrimerDesign Ltd, Southampton, UK) was used to determine the most appropriate
reference genes from a set of 6 PrimerDesign genes that are most likely stably expressed
(Csnk2a2, Cdc40, UBC, Pak1ip1, Fbxw2 and Ap3d1). As per manufacturer’s
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instructions, a total of 16 samples were tested for reference genes, 2 samples per
experimental group (4) per region (2) plus controls. In brief, primers provided were
resuspended in 220µl of RNase/DNase free water then vortexed thoroughly and used
immediately. Primers were added to SYBR Green master mix (FastStart, Roche, Basel,
Switzerland) as per manufacturer’s instructions before pipetting into 96 well plates. The
cDNA template was then added to each primer mix in duplicate, including a no template
control before running on the Roche LightCycler 480 II (Table 3.2-2 Thermal cycling
parameters: geNorm). Data analysis was performed using the qBase Plus software
provided with the geNorm kit. Reference gene details were added to the software
module before import of LightCycler data was performed according to instructions. All
annotations for plate and sample details were checked upon import for final well
annotation including sample name, target gene and CT value with sample type
“unknown” selected. Data was automatically analysed using the qBase Plus geNorm
software module with results generated in graph and written form (Appendix A). The
reference genes chosen for use in RT-qPCR experiments for brain tissue obtained under
the specific experimental conditions of this study were Ap3d1 and Fbxw2.
Table 3.2-2 Thermal cycling parameters: geNorm
Step
Enzyme activation
Denaturation
Data Collection
d)

Temperature (°C)
95
95
60

Time (min:sec)
10:00
0:15
0:60

Cycles
1
50

Array based RT-qPCR

A customised RT2 Profiler PCR Array Kit (SA Biosciences) based on SYBR green
chemistry (FastStart, Roche) was utilised to measure cytokine gene expression in brain
tissue following the manufacturers’ instructions. In brief, sample cDNA was added to
the RT2 qPCR master mix and pipetted into the PCR array plate provided in the kit as
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required for each gene location. The PCR was performed on the Roche LightCycler 480
II (Table 3.2-3 Thermal cycling parameters: RT2 profiler PCR array) with CT values
determined using the second derivative maximum built in software calculation.
Table 3.2-3 Thermal cycling parameters: RT2 profiler PCR array
Step
Temperature (°C) Time (min:sec)
Cycles
PCR initial heat activation
95
10:00
1
Denaturation
95
0:15
45
Combined Annealing/ extension 60
1:00
Fluorescent data collection performed at the combined annealing/ extension step
Data was further analysed using web-based PCR ARRAY Data Analysis Software (SA
Biosciences) as well as using the delta delta CT method (Livak and Schmittgen, 2001)
and SPSS statistical analysis. The genes included on the custom array plate for IL-6related analyses were IL6, IL6ra and IL6st, with Fbxw2 and Ap3d1 as reference genes
with a positive control, reverse transcription control and mouse genomic DNA control
included. Each experiment represents 3-4 biological samples tested in triplicate. Note
that the IL-6 primers provided on the custom array plate were unable to detect mRNA
expression within the control parameters. The RT-qPCR was therefore repeated using
cDNA synthesised from the same tissue using a Taqman IL-6 individual gene
expression assay described below.
e)

Individual gene expression analysis

Following cDNA synthesis (2.2.7b), the QuantiFast Probe RT-PCR Kit (Qiagen) was
used per manufacturers’ instructions to measure relative mRNA levels of IL-6. In brief,
5µl 2x QuantiFast Probe PCR master mix, 0.4µM primer (forward and reverse), 0.2µM
probe and diluted cDNA template up to a total sample reaction mix of 10µl were gently
mixed and pipette into a 96 well place. All preparation steps were completed at RT.
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The individual IL-6 taqman primer/probe assay was purchased off the shelf from
Applied Biosystems. RT-qPCR as performed on a LightCycler 480 II using the second
derivative maximum method to determine CT values (Roche) with the cycling
conditions detailed in Table 3.2-4.
Table 3.2-4 Thermal cycling parameters: Taqman brain tissue
Step
Temperature (°C) Time (min:sec) Cycles
PCR initial heat activation
95
3:00
1
Denaturation
95
0:03
45
Combined Annealing/ extension
60
0:30
Fluorescent data collection performed at the combined annealing/ extension step
Results are presented as fold change in expression levels (Livak and Schmittgen, 2001;
Schmittgen and Livak, 2008) with untreated WT expression levels normalised to 1 ±
SEM with other values presented as comparison fold change.
3.2.7

Statistics

After confirming normal distribution with the Kolmogorov-Smirnov test, 3-way
ANOVA was used to analyse western blot protein levels (factors: brain region x
genotype x immune challenge) followed by two-tailed independent samples t-tests to
further explore differences between experimental groups. The 3-way ANOVA was used
to elicit potential novel findings in this exploratory series of experiments. To ensure the
data was appropriately robust, 2-way ANOVA (genotype x immune challenge) was also
conducted on the brain regions separately. Main effects and interactions were consistent
with those found in the 3-way ANOVA, therefore this data is not shown. RT-qPCR
results were analysed using a 2-way ANOVA (factors: genotype x immune challenge)
using two-tailed independent samples t-tests to further explore results. Due to different
starting amounts of mRNA from the PFC and the hippocampus, direct regional
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comparisons were not performed. Pearson’s correlation coefficient was used to
determine the strength of the relationship between the 46kDa and the 29kDa IL-6 band
detected in western blots. Significance was set at p<0.05. All p-values are reported as
uncorrected values.
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3.3

Results

3.3.1

Interleukin-6 protein is lower in the prefrontal cortex but not the
hippocampus of immune challenged Nrg1 Het mice

IL-6 was measured in the PFC and the hippocampus using western blot and RT-qPCR.
IL-6 expression levels were not detected using the custom PCR array, therefore an
additional individual taqman assay was performed for IL-6 only using the same cDNA
template. IL-6 was detected using the individual taqman assay in both the PFC and the
hippocampus however no differences were found in mRNA expression levels in either
region (see Table 4.3-1)
Western blot bands were observed at approximately 29kDa and 46kDa representing
monomeric and dimeric IL-6 (May et al., 1991), for a representative blot image, see
Appendix B.. The levels of protein present in these two bands were correlated
(Pearson’s R=0.915, n=47, p<0.001) with the dimer approximately 4x more abundant
(arbitrary units of relative net intensity) using anti-actin as a loading control (Figure 3.31). The correlation is also present by region: PFC Pearson’s R = 0.966 (n=15, p<0.001)
and hippocampus Pearson’s R = 0.624 (n=32, p<0.001) (region scatterplots not shown).
Table 3.3-1: Interleukin 6 mRNA expression levels in the PFC and hippocampus of
Nrg1 Het and WT mice with or without an immune stimulus.
Control

Immune challenged

WT

Nrg1 Het

WT

Nrg1 Het

Prefrontal cortex

1.00 ±0.24

1.13 ±0.31

0.91 ±0.07

1.45 ±0.43

Hippocampus

1.00 ±0.40

1.16 ±0.38

0.58 ±0.08

0.73 ±0.24

Data represent mean fold change ± SEM, n=3 pooled samples per group (PFC), n=4 per group (Hipp).
WT expression levels normalised to 1 and fold change for other groups calculated as a comparison.
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Figure 3.3-1: Correlation of the IL-6 dimer and monomer bands detected by western
blot.
Both a ~29kDa band and a ~46kDa were detected by western blot using the Rabbit
polyclonal anti-IL-6 (H-183): sc-7920 (Santa Cruz). Quantification and analysis of both
bands determined that they were correlated (Pearson’s R=0.915, p<0.001). Bands are
discussed as an IL-6 monomer (~29kDa) and dimer (~46kDa) (May et al., 1991).
An interaction between region, genotype and immune challenge was found using a 3way ANOVA (dimer F1,45=10.76, p=0.002; monomer: F1,45=8.01, p=0.007), as well as a
genotype x immune challenge interaction (dimer: F1,45=11.18, p=0.002; monomer:
F1,45=11.47, p=0.002). The IL-6 dimer showed an immune challenge x region
interaction (F1,45=12.91, p=0.001), whilst the monomer had a trend toward interaction
(F1,45=3.65, p=0.064).
Both the dimer and the monomer showed a main effect of region (dimer: F1,45=29.70,
p<0.001; monomer: F1,45=51.00, p=0<001). A main effect was also seen for immune
challenge in the IL-6 dimer (F1,45=14.83, p<0.001) and the monomer (F1,45=9.01,
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p=0.005) bands. Genotype alone did not show any main effect, and no specific genotype
x region interaction was seen.
Differences between groups within each region were then analysed using independent
samples t-tests. Nrg1 Het mice were found to have between 52% (dimer) and 67%
(monomer) less IL-6 in the PFC when subject to immune challenge compared to the
unchallenged Nrg1 Het group (dimer: p=0.014; monomer: p=0.018). Although there
appears to be a tendency towards increased levels of IL-6 in unchallenged Nrg1 Het in
the PFC when compared to unchallenged WT mice, this was not statistically significant
(dimer: p=0.093; monomer: p=0.091). No change due to the immune challenge was
found for the WT groups in the PFC and no differences were seen in the hippocampus
between any of the experimental groups (Figure 3.3-2).
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Figure 3.3-2: Lower IL-6 levels in the PFC of Nrg1 Het mice subject to an immune
stimulus.
IL-6 protein levels were lower in the PFC of Nrg1 Het challenged animal when
compared to Nrg1 Het unchallenged mice but not in the hippocampus. IL-6 protein
levels in the PFC (left panel) and the hippocampus (right panel) where (a) is the relative
net intensity, of the normalised IL-6 dimer and (b) is the IL-6 monomer in immune
challenged and unchallenged Nrg1 Het and WT mice. Data represents western blot
protocol: membranes were probed with anti-IL-6 antibody, stripped then re-probed with
an anti-actin loading control and analysed using Molecular Imaging Standard Edition
software (v5.0.2.30, Carestream). PFC n=4 (except Nrg1 Het unchallenged: n=3),
hippocampus n=8 per group. *p<0.05 (mean ± SEM)
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3.3.2

Elevated levels of total IL-6Rα in the prefrontal cortex of immune
challenged Nrg1 Het mice compared with WT littermates

Total IL-6Rα was measured in brain lysate using western blot. A band was observed at
approximately 73kDa and this band was analysed, for a representative blot image, see
Appendix B. A main effect of region was shown using 3-way ANOVA (F1,45=5.67,
p=0.022). No other main effects or interactions were found. Using independent samples
t-tests to compare experimental groups within each region, the Nrg1 Het mice had 23%
higher levels of IL-6Rα in the PFC when subject to immune challenge compared to the
WT immune challenged mice (p=0.001). No other differences were found between the
groups in the PFC or the hippocampus (Figure 3.3-3a). The mRNA expression levels in
the PFC of Nrg1 Het mice with the immune challenge was elevated compared to
challenged WT mice (independent samples t-test; p=0.034; Figure 3.3-3b).
3.3.3

Soluble IL-6Rα has regional differences between the prefrontal cortex
and hippocampus but was not altered by genotype or immune challenge

As the soluble form of the IL-6Rα can further enhance IL-6 signalling, the soluble form
was measured with bead based flow cytometry using Luminex and is presented as pg/µg
total protein. Several duplicate results were below the limit of detection or did not reach
required bead count for analysis. These samples were removed from analysis resulting
in: WT unchallenged n=4 (PFC), n=7 (hipp); Nrg1 Het unchallenged n=3 (PFC), n=6
(hipp); WT challenged n=4 (PFC), n=10 (hipp); Nrg1 Het challenged n=3 (PFC), n=8
(hipp).
A 3-way ANOVA (genotype x treatment x region) showed a main effect of region
(F1,42=72.47, p<0.001) with no other effects or interactions (Figure 3.3-3c).
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Figure 3.3-3: Elevated total, not sIL-6Rα protein levels and elevated mRNA expression
in the PFC of Nrg1 Het mice subject to an immune stimulus.
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Figure 3.3-3 legend continued from previous page:
Total IL-6Rα protein was higher in the PFC (left panel) of Nrg1 Het immune challenged
mice compared to WT challenged controls (a) measured by relative net intensity of the
normalised 73kDa band where membrane was probed with anti- IL-6Rα antibody and
anti-actin loading control then analysed using Molecular Imaging Standard Edition
software. Nrg1 Het immune challenged mice also demonstrated higher levels of mRNA
expression in the PFC (left panel) but not the hippocampus (right panel) (b) measured as
relative fold change in mRNA expression using RT-qPCR, sIL-6Rα levels measured by
Luminex flow cytometry analysis show no difference between genotypes with or
without immune challenge in either brain region(c). PFC n=3-4, hippocampus n=6-9 per
group. **p<0.01 (mean ± SEM).
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3.3.4

Total gp130 receptor protein demonstrated interactions between region,
genotype and immune challenge in Nrg1 Het mice

Total gp130 was measured using western blot. A band was observed at approximately
130kDa and analysed using relative net intensity and anti-actin as the loading control,
for a representative blot image, see Appendix B. An interaction between region,
genotype and immune challenge was found using a 3-way ANOVA (F1,45=4.57,
p=0.039), as well as a region x immune challenge interaction (F1,45=6.15, p=0.018). A
main effect of region (F1,45=81.88, p<0.001) and immune challenge (F1,45=6.44,
p<0.015) were also seen. No differences were found between groups using independent
samples t-tests (Figure 3.3-4). No differences in mRNA expression levels were found
using RT-qPCR.
3.3.5

Nrg1 Het mice have a lower levels of soluble gp130 in the hippocampus
with an immune challenge

Since relative increases in the level of sgp130 can inhibit IL-6 signalling, the soluble
form was measured separately with bead based flow cytometry using Luminex and is
presented as pg/µg total protein. Several duplicate results were below the limit of
detection or did not reach required bead count thus the respective sample was removed
from analysis. Final experimental groups consisted of: WT unchallenged n=4, n=6
(hipp); Nrg1 Het unchallenged n=3 (PFC), n=6 (hipp); WT challenged n=4 (PFC), n=11
(hipp); and Nrg1 Het challenged n=3 (PFC), n=8 (hipp) for statistical analysis.
A 3-way ANOVA for sgp130 revealed a main effect of region (F1,35=328.89, p<0.001)
with no other effects or interactions, although there was a slight trend towards a region
x immune challenge interaction (F1,35=3.04, p=0.092). Further independent t-tests
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revealed decreases in the levels of sgp130 in the hippocampus only. WT challenged
mice had 55% lower sgp130 levels compared to the WT unchallenged (p=0.007) while
the Nrg1 Het challenged animals also showed 63% lower levels of sgp130 when
compared to the Nrg1 Het unchallenged groups (p=0.002). Additionally, the Nrg1
unchallenged animals displayed a trend towards 38% lower levels of sgp130 when
compared with the unchallenged WT group (p=0.077) and the Nrg1 immune challenged
mice displayed a similar trend for 48% lower sgp130 levels compared to their tumour
challenged WT littermates (p=0.055). No differences were found in the PFC (Figure
3.3-4).
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Figure 3.3-4: Soluble but not total gp130 levels were reduced in the hippocampus of
unchallenged Nrg1 Het and WT mice with an immune stimulus.
Additionally, both Nrg1 unchallenged and immune challenged mice had a tendency
towards reduced sgp130 when compared with their WT counterparts. Total gp130
protein levels in the PFC (left panel) and the hippocampus (right panel). Although a 3way ANOVA revealed an interaction between region, genotype and immune challenge
(F1,45=4.57, p=0.039), independent samples t-tests did not demonstrate any difference
between groups in either the PFC or the hippocampus (a) measured using western blot, ,
relative net intensity, reflecting the normalised 130kDa band. Flow cytometry analysis
for sgp130 showed both WT and Nrg1 Het challenged mice had lower levels of protein
than the respective unchallenged groups (b) using Luminex (pg/µg). Data represent
mean ± SEM. PFC n=3-4, hippocampus n=8-11 (western blot); n=5-7 (Luminex) per
group **p<0.01 #p=0.077, ##p=0.055
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3.4

Discussion

3.4.1 IL-6 and IL-6 receptor molecules were found altered in Nrg1 Het mice
when combined with an immune stimulus
With the finding of higher circulating plasma IL-6 in Nrg1 Het mice with an immune
stimulus, we investigated whether these changes were similar in the brain. Alterations in
Il-6 or the IL-6 signalling molecules were found in both brain regions studied;
differences were also seen in the level of these molecules in the PFC and the
hippocampus, while alterations in response to the immune stimulus varied between the
two regions. The PFC had approximately 60% lower IL-6 levels in Nrg1 Het immune
challenged compared to Nrg1 Het unchallenged mice. While total IL-6Rα protein and
mRNA expression was 23% higher in the PFC of Nrg1 Het immune challenged mice
compared to challenged WT mice, the sIL-6Rα did not vary. In the hippocampus, no
corresponding changes were found in IL-6, total or sIL-6Rα; however sgp130 was 55%
lower in the WT challenged and 63% lower in the Nrg1 Het immune challenged groups
compared to their respective unchallenged controls.
3.4.2 IL-6 protein levels were lower while mRNA expression is unchanged in the
prefrontal cortex of Nrg1 Het immune challenged mice
Previous studies demonstrated IL-6 is able to cross the BBB (Banks et al., 2009). We
therefore anticipated that central IL-6 levels in the Nrg1 Het mice would be higher in
the PFC and the hippocampus in animals subject to the immune stimulus, corresponding
to elevated circulating plasma levels. However, the PFC demonstrated approximately
60% lower levels of IL-6 protein (Figure 3.3-2) in these mice with no change in mRNA
expression levels (Table 3.3-1), while the hippocampus had no change in protein or
mRNA (Figure 3.3-2; Table 3.3-1). This finding is consistent with the results of
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Desbonnet (2012) where a chronic social defeat paradigm increased spleen IL-6 levels
in Nrg1 Het mice with no corresponding increase in IL-6 in the PFC or hippocampus.
Transport of IL-6 into the brain occurs via saturable transporters and has been shown to
result in degradation of the intact form of IL-6 (Banks et al., 1994, 2009). This suggests
that the transport across the BBB is physiologically limited and may potentiate central
responses, rather than as a boost to the central response itself, this however requires
further investigation.
Fillman et al (2013) found elevated expression of IL-6 mRNA in the dorsolateral PFC
of post-mortem schizophrenia patients. However the authors were unable to replicate
their data in a subsequent study, finding only a pattern suggesting elevated IL-6 mRNA
expression in schizophrenia patients (Fillman et al., 2014). Additionally, mRNA levels
for IL-6 in Nrg1 Het mice were unchanged in the PFC or the hippocampus at baseline
or following a chronic stress paradigm (Desbonnet et al., 2012), consistent with the
mRNA findings in the present study (Table 3.3-1).
Previous studies in yeast and human liver have shown that there is insufficient
correlation between mRNA levels and protein levels to predict protein abundance
directly from gene expression data and demonstrating that post-transcriptional
regulation is present in various species (Anderson and Seilhamer, 1997; Gygi et al.,
1999). This suggests that mRNA is not an accurate predictor of protein levels, with
post-transcriptional modification mechanisms the likely effectors of differences seen
between mRNA expression and protein levels.
With unchanged IL-6 gene expression and lower protein levels in the Nrg1 Het mice,
production or degradation of IL-6 would appear to be affected by a Nrg1 mutation.
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Although not yet well characterised, IL-6 has been shown vulnerable to posttranscriptional regulation, with molecules that can both stabilise and destabilise the
transcription product (Iwasaki et al., 2011; Masuda et al., 2013; Matsushita et al., 2009).
Although these modulators of IL-6 mRNA stability have not been shown directly linked
to Nrg1, a mutation in Nrg1 has the potential to indirectly alter IL-6 post-translational
stability. For example, degradation of the Regnase-1 protein results in increased IL-6
stability through activation of the Nuclear Factor Kappa B (NFκB) (Iwasaki et al.,
2011). Nrg1 was shown to activate the NFκB pathway in schwann cells (Limpert and
Carter, 2010). It is therefore plausible that a mutation in Nrg1 as seen in the Nrg1 Het
mice could reduce the activation of the NFκB pathway, resulting in higher IL-6
transcript instability. These potential post-transcriptional modifications are also likely to
be differentially regulated in the periphery and across brain regions as higher circulating
levels of IL-6 were seen in plasma, lower protein levels in the PFC and unchanged
levels in the hippocampus of the Nrg1 Het mice. With limited data available on IL-6
levels in the brain of schizophrenia patients and with mRNA expression studies
showing conflicting data (Fillman et al., 2013, 2014) little can be speculated on the
possible mechanism resulting in reduced IL-6 in the PFC of the Nrg1 Het mice.
It is important to note for IL-6 and its signalling proteins that results in the PFC should
be interpreted with care. Due to the compromise between the amount of tissue needed,
the number of analytes investigated and the restricted number of experimental animals
available, along with the relatively small size of the PFC in mice, the sample size for
this region is small. With a low sample number, significant interactions may not be
evident in ANOVA analysis. In an attempt to overcome this limitation, the independent
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student t-tests were used. It will be important to confirm all observations from the PFC
in repeat studies.
3.4.3 Total but not soluble IL-6Rα levels were increased in the prefrontal cortex
of Nrg1 Het immune challenged mice
The IL-6Rα was investigated to provide a more complete picture of the overall potential
for IL-6 signalling to be up- or down-regulated in the Nrg1 Het mice. Total IL-6Rα
protein levels in the PFC were 23% higher in the Nrg1 Het immune challenged mice,
compared to WT challenged animals, with mRNA expression levels similarly elevated.
Further, an increase in sIL-6Rα would suggest widespread enhanced IL-6 signalling
ability in the Nrg1 Het mice; however with no change in the soluble form of the
receptor in the PFC the increase in total protein is most likely the membrane bound
form (Figure 3.3-3). Lower histamine induced IL-6 levels have been shown combined
with elevated IL-6 receptor expression in liver cells of histamine deficient mice,
demonstrating that an inverse relationship between IL-6 and the IL-6 receptor exists
(Horváth et al., 2002). Although these findings in liver cells are consistent with the
findings in this study, specific studies showing the relationship between IL-6 and the
IL-6 receptor levels in the brain were not found, indicating that additional studies are
warranted to confirm whether this inverse relationship seen in the Nrg1 Het mice is an
exaggeration of a normal compensatory response.
3.4.4 The hippocampus demonstrated reduced levels of soluble gp130 in both
Nrg1 Het and WT mice subject to the melanoma challenge
To complete the picture of IL-6 and IL-6 signalling partners, total and sgp130 were
investigated in the PFC and the hippocampus. When considering the total levels of
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gp130, the graphical representation gives the impression of a tendency towards increase
in total gp130 in the PFC and possible interactions were indicated by the ANOVA
analysis (4.3.4; Left panel, Figure 4.3.4a), however further analysis using student t-test
did not show any alterations in protein levels by group. The mRNA expression levels
for gp130 in the PFC were also unchanged. Further, there was no difference in the total
gp130 protein or mRNA expression in the hippocampus. This lack of difference in total
gp130 contrasts with the increased levels of IL-6Rα seen in the PFC, where the
expectation was that the two receptors would be regulated in parallel (Falus et al.,
1992). However different tissue types have demonstrated differential regulation of these
two receptors (Nesbitt and Fuller, 1992). In particular, the expression of mRNA
transcripts for these IL-6 receptors has shown regional specificity in response to an LPS
immune stimulus (Vallières and Rivest, 1997). These differences could result from the
small sample size but may yet represent a physiologically relevant difference; additional
experiments would be required to confirm this.
Soluble gp130 was also investigated. In the hippocampus lower levels of sgp130 were
found in both WT and Nrg1 Het immune challenged animals. The WT mice had 55%
lower sgp130 in the hippocampus when subject to the immune stimulus compared to
unstimulated WT mice. The Nrg1 Het mice showed a 63% lower level in animals
subject to the immune stimulus compared to unstimulated Nrg1 Het mice. In addition, it
can been seen that there is a trend toward lower levels in the Nrg1 Het mice when
compared to WT both in the unchallenged and the immune challenged groups in the
hippocampus (Right panel, Figure 3.3-4b). As sgp130 is a powerful inhibitor of IL6/sIL-6Rα trans-signalling (Jostock et al., 2001), reduced levels of this protein in the
immune challenged animals suggests a removal of signalling inhibition. With no other
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changes in the IL-6 signalling molecules in the hippocampus, it is difficult to speculate
on why inhibition would need to be reduced in this case. As gp130 is an obligate
receptor for a number of other cytokines from the IL-6 family which were not
measured, and sgp130 has been shown to partially inhibit the activities of these other
cytokines (Jostock et al., 2001), it is possible that this alteration is not related to the IL-6
changes.
3.4.5 Regional differences and hippocampal finding limitations
Finally, each of the molecules demonstrated a main effect of region using 3-way
ANOVA analysis, suggesting different levels of IL-6 and the IL-6 signalling proteins
between the PFC and the hippocampus. Differential regulation of IL-6 and its signalling
molecules in response to an immune challenge is consistent with previous in situ mRNA
expression findings following an LPS stimulus (Vallières and Rivest, 1997). IL-6
mRNA was not detected in the basal state, but increased expression was seen in a
number of brain regions following an acute immune stimulus. The receptors (IL-6Rα
and gp130) were constitutively expressed in the basal state, and also selectively
increased in specific brain regions following the LPS challenge. The increases in
mRNA expression were not consistent in all brain regions or across all three analytes
(Vallières and Rivest, 1997). Further, with the higher levels of plasma IL-6, lower levels
in the PFC and unchanged levels in the hippocampus of the Nrg1 Het challenged mice
found in this study, protein levels within the different brain regions may not be reliant
on BBB cross over. The possible differential regulation of each analyte within specific
brain regions is likely to be more important in the central response to immune stimuli,
particularly in the Nrg1 Het mice. However the need to pool the PFC samples to obtain
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enough protein for analysis makes this comparison difficult to interpret without further
studies.
The findings in the hippocampus for these studies may also be obscured because of
random allocation of hippocampal dissections to protein or mRNA studies. Differences
in brain symmetry have been shown previously, in particular, lateralisation of the
hippocampus. Neuron size and shape within subregions of the hippocampus, as well as
the volume and symmetry of the left and right hippocampus are altered in schizophrenia
patients (Zaidel et al., 1997a, 1997b). An improved experimental design using
hippocampi dissected into left and right as well as dorsal and ventral segments or
histological examination of the CA regions may reveal details obscured here by the
random assignment of portions of the whole hippocampus from each individual animal.
3.4.6 Conclusion
IL-6 and the IL-6 signalling molecules are altered in the brain of Nrg1 Het mice
subjected to a melanoma immune stimulus; although interestingly the alterations are not
consistent in the two brain regions studied. Additionally, the increase in plasma IL-6
seen in the periphery was not reflected in either brain region, with PFC levels lower in
the Nrg1 Het mice and hippocampal levels unchanged. Together these data suggest that
IL-6 and its cognate receptors are differentially regulated in the PFC and the
hippocampus with central levels of IL-6 not a simple reflection of peripheral levels.
Furthermore, with mRNA expression levels inaccurate predictors of protein levels,
measurement of both in exploratory studies such as this one, provide a broader
understanding of potential influences requiring further study. It is worth reiterating that
there are several limitations to these data, including low sample numbers for the PFC
and a lack of insight into hippocampal lateralisation or details of hippocampal subregion
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responses. Despite the limitations, these data provided the first evidence of
approximately 60% lower IL-6 protein levels in conjunction with a 23% elevation in IL6Rα in the PFC of Nrg1 Het mice subject to a peripheral immune stimulus. This study
also demonstrated a novel 55-63% reduction in sgp130 protein in the hippocampus of
mice subject to an immune stimulus, which was consistent in both genotypes. These
data therefore confirm a role for IL-6 in the dysregulation of the immune response to a
direct immune stimulus in the Nrg1 Het mice. This role for IL-6 is shown to be not only
a disruption in the peripheral immune response, but also an aberration in the central
response. Further; the importance of considering not only cytokines but likewise
measuring their signalling receptors is demonstrated by the changes seen in IL-6Rα and
sgp130.

Peta Snikeris

100

A demonstration of neuroimmune interactions between the candidate
schizophrenia vulnerability gene Neuregulin 1, and peripheral and central
cytokine levels: focus on IL-6 and G-CSF

CHAPTER FOUR

Granulocyte-colony stimulating factor in the
brain

Peta Snikeris
University of Wollongong

4.1

Granulocyte-colony stimulating factor in the brain

G-CSF is a haematopoietic growth factor with a well-defined role in the proliferation of
cells of the myeloid linage. As discussed earlier (2.4.2), the maturation and release of
peripheral neutrophils during inflammation is stimulated by G-CSF and a lack of GCSF results in neutropenia. G-CSF has also been shown to influence a range of brain
functions, where a deficiency in the brain results in reduced motor skill learning,
impaired spatial memory formation, reduced short term recognition memory and
impaired long term memory in G-CSF knockout mice (Diederich et al., 2009a).
Recombinant G-CSF has been used in schizophrenia patients as a treatment for antipsychotic induced neutropenia, with G-CSF also demonstrating anti-apoptotic
characteristics in cells of the myeloid lineage (Fukunaga et al., 1991; Nagata and
Fukunaga, 1991; Schneider et al., 2005a, 2005b). Although G-CSF levels have been
studied in schizophrenia patients, these studies are limited in number and scope, with
alterations in circulating plasma levels of G-CSF not consistent.
4.1.1 G-CSF structure, function and expression
G-CSF is a 19kDa glycoprotein produced by several peripheral cell-types with
differentially regulated expression dependent on cell type or stimulus (Fukunaga et al.,
1991; Nagata and Fukunaga, 1991; Schneider et al., 2005b). G-CSF is produced by
bone marrow stromal cells and macrophages when stimulated by endotoxins, as well as
by fibroblasts or endothelial cells when stimulated with TNFα or IL-1. LPS and several
additional cytokines have also been shown to induce peripheral macrophage production
of G-CSF (Li et al., 2009d). LPS significantly induces G-CSF in peripheral blood
mononuclear cells and bone marrow stromal cells. In peripheral blood mononuclear
cells, LPS stimulation induces G-CSF production via IL-1. IL-6 however, inhibits GPeta Snikeris
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CSF production in peripheral blood mononuclear cells. In bone marrow stromal cells,
G-CSF production is also stimulated by IL-1 but is not affected by IL-6 (Hannen et al.,
1999).
G-CSF expression has also been shown in neurons throughout all brain regions,
including expression in the frontal cortex as well as in the hippocampus (Schneider et
al., 2005a). Schneider et al (2005a) further demonstrated that G-CSF results in the
differentiation of neuronal stem cells both in vitro and in vivo. Astrocyte cultures have
been found to express G-CSF, dependent upon surrounding conditions, including
culture medium in vitro or disease states in vivo (Li et al., 2009d; Schneider et al.,
2005a; Xiao et al., 2007). While the role of microglia in the expression of both G-CSF
and its receptor is yet to be confirmed (Xiao et al., 2007). Additionally, it has been
demonstrated that G-CSF can pass through the intact BBB from the blood to the brain
(Schneider et al., 2005a; Zhao et al., 2007). With G-CSF able to cross the BBB and be
produced in the brain, as well as neuronal responses to G-CSF shown, the previous
finding of higher levels of circulating plasma G-CSF in Nrg1 Het mice with a
stimulated immune system suggested that the brain, particularly the PFC and the
hippocampus, may reflect a similar alteration to that seen in the periphery.
4.1.2 G-CSF receptor structure, function and expression
G-CSF signals through the G-CSF receptor (G-CSFR, also known as CD114) which
displays similarity with many cytokine receptor extracellular regions. In addition the GCSFR shares homology with gp130, the IL-6 family receptor subunit that produces
receptor signalling, but does not show homology with the IL-6Rα chain. However, other
cytokines including IL-6 have not been seen to compete for binding to the G-CSFR.
Equally, in spite of the receptor homology, gp130 does not bind G-CSF (Nagata and
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Fukunaga, 1991). Studies first suggested that the G-CSFR was restricted to cells of
neutrophilic granulocyte lineage in bone marrow and spleen, however it has since been
found on monocytes, platelets and endothelial cells (Schneider et al., 2005b). Further,
expression of the G-CSFR occurs in dopaminergic neurons in the adult brain and cell
cultures (reviewed in Xiao et al. 2007). The G-CSFR is also widely distributed on rat
neurons and adult neural stem cells in particular in the cortex and the hippocampus
(Schneider et al., 2005a).
G-CSF production is localised to areas of G-CSFR expression in the brain and it is
thought that regulation occurs through an autocrine signalling mechanism in neurons
(Schneider et al., 2005a). Both G-CSF and its receptor are up-regulated following
ischemia in rodents with comparable results seen in human stroke patients, suggesting
rodent models are appropriate for the study of G-CSF and its receptor in the brain
(Schneider et al., 2005a). Further, challenge with the bacterial mimic LPS has been
shown to induce G-CSF production in rat neurons (Li et al., 2009d) which suggests that
the response is not limited to physical stimuli within the brain but that G-CSF in the
brain may be responsive to peripheral immune challenges.
4.1.3

Summary

With limited studies of G-CSF in schizophrenia patients, evidence of a role for G-CSF
in brain functions related to schizophrenia, and a robust finding of increased levels in
the periphery of the Nrg1 Het mice subject to the immune stimulus, this study focused
on determining the concomitant levels of G-CSF and the G-CSFR in the brain of
immune challenged mutant mice.
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4.2

Methods

4.2.1

Animal housing and breeding

Described in chapter 2 (2.2.1).
4.2.2

Genotyping and weaning

Described in chapter 2 (2.2.2).
4.2.3

B16F0 melanoma model

Described in chapter 2 (2.2.3). Nrg1 Het n=8, WT n=11.
4.2.4

Collection and dissection of brain tissue

Described in chapter 3 (3.2.4).
4.2.5

Protein analysis

a)

Protein isolation and storage

Described in chapter 3 (3.2.5a).
b)

Protein quantification

Described in chapter 3 (3.2.5b). Protein concentration details are detailed within
individual methods sections as applicable.
c)

Western blot

Western blot was performed as previously described (3.2.5c). Differences in the
protocol are described below.
A total of 20 µg of protein per well was used for G-CSF blotting for both the PFC and
the hippocampus while 5µg of total protein per well was used for G-CSF receptor
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blotting for both the PFC and the hippocampus. As for chapter 3, hippocampus n=8
while PFC n=4 pooled samples. Primary and secondary antibodies as well as blocking
buffer details are shown in Table 4.2-1.
Table 4.2-1: Antibodies used for Western blotting of G-CSF and the G-CSF receptor,
including secondary antibody and buffer details
Primary Antibody
Goat polyclonal anti-G-CSF
(K-15): sc-49679a
(1/250)
Sheep anti-mouse G-CSF R/
CD114 (#AF6039) b
(1/1000)
Mouse anti-mouse actinc
(1/50,000)

Secondary
Antibody
Donkey-anti-goat
IgG-HRPb
(1/2500)
Donkey-anti-sheep
IgG-HRPb
(1/2500)
Donkey-anti-mouse
IgG-HRPb
(1/2500)

Blocking Buffer
(5% in TSBT)
BSA

Incubation Buffer
(0.5% in TBST)
BSA

Skim Milk

Skim Milk

a) Santa Cruz Biotechnology Inc, b) R&D Systems Inc, c) Millipore. Figure in ( ) is dilution factor

A peptide competition binding assay was conducted per manufacturers’ instructions to
determine the correct band to analyse for G-CSF as the antibody detected several nonspecific bands. The peptide (sc-49679 P) was pre-incubated with the G-CSF antibody
using a 5x excess peptide concentration, for 1 hour at RT (Santa Cruz,), before the
above western blot protocol was conducted. Two parallel gels were run and transferred
to membranes; one incubated in G-CSF primary antibody only, the second membrane
was incubated with the antibody-peptide mix. This process resulted in the disappearance
of just one band at 50kDa which was subsequently analysed as previously detailed.
Representative images are shown in Appendix B.
Due to the consistent failure of one sample and insufficient protein to repeat the sample
in triplicate, all western blot results in the PFC for the Nrg1 Het unchallenged groups
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were based on n=3, the other PFC groups remain n=4. Western blot for the
hippocampus was n=8 for all groups.
4.2.6

Gene expression analysis

a)

RNA extraction

Described in chapter 3 (3.2.6a).
b)

cDNA synthesis

Described in chapter 3 (3.2.6b).
c)

Determination of reference genes

Described in chapter 3 (3.2.6c).
d)

Array based RT-qPCR

Described in chapter 3 (3.2.6d). The genes included on the custom array plate for GCSF-related analyses were G-CSF (csf3), and G-CSFR (csf3r). Note that the G-CSF
primers provided on the custom array plate were unable to detect mRNA expression
within the control parameters. The RT-qPCR was therefore repeated using cDNA
synthesised from the same tissue using a Taqman G-CSF individual gene expression
assay described in chapter 3 (3.2.6e).
4.2.7

Statistics

After confirming normal distribution with the Kolmogorov-Smirnov test, 3-way
ANOVA was used to analyse western blot protein levels (factors: brain region x
genotype x immune challenge) with two-tailed independent samples t-tests to further
explore differences between experimental groups. The 3-way ANOVA was used to
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elicit potential novel findings in this exploratory series of experiments. To ensure the
data was appropriately robust, 2-way ANOVA (genotype x immune challenge) was also
conducted on the brain regions separately. Main effects and interactions were consistent
with those found in the 3-way ANOVA; therefore this data is not shown. RT-qPCR
results were analysed using a 2-way ANOVA (factors: genotype x immune challenge
using two-tailed independent samples t-tests to further explore results. Significance was
set at p<0.05. All p-values are reported as uncorrected values.
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4.3

Results

4.3.1

G-CSF protein higher in the hippocampus of WT immune challenged
mice and lower in Nrg1 Het challenged mice.

Studying G-CSF protein levels, no interactions were found using 3-way ANOVA
however, a main effect of region was shown (F1,43=5.67, p=0.006). Using independent
samples t-tests to compare experimental groups within each region, the Nrg1 Het mice
were found to have 24% lower levels of G-CSF in the hippocampus when subject to
immune challenge compared to the WT immune challenged mice (p=0.028). In
addition, WT immune challenged mice displayed 25% higher levels of G-CSF in the
hippocampus when compared to the unchallenged WT animals (p=0.047; Figure 4.3-1).
Representative western blot images are shown in Appendix B. Data for mRNA
expression levels of G-CSF could not be obtained under the experimental conditions in
this study, possibly due to a low abundance of the gene transcript, despite using both a
custom PCR array plate and individual taqman assay.
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Hippocampus
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Figure 4.3-1: WT mice had increased G-CSF protein in the hippocampus while Nrg1
Het mice showed decreased levels of G-CSF with an immune challenge.
WT mice had increased G-CSF protein in the hippocampus with an immune challenge
compared to unchallenged WT controls. While Nrg1 Het mice showed decreased levels
of G-CSF with an immune challenge when compared to the WT challenged animals. GCSF protein levels in the PFC (left panel) and the hippocampus (right panel), mean ±
SEM, relative net intensity shown, reflecting the normalised G-CSF ~50kDa band
probed with antibody to G-CSF and an anti-actin loading control, *p<0.05.
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4.3.2

G-CSF receptor present at higher levels in the prefrontal cortex
compared to the hippocampus with no genotype or immune stimulus
differences

The G-CSF receptor was measured using western blot. The band at approximately
110kDa was analysed using relative net intensity and anti-actin as the loading control,
for a representative blot image see Appendix B. No interactions were found using a 3way ANOVA (region x genotype x immune challenged) however a main effect of
region was shown (F1,43=92.30, p<0.001). Using independent samples t-tests to compare
experimental groups within each region no additional differences were found (Figure
4.3-2). Further, no differences were shown in mRNA expression levels with mRNA
expression for the G-CSF receptor stable in both regions across all experimental groups
(Table 4.3-1).
Table 4.3-1: G-CSF receptor mRNA expression levels in the PFC and hippocampus of
Nrg1 Het and WT mice with or without an immune stimulus.
Control

Immune challenged

WT

Het

WT

Het

Prefrontal cortex

1.00 ±0.06

1.09 ±0.10

1.02 ±0.07

1.11 ±0.09

Hippocampus

1.00 ±0.14

0.98 ±0.14

0.97 ±0.08

0.86 ±0.05

Data represent mean fold change ± SEM., n=3 pooled samples per group (PFC), n=4 per group (Hipp).
WT expression levels normalised to 1 and fold change for other groups calculated as a comparison.
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Hippocampus
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Figure 4.3-2: The G-CSF receptor protein showed no differences between Nrg1 Het and
WT animals in either the PFC or the hippocampus.
G-CSFR protein levels in the PFC (left panel) and the hippocampus (right panel), mean
± SEM, relative net intensity shown, reflecting the normalised G-CSFR 110kDa band.
*p<0.05.
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4.4

Discussion

4.4.1 G-CSF protein was elevated in WT but reduced in Nrg1 Het mice when
subject to melanoma immune challenge
An investigation was conducted into the levels of G-CSF and the G-CSF receptor in the
PFC and the hippocampus based on the finding of elevated of G-CSF in the plasma of
Nrg1 Het mice with an immune challenge. As G-CSF can cross the blood brain barrier,
and the combination of genetic mutation and immune stimulus resulted in the peripheral
change, it was hypothesized that increases in G-CSF would be similarly seen in these
brain regions in the Nrg1 Het mice only. However, as with IL-6, the peripheral response
was not directly reflected in the brain and the individual brain regions had different GCSF responses. There was no change in G-CSF protein in the PFC, while the
hippocampus displayed changes in both WT animals with the immune stimulus and
Nrg1 Het mice with the immune stimulus. The WT animals demonstrated 25% higher
levels of G-CSF when challenged with the melanoma, while Nrg1 Het animals had 24%
less G-CSF protein. The G-CSF mRNA expression levels were not detectable and the
changes seen in G-CSF levels were not reflected in the receptor as G-CSFR did not
differ between groups in either protein or mRNA expression levels.
4.4.2 Elevated levels of G-CSF protein in the hippocampus of WT immune
challenged mice may represent a neuroprotective mechanism
G-CSF is shown to be a neuroprotective protein in a number of circumstances, in line
with the current findings of elevated G-CSF in the hippocampus of WT mice subject to
the immune stimulus compared to WT control (Figure 4.3-1). Li et al (2009)
demonstrated that pre-treatment of neurons with the immune stimulus LPS, increases GCSF production in primary hippocampal neuron cultures and that these neurons were
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protected from excitatory injury. A protective role for G-CSF in stroke has also been
demonstrated with G-CSF able to interfere with apoptotic pathways in primary cortical
rat neuronal cell cultures (Schneider et al., 2005a, 2005b). The results of the present
study are therefore consistent with these previous studies, suggesting that an on-going
peripheral stimulus, such as the melanoma challenged used, results in the induction of a
neuroprotective mechanism in the hippocampus in WT mice.
4.4.3 Lower levels of G-CSF protein in the hippocampus of Nrg1 Het immune
challenged mice may imply a disruption of the protective mechanism
In contrast to the WT animals, this study demonstrated lower levels of G-CSF protein in
the hippocampus of the Nrg1 Het mice subject to the immune stimulus, suggesting a
reduction in neuroprotection. It has been demonstrated, that G-CSF deficient mice show
increased infarct size in experimentally induced stroke (Sevimli et al., 2009).
Additionally, neurons pre-treated with anti-G-CSF in conjunction with excitatory
neurotransmitters, showed reduced levels of neuroprotection, suggesting that neuronal
toxicity may be potentiated by interfering with G-CSF signalling (Li et al., 2009d). GCSF antibodies are also capable of abolishing the anti-apoptotic properties of G-CSF
shown in ischemia (Schneider et al., 2005a, 2005b). Although both of these studies
utilised anti-G-CSF antibody to reduce G-CSF protective capabilities, it is possible that
the lower levels of the protein might result in the same effects. Further studies however,
are required to confirm this in the Nrg1 Het mice.
4.4.4 G-CSF relevance to schizophrenia
With disruptions in memory function a hallmark of schizophrenia the alterations found
in the performance of spatial memory tasks using G-CSF treatment in adult rats are
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noteworthy (Diederich et al., 2009b). G-CSF treatment improved formation of reference
memory, but not working memory during initial acquisition training in a spatial memory
task. Yet in the re-acquisition phase working memory improved in the G-CSF treated
animals. These authors initially suggested that new born neurons, which are reduced
when G-CSF is deficient, may have influenced the memory outcomes. However,
treatment with G-CSF did not significantly increase the number of new-born cells. GCSF did however, increase survival of adult-born neurons generated during this period.
Diederich et al (2009b) hypothesized therefore that the initial improvement is due to
signalling pathways activated by the G-CSFR, and cannot be attributed to new born
neurons. This provides some evidence to suggest that the lower levels of G-CSF in the
Nrg1 Het mice could result in impaired signalling through the G-CSF receptor,
potentiating neurotoxicity, or at least lessening neuroprotection, similar to those seen in
Li et al (2009d) and Schneider et al (2005a, 2005b) discussed above.
G-CSF has been reported in the schizophrenia literature as an adjunct treatment in
patients who develop anti-psychotic medication (clozapine) induced agranulocytosis
(Pollmächer et al., 1997; Schuld et al., 2000). Although changes in neutrophil levels
prior to clozapine treatment may be indicative of those at risk to develop clozapine
induced agranulocytosis, G-CSF plasma levels have not been consistently correlated
with development of this complication (Khan et al., 2013). Despite this lack of
correlation, recombinant G-CSF is successfully used as an adjunct therapy with
clozapine treatment in these patients (Khan et al., 2013; Pollmächer et al., 1997; Schuld
et al., 2000). G-CSF appears to be well tolerated as a therapeutic although there are
concerns long term treatment may have negative side effects (Khan et al., 2013; Welte
et al., 1996). Although no correlation has been reported, it remains unclear if G-CSF
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levels could be predictive of agranulocytosis in patients and whether the lack of
association with schizophrenia is because G-CSF is unchanged or because it has not
been widely studied.
4.4.5

Prefrontal cortex and hippocampal differences

Both G-CSF and the G-CSFR were found to have a main effect of region using 3-way
ANOVA tests, suggesting a difference in protein levels between the PFC and the
hippocampus. Expression of both analytes has been demonstrated previously in these
brain regions, with known expression in the cortex, hippocampus and sub ventricular
zone among others, although specific regional comparisons in protein levels was not
performed (Schneider et al., 2005a).
As discussed in chapter 3, there are several limitations with the data in the present
study, including the low sample number for PFC comparisons (3.4.2), as well as the use
of randomly assignment hippocampi (3.4.5) which may obscure differences in
lateralization, where hippocampal neuron size, neuron shape, volume and symmetry
have previous been shown altered in schizophrenia (Zaidel et al., 1997a, 1997b).
Therefore, due to these limitations, further experiments are required to determine the
existence of regional differences, or lateral differences in the hippocampi.
4.4.6

Conclusion

Despite the lack of focus on G-CSF in the schizophrenia literature, the results of the
present study suggest further investigation into the potential role of the interactions
between immune stimuli and brain function relevant to schizophrenia. With a proven
effect on neuroprotection, the 25% elevation in G-CSF levels in the hippocampus of
WT mice subject to the immune stimulus is thought to represent the normal brain
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response to this challenge and would be expected to confer neuroprotection from any
immune stimulated damage. The demonstration of 24% lower levels in the
schizophrenia vulnerability Nrg1 Het model subjected to an immune stimulus suggests
that these mice may lack the necessary G-CSF provided neuroprotection to cope with
on-going immune insults, resulting in neural damage. Therefore, vulnerable individuals
subjected to a similar immune type stimulus may suffer immune mediated toxicity in
the brain, potentially relevant to disease development, progression or symptomatology
in schizophrenia.
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A demonstration of neuroimmune interactions between the candidate
schizophrenia vulnerability gene Neuregulin 1, and peripheral and central
cytokine levels: focus on IL-6 and G-CSF

CHAPTER FIVE

An exploration of signalling molecule
expression levels

Peta Snikeris
University of Wollongong

5.1

Signalling molecule expression

A limited number of studies demonstrate common signalling mechanisms between
neuronal and immune function, and none attempt to directly link schizophrenia
pathophysiology with altered immune function in a schizophrenia relevant model. As
discussed in chapter 1 (1.2.4e), schizophrenia patients have shown various differences
in multiple cytokines in the periphery, and these immunologically significant findings in
patients make the existence and relevance of common signalling mechanisms highly
likely. Indeed, this project has shown a link between a schizophrenia genetic
vulnerability model and immune alteration by demonstrating that both peripheral and
central cytokine responses are different in Nrg1 Het mice subject to inoculation with
B16F0 melanoma cells. To further understand the possible signalling interactions
between a Nrg1 mutation and the IL-6 and G-CSF alterations in the brain, a preliminary
exploration of mRNA expression of signalling molecules potentially involved in both
Nrg1 signalling and cytokine production was conducted.
5.1.1 Nrg1 and the ErbB receptors in signalling
The mechanisms of Nrg1/ ErbB signalling have been extensively studied over recent
years (Mei and Xiong, 2008; Talmage, 2008). Most of the schizophrenia literature
focusses on the Nrg1/ErbB4 interaction, since no association between ErbB2 or -3
mutations and schizophrenia-like behaviours have been shown (Mei and Xiong, 2008).
Despite this focus on ErbB4, which not only signals in a homodimeric form, but also as
a heterodimer with ErbB2 (1.2.3) the potential importance of these heterodimers in
Nrg1 signalling should not be ignored (Yarden and Sliwkowski, 2001b). The canonical
forward signalling pathway is activated following the cleavage of the Nrg1 extracellular
domain with the soluble Nrg1 protein functioning as a ligand for the ErbB receptors
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(Mei and Xiong, 2008). Once triggered, the ErbB kinases activate various intracellular
signalling pathways including the PI3K/Akt pathway (Banerjee et al., 2010) and
Jak/Stat phosphorylation (Liu and Kern, 2002).
5.1.2 Nrg1 and the PI3K/Akt pathway
Nrg1 has been shown to be a major activator of the PI3K/Akt pathway, acting through
its ErbB receptors, in particular ErbB4 (Mei and Xiong, 2008). The PI3K/Akt signalling
pathway also modulates the production of several cytokines, critical for immune
function. With Nrg1 a candidate gene for schizophrenia susceptibility, the PI3K/Akt
pathway represents an attractive candidate for integrating the neuropathology of
schizophrenia and immune dysfunction (Okkenhaug and Vanhaesebroeck, 2003).
The PI3K/Akt pathway is of high complexity and is involved in a large number of
intracellular signalling processes. A simplified explanation of the pathway and the
molecules involved has been adopted here, with a number of the intermediate steps and
pathway molecules not discussed. In brief, the PI3K/Akt signalling pathway is activated
when a ligand, such as Nrg1, binds to a receptor tyrosine kinase, such as the ErbB
receptors. When PI3K is activated it phosphorylates Akt following a number of
intermediate steps. The main negative regulator of the PI3K/Akt pathway is
phosphatase and tensin homolog on chromosome 10 (Pten) (Hemmings and Restuccia,
2012). To find an indication of a potential dysregulation in the PI3K/Akt pathway, Akt
and Pten were therefore investigated for mRNA expression levels in the PFC and
hippocampus.
Akt has three isoforms in both humans and mice, Akt1, Akt2 and Akt3, all
demonstrating similar regulation (Masure et al., 1999; Nakatani et al., 1999). The
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distribution of the isoforms, however, is not constant: Akt1 shows wide tissue
distribution, including the brain; Akt2 is concentrated in muscle tissue and adipocytes;
and Akt3 is mainly in the brain and the testes. This distribution is consistent with
murine mutant models where Akt1 deficiency results in developmental defects, Akt2
deficiency results in defects in glucose homeostasis and Akt3 deficiency results in
defective brain development (Cohen, 2013; Hers et al., 2011; for detailed review see:
Manning and Cantley, 2007).
In addition to its neuronal cell functions, the PI3K/Akt signalling pathway modulates
the production of several cytokines, critical for immune function, including IL-6
(Koyasu, 2003). Cytokines can also influence PI3K/Akt signalling, for example IL-6
participates in a signalling feedback loop using this pathway (Chakraborty et al., 2003;
Sudheerkumar et al., 2008). Further, G-CSF was shown to induce increased
phosphorylation of Akt in neurons and this increase in Akt activity that was thought to
confer some anti-apoptotic properties. Blocking PI3K/Akt was able to partially block
the G-CSF mediated protection against apoptosis (Schneider et al., 2005b). Although
cell type, cellular environment and co-factors have to be considered, this indicates that
this pathway may be common in CNS and immune system dysregulation. It is yet to be
determined if a schizophrenia-relevant mutation of Nrg1 can act on the PI3K/Akt
pathway and influence its interaction with the immune system.
5.1.3 The Jak/Stat signalling pathway: an intersection of IL-6 and G-CSF
signalling
Given the complexity of signalling in any biological processes, a second pathway with
the potential to integrate Nrg1 gene mutation resulting in schizophrenia vulnerability
with perturbed immune function was explored. In this case we focused on a common
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signalling pathway to IL-6 and G-CSF with the potential to be impacted by Nrg1
alteration: the Jak/Stat pathway. Upon stimulation with the IL-6/ IL-6Rα complex,
gp130 becomes phosphorylated on tyrosine, which is mediated by members of the Jak
family. The Jak kinases: Jak1, Jak2 and Tyk2, are constitutively associated with gp130,
however, in the absence of Jak1, IL-6 cannot effectively mediate signalling via Stat
phosphorylation (Guschin et al., 1995). Therefore, IL-6 signalling results in Jak1
phosphorylation, activating Stat1 and Stat3 (Fischer and Hilfiker-Kleiner, 2008;
Schindler et al., 2007). It was also shown that in the absence of Jak1 certain cell types
can still phosphorylate Stat3 (Kopantzev et al., 2002). The activation of Jak/Stat by IL-6
plays an important role in neurogenesis (Li et al., 2009b), suggesting this pathway could
represent a link between altered IL-6 levels in the brain of the Nrg1 Het mice and the
vulnerability to schizophrenia-like behaviours.
Jak1 was also demonstrated as the critical signalling molecule for the G-CSFR, with
downstream activation of Stat3 also shown (Shimoda et al., 1997). In myeloid cells, GCSF has been shown to signal preferentially via the Jak/Stat signalling pathway,
although this pathway is only moderately activated in neurons where the PI3K/Akt
pathway is favoured (Schneider et al., 2005b). The main negative regulator of the
Jak/Stat signalling pathway favoured by both IL-6 and G-CSF is suppressor of cytokine
signalling 3 (SOCS3) (Murray, 2007; White and Nicola, 2013). The details discussed
above represent a summary of the available literature (for a review of this pathway see
Harrison, 2012), from which the present study explored the mRNA expression levels of
Jak1, Stat3 and SOCS3 in the PFC and hippocampus of the Nrg1 Het animals.
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5.1.4 Summary
With evidence that both neuronal and immune system alterations demonstrated in
schizophrenia may have a similar molecular basis, such as the Nrg1 mutation studied
here, the potential for common signalling pathway involvement in the development of
these alterations is strong. The current study focussed on the mRNA expression levels
of the major signalling molecules involved in the activation of the PI3K/Akt signalling
pathway via Nrg1 relevant to schizophrenia: ErbB2, -3, and 4; as well as Akt1, -2 and 3;
and finally the pathway regulator Pten (Hemmings and Restuccia, 2012). Additionally,
the main signalling molecules indicated by the alterations in IL-6 and G-CSF in both the
periphery and the brain were considered: Jak1, Stat3 and the negative regulator of this
pathway, SOCS3 (Murray, 2007).
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5.2

Methods

5.2.1

Animal housing and breeding

Described in chapter 2 (2.2.1).
5.2.2

Genotyping and weaning

Described in chapter 2 (2.2.2).
5.2.3

B16F0 melanoma model

Described in chapter 2 (2.2.3).
5.2.4

Collection and dissection of brain tissue

Described in chapter 3 (3.2.4).
5.2.5

Protein analysis

a)

Protein isolation and storage

Described in chapter 3 (3.2.5a).
b)

Protein quantification

Described in chapter 3 (3.2.5b). Protein concentration details are detailed within
individual methods sections as applicable.
c)

Luminex

Protein levels of Akt and phosphorylated Akt (pAkt) were measured using Luminex
cytometric bead assays targeting pan-Akt and pan-pAkt epitopes. MILLIPLEX MAP
Total Akt/PKB MAPmate (MP46-605) and phosphoAkt/PKB (Ser473) MAPmate
(MP46-601) beads and the MILLIPLEX MAP cell signalling buffer and detection kit
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were used with assay buffer 1 following manufacturer instructions (Millipore). Total
and phosphorylated analytes cannot be multiplexed, therefore Akt and pAkt were run in
parallel plates, both following the same protocol and using the same reagent kit. In
brief, wash buffer was used to pre-wet the filters in a 96 well assay plate by 10min
incubation with agitation at RT before removal of buffer. All removal of reagents was
performed by vacuum. All vacuum steps were followed by blotting the bottom of the
plate to remove excess liquid reagents. All preparation steps were completed at RT.
Positive controls were added onto plates as required per manufacturer instructions
(Millipore). Assay buffer was added to each sample well. Beads were added to all wells
as required. All wells contained sample (or control) at the ratio of 1 part sample to 2
parts reagents. The plate was sealed and incubated overnight at 4°C with agitation. The
following day, reagents were removed and wells washed twice with wash buffer.
Detection antibodies were added into each well and incubated in sealed plate for 1 hour
in the dark, with agitation, at RT. Detection antibodies were removed by vacuum and
Streptavidin-PE was added to the detection antibodies and incubated for 15min, with
agitation, at RT in the dark. Amplification buffer was then added to the Streptavidin-PE
and incubated for a further 15min under the same conditions. Reagents were then
removed by vacuum followed by two washes and final suspension in 150µl of Luminex
xMap sheath fluid (Luminex Corporation, Austin, TX, USA) by 5min agitation at RT
on plate shaker. The plate was run on a Luminex 100™ System using xPONENT® 3.1
Software (Luminex Corporation). Data output was analysed using MasterPlex® QT:
Multiplex Quantitative Analysis Curve-Fitting Software (Hitachi Solutions America
Ltd, South San Francisco, CA, USA) with results reported in arbitrary units as relative
mean fluorescence intensity. Additional information on Luminex can be found in
3.2.5d).
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5.2.6

Gene expression analysis

a)

RNA extraction

Described in chapter 3 (3.2.6a).
b)

cDNA synthesis

Described in chapter 3 (3.2.6b).
c)

Determination of reference genes

Described in chapter 3 (3.2.6c).
d)

Array based RT-qPCR

Described in chapter 3 (3.2.6d). The signalling related genes included on the custom
array plate were: Nrg1, Erbb2, Erbb3, Erbb4, Akt1, Akt2, Akt3, Jak1, Stat3, Pten, and
Socs3 with Fbxw2 and Ap3d1 as reference genes, plus a positive control, reverse
transcription control and mouse genomic DNA control. Each experiment represents n=3
(PFC) and n=4 (Hippocampus) biological samples, tested in triplicate.
5.2.7

Statistics

2-way ANOVAs were conducted on the PFC and hippocampus independently with the
factors genotype and immune challenge. Independent samples t-tests were used for
additional analysis. All analysis was conducted on fold change calculated using the
Livak method (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). Significance
was set at p<0.05. All data are presented as uncorrected p-values.
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5.3

Results

5.3.1

ErbB2 mRNA expression levels higher in the prefrontal cortex of Nrg1
Het immune challenged mice

We first measured the expression levels of pan Nrg1 mRNA as well as the Nrg1
signalling receptors ErbB2, ErbB3 and ErbB4. In the PFC, the expression of Nrg1
mRNA did not show an interaction between genotype and immune challenge using 2way ANOVA, however, genotype was found to have a main effect on expression levels
(genotype, F1,11=10.78, p=0.011). Similarly, in the hippocampus, no interaction was
found, but a trend for a main effect of genotype was shown (F1,13=4.72, p=0.055). Using
independent samples t-test no significant differences were seen in Nrg1 mRNA
expression between the four experimental groups in either the PFC of the hippocampus.
The PFC however did display a tendency toward lower expression levels in the Nrg1
Het mice, at baseline and with the immune stimulus (p=0.079) (Figure 5.3-2).
The mRNA expression levels of the Nrg1 receptors: ErbB2, ErbB3 and ErbB4 were
also measured. In the PFC, a genotype x treatment interaction was seen for ErbB2
(F1,11=8.68, p=0.019) as well as a main effect of genotype (F1,11=17.11, p=0.003).
ErbB2 had elevated expression levels in Nrg1 Het challenged mice compared to WT
challenged mice in the PFC (p<0.01; independent samples t-test). A trend towards lower
expression levels in WT mice with the immune challenge compared to unchallenged
WT controls was also seen in the PFC (p=0.057). The hippocampus showed no
differences in expression levels for ErbB2 (Figure 5.3-2). ErbB3 and ErbB4 mRNA was
not differentially expressed in either brain region (Table 5.3-1, PFC and Table 5.3-2,
Hippocampus).
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Figure 5.3-1: Nrg1 mRNA expression showed a tendency toward lower levels in the
Nrg1 Het mice in the PFC
Nrg1 mRNA expression levels are shown for the PFC (left panel) and the hippocampus
(right panel). 2-way ANOVA indicated a main effect of genotype in both regions, while
independent samples t-test revealed only a tendency toward lower expression in the
Nrg1 Het mice regardless of immune stimulation. Data represent mRNA as mean
relative fold change ± SEM using RT-qPCR, n=3 pooled samples per group (PFC), n=4
per group (Hippocampus). WT unchallenged expression levels normalised to 1. (p
values shown on graph; independent samples t-test).
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Figure 5.3-2: ErbB2 mRNA expression elevated in the PFC of immune challenged Nrg1
Het mice.
ErbB2 mRNA expression levels are shown for the PFC (left panel) and the
hippocampus (right panel). A genotype x immune challenge interaction, with a main
effect of genotype was indicated by 2-way ANOVA. Independent samples t-test
revealed higher levels of ErbB2 in the PFC of Nrg1 Het mice with an immune challenge
compared to the challenged WT, while a trend toward lower levels was seen in the WT
challenged compared to WT unchallenged mice. Data represent mRNA as mean relative
fold change ± SEM using RT-qPCR, n=3 pooled samples per group (PFC), n=4 per
group (Hippocampus). WT unchallenged expression levels normalised to 1 (**p<0.01;
independent samples t-test).
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5.3.2

Akt mRNA levels

One of the major downstream signalling molecules of the Nrg1 pathway is Akt which is
present in three main mRNA isoforms, Akt1, Akt2 and Akt3. All three isoforms were
analysed using RT-qPCR. No interaction between genotype and immune challenge were
seen using 2-way ANOVA, however, the PFC showed a main effect of genotype for
Akt1 and Akt2 (F1,11=10.98, p=0.011; F1,11=7.99, p=0.022 respectively). No interactions
or effects were seen in the mRNA expression levels in the hippocampus using 2-way
ANOVA.
Further analysis shows Akt1 mRNA expression is higher in the PFC of unchallenged
Nrg1 Het mice compared to unchallenged WT littermates (p<0.05; independent samples
t-test). Both Akt1 and Akt 2 also show a trend towards higher mRNA expression levels
in the PFC of Nrg1 Het mice subject to immune challenge compared to WT challenged
mice (p=0.099; p=0.057 respectively; independent samples t-test). No differences
between the groups were seen in the hippocampus when analysed with independent
samples t-tests (Figure 5.3-3). Further, Akt3 expression levels remained consistent
across both brain regions when analysed with 2-way ANOVA or independent samples ttest (Table 5.3-1, PFC and Table 5.3-2, Hippocampus).
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Figure 5.3-3: Higher levels of Akt1 mRNA expression at baseline in Nrg1 Het mice
compared to WT littermates in the PFC with no change in Akt2.
mRNA expression levels are shown for the PFC (left panel) and the hippocampus (right
panel): (a) Akt1 mRNA showed higher expression levels in the Nrg1 Het unchallenged
mice along with a tendency toward higher levels in the immune challenged mice; (b)
Akt2 mRNA demonstrated a trend to higher expression levels in the Nrg1 Het immune
challenged mice compared to challenged WT. Data represent mRNA as mean relative
fold change ± SEM using RT-qPCR, n=3 pooled samples per group (PFC), n=4 per
group (Hippocampus). WT unchallenged expression levels normalised to 1 (*p<0.05;
independent samples t-test).
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5.3.3

Phosphorylated Akt protein levels lower in the hippocampus of Nrg1
Het mice without an immune stimulus.

With pAkt representing activated signalling of the PI3K/Akt pathway, the protein level
of total Akt and pAkt was measured in the hippocampus using a Luminex bead based
assay. Due to tissue limitation we were unable to measure the protein levels in the PFC.
In the hippocampus, a genotype x immune challenge interaction was seen in Akt protein
levels using 2-way ANOVA (F1,32=4.486, p<0.05) whilst pAkt showed a tendency
towards a genotype x immune challenge interaction (F1,32=3882, p=0.058) with a main
effect of genotype (F1,32=6.127, p<0.05). Phosphorylated Akt protein was shown to be
41% lower in the Nrg1 unchallenged animal compared to WT in the hippocampus
(p<0.01; independent samples t-test) (Figure 5.3-4). No between group effects were
seen in the level of total Akt protein using independent samples t-test, however there
was a trend toward lower protein levels (27%) in the Nrg1 unchallenged animals
compared to WT (p=0.056).
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Figure 5.3-4: Total and phosphorylated Akt protein in the hippocampus
Phosphorylated Akt (right panel) was lower in the Nrg1 Het mice compared to WT
without and immune challenge. Total Akt showed a trend towards similar lower levels
but was not significant. Data represent mean fluorescent intensity using Luminex flow
cytometry (mean ± SEM), n=8 per group except WT immune challenged where n=9
(**p<0.01; independent samples t-test).
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5.3.4

Melanoma challenge results in higher Pten mRNA expression in the
prefrontal cortex of Nrg1 Het mice

As a downstream effector of Akt signalling and shown to have an important role in
cancer progression, we measured Pten mRNA expression levels. Analysis using 2-way
ANOVA did not show any genotype x immune challenge interactions in either the PFC
or the hippocampus. The hippocampus only demonstrated a trend toward a genotype
main effect in Pten mRNA expression (F1,13=4.93, p=0.051). Between groups analysis
using independent samples t-test showed mRNA expression level for Pten was higher in
the immune challenged Nrg1 mutant mice compared to the challenged WT mice in the
PFC (p<0.05, independent samples t-test) while no differences were seen in the
hippocampus (Figure 5.3-5).
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Figure 5.3-5: Elevated levels of Pten mRNA expression in the PFC of Nrg1 Het
immune challenged mice.
The expression levels of Pten mRNA are shown for the PFC (left panel) and the
hippocampus (right panel). Data represent mRNA as mean relative fold change ± SEM
using RT-qPCR, n=3 pooled samples per group (PFC), n=4 per group (Hippocampus).
WT unchallenged expression levels normalised to 1 (*p<0.05; independent samples ttest).
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5.3.5

Jak1 mRNA expression is reduced in the hippocampus of immune
challenged Nrg1 Het mice

With the Jak/Stat pathway one of the possible common pathways linking Nrg1, IL-6
and G-CSF measured Jak1 and Stat3 were. Jak1 mRNA expression did not demonstrate
a genotype x immune challenge interaction in either brain region using 2-way ANOVA.
However both the PFC and the hippocampus showed a main effect of genotype on Jak1
expression (F1,11=10.85, p=0.011; F1,13=5.54, p=0.040 respectively). Lower expression
of Jak1 mRNA was found in the hippocampus of Nrg1 immune challenged mice
compared to challenged WT (p<0.05; independent samples t-test), while a trend toward
higher levels of mRNA expression in the same groups was seen in the PFC (p=0.070;
independent samples t-test) (Figure 5.3-6). Stat3 mRNA was stably expressed in both
regions (Table 5.3-1, PFC and Table 5.3-2, Hippocampus).
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Figure 5.3-6: Lower levels of Jak1 mRNA expression in Nrg1 Het immune challenged
mice compared to challenged WT in the hippocampus.
Expression levels of Jak1 mRNA are shown for the PFC (left panel) and hippocampus
(right panel). Data represent mRNA mean relative fold change ± SEM using RT-qPCR,
n=3 pooled samples per group (PFC), n=4 per group (Hippocampus). WT unchallenged
expression levels normalised to 1 (*p<0.05; independent samples t-test).
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5.3.6

Nrg1 transmembrane domain mutation results in elevated SOCS3
mRNA expression in the prefrontal cortex of affected mice

As a major cytokine regulator, particularly relating to the Jak/Stat pathway we also
measured the mRNA expression levels of SOCS3. SOCS3 mRNA expression
demonstrated a main effect of genotype using a 2-way ANOVA (genotype, F1,11=5.33,
p=0.050) in the PFC. Further between groups analysis showed SOCS3 mRNA
expression to be higher in the PFC of Nrg1 Het unchallenged mice when compared to
unchallenged WT animals (p=0.012; independent samples t-test). No differences were
found in the mRNA expression levels of SOCS3 in melanoma challenged animals in the
PFC and mRNA expression of SOCS3 was stable in the hippocampus (Figure 5.3-7)
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Figure 5.3-7: Elevated levels of SOCS3 mRNA expression at baseline in Nrg1 Het mice
in the PFC.
The expression levels of SOCS3 mRNA are shown for the PFC (left panel) and the
hippocampus (right panel). Data represent mRNA as mean relative fold change ± SEM
using RT-qPCR, n=3 pooled samples per group (PFC), n=4 per group (Hippocampus).
WT unchallenged expression levels normalised to 1 (*p<0.05; independent samples ttest).
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Table 5.3-1: Signalling molecule mRNA expression levels in the PFC of Nrg1 Het and
WT mice with or without an immune stimulus.
PFC

Control

Immune challenged

WT

Het

WT

Het

ErbB3

1.00 ± 0.29

1.23 ± 0.27

1.14 ± 0.09

1.26 ± 0.04

ErbB4

1.00 ± 0.10

1.10 ± 0.06

1.08 ± 0.05

1.19 ± 0.07

Akt3

1.00 ± 0.05

0.95 ± 0.01

0.92 ± 0.03

0.99 ± 0.04

STAT3

1.00 ± 0.06

1.27 ± 0.15

1.07 ± 0.03

1.23 ± 0.15

Data represent mean fold change ± SEM, n=3 pooled samples per group (PFC), n=4 per group (Hipp).
WT expression levels normalised to 1 and fold change for other groups calculated as a comparison.

Table 5.3-2: Signalling molecule mRNA expression levels in the hippocampus of Nrg1
Het and WT mice with or without an immune stimulus.
Hipp

Control

Immune challenged

WT

Het

WT

Het

ErbB3

1.00 ± 0.23

1.12 ± 0.26

0.82 ± 0.13

0.96 ± 0.16

ErbB4

1.00 ± 0.04

1.07 ± 0.12

0.93 ± 0.01

0.96 ± 0.04

Akt3

1.00 ± 0.17

1.13 ± 0.05

1.21 ± 0.04

1.17 ± 0.04

STAT3

1.00 ± 0.14

0.99 ± 0.19

1.05 ± 0.03

1.09 ± 0.08

Data represent mean fold change ± SEM, n=3 pooled samples per group (PFC), n=4 per group (Hipp).
WT expression levels normalised to 1 and fold change for other groups calculated as a comparison.
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5.4

Discussion

This study analysed a number of molecules associated with the signalling pathways
PI3K/Akt and Jak/Stat, as both pathways are common to a variety of Nrg1, IL-6 or GCSF functions. This preliminary exploration, using limited sample numbers,
demonstrated changes in mRNA expression levels of ErbB2, Akt1, Pten, Jak1 and
SOCS3 in Nrg1 Het mice either as a consequence of the genetic mutation or in response
to an immune challenge, with no change found in Nrg1 mRNA expression itself. In
addition, the protein levels of pAkt also displayed alteration in the hippocampus in the
presence of the immune challenge.
5.4.1 Unchanged expression of Nrg1 mRNA
The unchanged Nrg1 mRNA expression levels (Figure 5.3-1) may appear unexpected in
a heterozygous mutant mouse model. However a main effect of genotype was shown
using a ANOVA in the PFC, with a trend towards the same effect in the hippocampus,
which is consistent with previous findings (Long et al., 2010a). In the Nrg1 Het mice,
Long et al (2010a) showed reduced mRNA expression of the transmembrane and
intracellular domains of Nrg1 coupled with unchanged expression of the common
extracellular epidermal growth factor-like domain. The present study used a commercial
primer for pan Nrg1 detection which did not target the specific Nrg1 domains targeted
by Long et al (2010a). Therefore, the lack of difference shown for mRNA expression of
Nrg1 using a non-specific primer design provides similar results to this found in the
PFC and hippocampus in the Long et al study (2010a) and the possibility remains that
the Nrg1 Het gene mutation results in an underlying change in a biologically relevant
specific domain of the Nrg1 mRNA transcript. Additional data (Long et al,
unpublished) show Nrg1 protein levels unchanged in both the PFC and the
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hippocampus in these mice. Therefore it is suggested that the Nrg1 Het model cannot be
characterised as either a simple gain or loss of function model due to the mutation
(Long et al., unpublished). Further investigations measuring protein levels and
functionality will elucidate the exact effect of the Nrg1 Het mutation in these mice.
Despite the lack of insight into the exact nature of the Nrg1 mutation effects, with
alterations not apparent from mRNA expression studies or protein investigations
(Figure 5.3-1; Long et al., 2010a; Long et al., unpublished), a range of experimental
results in these mice demonstrate significant and schizophrenia-relevant alterations do
occur as a consequence of the mutation. Nrg1 Het mice were shown to have alterations
in both behavioural and cognitive characteristics (Chesworth et al., 2012; Duffy et al.,
2010; Karl et al., 2007). Further, a series of studies on the effects of the main active
constituents of cannabis (Delta(9)-tetrahydrocannabinol and cannabidiol) found distinct
biological and behavioural effects in the Nrg1 Het mice (Boucher et al., 2007a, 2007b,
2010, Long et al., 2010b, 2012, 2013). In addition, Desbonnet et al (2012) demonstrated
specific interactions between chronic stress paradigms and the response of the Nrg1 Het
mice. These studies together with our findings of alterations in the immune response
underline the continuing relevance of the Nrg1 Het mouse model in studies of
schizophrenia pathophysiology, in particular when combined with additional
environmental risk factors (Karl, 2013). Further, although not indicated by the mRNA
expression results presented in this study, the search for alterations in Nrg1 abundance
or function in the Nrg1 Het mice is indicated by the behavioural and cognitive studies
discussed above. Alterations are assumed to exist but continuing studies are necessary
to clarify the underlying biochemical mechanisms.
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5.4.2 ErbB2 mRNA expression was elevated in the PFC of Nrg1 animals subject
to immune challenge
The immune challenged Nrg1 Het animals displayed elevated levels of ErbB2 mRNA
expression compared to the challenged WT with a genotype by treatment interaction
seen in the PFC (Figure 5.3-2). Additionally, a tendency towards lower expression of
ErbB2 was seen in the immune challenged WT challenged animals in the PFC. No
changes in ErbB2 mRNA expression were seen in the hippocampus, and there were no
differences in the expression of ErbB3 or ErbB4 mRNA. This suggests that the
expected response to a melanoma challenge is to maintain or reduce availability of
ErbB2 for signalling in the PFC and that this response is reversed in Nrg1 Het mice.
ErbB2 does not bind Nrg1 and an ErbB2 dimer cannot initiate the Nrg1 signalling
cascade. A heterodimer of ErbB2 with ErbB3 or ErbB4 is required for signalling (Mei
and Xiong, 2008). Ctiri and Yarden (2006) suggest ErbB2 is a “non-autonomous
amplifier of the ErbB signalling network”, suggesting that the higher level of ErbB2
expression seen in response to an immune challenge in the Nrg1 mice in this study
could be a simple compensatory mechanism if reduced Nrg1 signalling is assumed.
Despite unchanged ErbB3 and ErbB4 expression levels, additional ErbB2 may allow for
more heterodimer formation, increasing signalling. In fact, Hahn et al. (2006)
previously demonstrated an increase in ErbB2/ ErbB4 heterodimers in a human postmortem study. Should subsequent studies demonstrate that Nrg1 abundance and ability
to signal is not impaired in these animals, the alteration in ErbB2 mRNA expression
levels would likely not represent a compensatory mechanism. In this case current
literature does not provide for an alternate theory that would result in the changes seen
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in ErbB2. Further experimental investigation in alternate pathways for ErbB2 up- and
down- regulation would be required to interpret these data.
5.4.3 Higher level of Akt1 mRNA in the prefrontal cortex of Nrg1 Het mice at
baseline
Nrg1 activation of the PI3K/Akt signalling pathway is involved in many neuronal cell
functions also relevant to the development of schizophrenia, including growth,
proliferation and migration (Matheny and Adamo, 2009). Therefore the mRNA levels of
Akt -1,-2 and -3 were measured in the PFC and the hippocampus, with protein levels of
total Akt and pAkt measured in the hippocampus only. Protein levels in the PFC were
not measured in this study, as tissue limitations prevented performance of the assay.
Higher levels of Akt1 mRNA expression in the PFC were shown in Nrg1 Het mice
without an immune challenge when compared to the WT unchallenged mice (Figure
5.3-3). A tendency for higher expression levels of Akt1 was seen in the immune
challenged Nrg1 Het mice when compared to the challenged WT mice in the PFC
(Figure 5.3-3). Additionally, Akt2 mRNA expression levels in the immune challenged
Nrg1 Het mice also showed a tendency toward increase when compared to challenged
WT mice in the same brain region (Figure 5.3-3).
Polymorphisms in the Akt1 gene have been associated with susceptibility to
schizophrenia (Thiselton et al., 2008). Akt1 null mice have a reduced number of brain
cells, although of normal size where Akt1 represents one third of the Akt isoforms
present in the brain, Akt3 one half and Akt2 the remaining one sixth of Akt isoforms in
the brain (Easton et al., 2005). In addition, lower levels of Akt1 protein, but not Akt2 or
Akt3, were found in a post-mortem cohort study of schizophrenia patients (Emamian et
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al., 2004). While these studies demonstrate a lack of or decrease in Akt1 is related to
schizophrenia-like pathology, the present study found the opposite with an increase in
Akt1 mRNA expression. If the changes in Akt1 in this study are a downstream effect of
the presumed alteration in Nrg1 signalling, the increase, whilst not consistent with
mutant models lacking complete pathway elements, may be a compensatory mechanism
for changes in other pathway molecules not studied here.
5.4.4 Phosphorylation of Akt in the hippocampus was lower in the un-stimulated
Nrg1 Het mice compared to WT controls
Protein levels of pAkt were lower in the hippocampus of Nrg1 Het mice without an
immune challenge. The level of total Akt also tended towards lower levels in these mice
(Figure 5.3-4) suggesting less overall protein availability, and therefore hypo- activity
of this pathway in the hippocampus as a result of the Nrg1 mutation. Since Nrg1/ErbB
signalling preferentially uses the PI3K/Akt pathway for signalling and with pAkt being
a marker of pathway activation, this reduction in the hippocampus based on genotype
provides an added indication that Nrg1 signalling is disrupted in the mutant mice,
despite the specific change in Nrg1 remaining elusive (Keri et al., 2009; Mei and Xiong,
2008). Interestingly, when combined with an immune challenge, the levels of total and
pAkt did not differ between the Nrg1 Het and the WT animals.
This reduction in pAkt, with the possible reduction of total Akt substrate, is likely to
further promote a range of alterations in downstream signalling and these changes may
be more likely to present the genetic mutation is combined with an environmental
insult, such as the immune challenge used in this study. In particular, the return of pAkt
and Akt to levels consistent with the challenged WT mice in the Nrg1 Het mice subject
to an immune challenge may find a speculative mechanism from an earlier finding. In
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the IL-6 and its receptor molecules chapter, it was shown that sgp130 was reduced in
the hippocampus of Nrg1 Het mice not subject to the immune stimulus, with a further
decrease shown following the immune challenge; this same reduction in levels was seen
when comparing the WT immune stimulated mice with the un-stimulated WT controls
(Figure 3.3-4). The lower levels in unchallenged Nrg1 Het mice may represent an
apparent consequence of the genetic mutation; however the further reduction in
challenged mice was unexplained.
With the IL-6/IL-6Rα/gp130 signalling complex capable of activating the PI3K/Akt
pathway via phosphorylation of Akt and sgp130 acting as an inhibitor of IL-6/sIL-6Rα
trans-signalling, a decrease in sgp130 would remove this inhibition (Jostock et al., 2001;
Koyasu, 2003). This reduction in inhibition of the IL-6/IL-6Rα/gp130 pathway may
potentially provide additional Akt phosphorylation activity, therefore resulting in the
lower level of pAkt seen in unchallenged Nrg1 Het animals returning to the same level
as the WT when both are subject to an immune challenge. The WT mice show a similar
reduction in sgp130 but pAkt is unchanged between the immune challenged and
unchallenged animals. This suggests that if the changes in pAkt are actually linked to
sgp130 in the Nrg1 mice there must be an interaction between the Nrg1/ErbB and the
IL-6/IL-6Rα/gp130 signalling pathways in an analyte that was not measured here. This
speculative mechanism would require thorough investigation to determine which, if
any, of these molecular changes are dependent on others in the Nrg1 Het mice.
From this we can determine that a schizophrenia-relevant mutation of Nrg1 can act on
the PI3K/Akt pathway at least to the extent of mRNA expression changes in the PFC
and the constitutive levels of Akt and phosphorylated Akt protein. This could
potentially influence the interaction of the PI3K/Akt pathway within the immune
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system, particularly in the regulation of IL-6 and the functions of G-CSF. While the
present study hints at interactions, further exploration of the Akt isoforms at protein
levels, along with phosphorylation and functional studies would be required to gain any
detailed understanding of pathway effects and inform understanding of mechanisms or
potential outcome effects.
5.4.5 Higher levels of the PI3K/Akt pathway negative regulator Pten seen in Nrg1
immune challenged mice
Also called the tumour suppressor gene, Pten is mutated in several human cancers and
has also been shown to play an important role in brain development (Amiri et al., 2012;
Endersby and Baker, 2008; Li et al., 1997; Williams et al., 2015). Brain defects linked
to mutations in Pten include macrocephaly, seizures and mental retardation (Endersby
and Baker, 2008; Orrico et al., 2009; Waite and Eng, 2002) although these defects have
not been directly related with schizophrenia. In this study, the Nrg1 Het mice subject to
the melanoma challenge showed elevated mRNA expression levels of Pten in the PFC
when compared to WT challenged animals. As Pten is a negative regulator of the
PI3K/Akt pathway (Wu et al., 1998), a higher level of mRNA expression might be
expected to reduce the expression or activation of Akt if translated into functional
protein. With tissue limitations preventing the measurement of total Akt and pAkt
protein in the PFC, and protein levels of Pten not measured, it is not possible to draw
further conclusions on the relevance of the Pten increase in Nrg1 Het challenged mice,
other than that this increase is possibly a result of an overactive PI3K/Akt pathway in
the PFC or that the expression on Pten had been specifically influenced by the Nrg1
mutation combined with the immune response and would result in a marked reduction
in PI3K/Akt activation in this brain region. While the increased level of Pten in immune
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challenged Nrg1 Het mice needs to be mentioned, further studies are required to
determine the biological relevance of this elevated Pten mRNA.
5.4.6 Jak1 mRNA expression levels were decreased in the hippocampus of Nrg1
Het mice with an immune stimulus
The mRNA expression levels of Jak1, shown to be a critical factor in IL-6 and G-CSF
signalling, and Stat3, the major downstream mediator of Jak1 activity, were measured in
the PFC and hippocampus of Nrg1 Het and WT mice with or without an immune
stimulus (Kopantzev et al., 2002; Shimoda et al., 1997). Jak1 mRNA was shown to be
expressed at a reduced level in the hippocampus of Nrg1 Het mice subject to the
immune challenge compared to challenged WT animals (Figure 5.3-6). No further
difference in Jak1 mRNA expression was seen although there appears to be a tendency
towards higher levels in the PFC of the same groups. No differences were seen in Stat3
in either brain region.
The previous study of G-CSF levels in the brain of Nrg1 Het mice (see Chapter 4)
demonstrated that G-CSF levels are reduced in the hippocampus of the challenged Nrg1
Het mice compared to challenged WT littermates (Figure 4.3-1). With the G-CSF
receptor representing a moderate activator of the Jak/Stat pathway in neurons
(Schneider et al., 2005b), it is viable that a reduction in G-CSF signalling could result in
a reduced need for Jak1, and the resulting reduction in Jak1 mRNA expression seen
here. Despite the neuronal preference for G-CSF to activate the PI3K/Akt pathway over
the Jak/Stat pathway (Schneider et al., 2005b), no differences were found in mRNA
expression or protein levels of Akt in the same group in the hippocampus, indicating
that the reduced G-CSF levels may result in aberrant Jak/Stat signalling in the Nrg1 Het
mice when subject to an immune challenge. With no clear-cut picture to be observed in
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our study, this interaction requires further examination in the current experimental
system.
5.4.7 Basal mRNA expression levels of SOCS3 were elevated in Nrg1 Het mice
SOCS3 is a critical negative regulator of both the IL-6 and G-CSF signalling pathways
(Croker et al., 2004; White and Nicola, 2013). With SOCS3 mRNA expression
increased in the PFC of Nrg1 Het mice without an immune challenge, it is proposed that
the Nrg1 mutation itself creates an overexpression of SOCS3 in these animals. Given
the Nrg1 Het animals subject to an immune challenge demonstrated lower levels of IL-6
in the PFC and no changes in G-CSF, the focus here is on the potential interaction
between this baseline increase in SOCS3 and the reduction in IL-6 following immune
challenge. Under basal conditions, mRNA and protein levels of SOCS3 are highly
regulated (Starr et al., 1997). The expression of SOCS3 mRNA can however, be rapidly
induced by a number of cytokines. The rapid induction of SOCS3 by multiple cytokines
initially

led

to

the

understanding

of

SOCS3

as

an

anti-inflammatory,

immunosuppressive agent (White and Nicola, 2013; Yasukawa et al., 2003). Further
study using knockout mouse models has elucidated more specific functional roles for
SOCS3. Although the full body SOCS3 knock is embryonically lethal, targeted cell
specific deletion models have proven viable (Roberts et al., 2001; White and Nicola,
2013). Deletion of SOCS3 in neurons led to faster recovery from acute spinal injury
while

deletion

in

oligodendrocytes

provided

protection

from

drug-induced

demyelination and apoptosis (Emery et al., 2006; Okada et al., 2006). However, using
deletion models does not provide direct evidence for the role of increased levels of
SOCS3 under basal conditions.
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SOCS3 is rapidly induced by increased IL-6 in a negative feedback loop where
increased SOCS3 limits the IL-6 response, similarly, impaired SOCS3 enhances IL-6
signalling (Croker et al., 2003; Fischer et al., 2004; Schmitz et al., 2000). While SOCS3
can inhibit the IL-6 response, this has been shown to occur with different potencies in
different tissues (Croker et al., 2003). Given the elevated level of SOCS3 mRNA
expression in the PFC of Nrg1 Het mice without an immune stimulus, and the
concurrent lower level of IL-6 protein in the PFC of Nrg1 Het mice subject to the
immune challenge, it is conceivable that the Nrg1 mutation itself interferes with SOCS3
expression and the addition of an immune stimulus results in the inability of IL-6 to
maintain protein levels as seen in the WT animals with or without the immune stimulus
in the PFC.
It is also interesting to note the elevated levels of Pten mRNA expression in Nrg1 Het
mice subject to the immune stimulus. Previous studies have demonstrated that the
combined deletion of SOCS3 and Pten results in synergistic promotion of axonal
regeneration (Luo and Park, 2012; Sun et al., 2011). This suggests possible links
between SOCS3, Pten and IL-6 levels, demonstrating that the findings of this study are
consistent with existing hypotheses of the analytes acting together.
5.4.8 Conclusion
Overall this study represents a preliminary investigation of the potential signalling
pathways involved in the IL-6 and G-CSF alterations shown in the PFC and the
hippocampus of Nrg1 Het mice. This study presents mRNA expression comparison data
and a single protein investigation into total and pAkt in the hippocampus. Alterations
were shown in the mRNA expression of a number of the pathway molecules studied,
however, given the exploratory nature of the study, the low sample number, and the
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focus on mRNA, limited conclusions can be drawn and the role of each mRNA
expression level change described can only be considered speculative.
As noted in earlier chapters, mRNA levels and protein levels are often not correlated
and in most cases the prediction of protein abundance from gene expression data is
insufficient, and this remains true for the molecules discussed here (Anderson and
Seilhamer, 1997; Gygi et al., 1999). Still, alterations in mRNA levels indicate
alterations in cell activation and give reason to further studies. Additionally, the changes
in ErbB2, Akt1, Pten, Jak1 and SOCS3, as well as protein level changes in pAkt provide
data to suggest further investigations is warranted in both the PI3K/Akt and the Jak/Stat
pathways in the Nrg1 Het mice in conjunction with immune stimuli. In particular, the
elevated expression of Akt1 and SOCS3 in the unchallenged Nrg1 Het mice suggests
that the PI3K/Akt pathway may be primed to a dysfunctional response even before the
immune stimulus. Further, the elevated levels of ErbB2 and Pten in the Nrg1 Het
immune challenged animals further indicate a role for the PI3K/Akt signalling pathway.
The lower level of Jak1 expression in the hippocampus may be a direct result of the GCSF changes in this brain region, however, Jak 1 has also been shown to affect
PI3K/Akt signalling.
To determine a more complete picture and gain insight into the potential signalling
mechanisms, future investigations would need to include repeat mRNA studies as well
as protein and functional phosphorylation assays. Such studies may also consider the
possible differences between long-term immune stimulation as presented here, and
acute pathway stimulation. Therefore, while beyond the scope of this study,
investigations into protein and functionality are the next step in understanding the Nrg1
gene and immune stimulation interactions.
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A demonstration of neuroimmune interactions between the candidate
schizophrenia vulnerability gene Neuregulin 1, and peripheral and central
cytokine levels: focus on IL-6 and G-CSF

CHAPTER SIX

Conclusion and future directions

Peta Snikeris
University of Wollongong

6.1

Conclusion and future direction

This study aimed to determine if the mutation of a gene originally identified as a
schizophrenia vulnerability gene would influence the peripheral immune response.
Further, the study proposed that such a mutation would also change the production of
cytokines in the brain in the presence of a peripheral immune stimulus. In order to
examine this hypothesis, the Nrg1 Het mutant mouse model, a model of schizophrenialike genetic vulnerability, was subjected to a direct immune stimulus in the form of a
B16F0 melanoma. Following the immune challenge, a range of peripheral immune
measures were obtained, with a focus on cytokine responses. With alterations
determined in IL-6 and G-CSF in the periphery, these two cytokines were further
investigated in the brain. The levels of IL-6 and G-CSF in the PFC and the
hippocampus were measured, along with their obligate signalling receptors and
displayed a range of alterations. Finally two pathways, PI3K/Akt and Jak/Stat, common
to Nrg1, IL-6 and G-CSF signalling were subject to a preliminary investigation of
mRNA expression levels to determine if the dysfunction in protein could be linked to a
shared signalling pathway. The results shown in this thesis provide evidence of my
original contribution to science, demonstrating the following:
1) A Nrg1 mutation resulted in higher levels of IL-6 in the periphery in response to a
direct peripheral immune stimulus in mice (Chapter 2). Importantly, similar elevations
in IL-6 levels were shown in human schizophrenia patients and first degree relatives
with a Nrg1 mutation (Marballi et al., 2010);
2) Immune stimulation resulted in various alterations of IL-6 and its receptors in the
PFC and the hippocampus of Nrg1 mutant mice dependent on brain region or analyte
studied (Chapter 3);
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3) For the first time, an alteration in circulating plasma G-CSF levels and G-CSF in the
hippocampus was shown in response to a peripheral immune stimulus in Nrg1 Het mice
(Chapters 2 and 4);
4) A preliminary analysis of two signalling pathways involved in Nrg1, IL-6 and G-CSF
functioning in the brain suggests further investigation of signalling molecules that were
found altered. Although with limitations, the data provide indication that activation and
function in the common pathway PI3K/Akt is warranted (Chapter 5).
Although animal models, including our Nrg1 mutant mice, do not entirely reflect human
psychopathologies, our studies are a fundamental step in identifying neuroimmune
mechanisms that may contribute to the translation of the genetic vulnerability conferred
by a Nrg1 mutation into immune system dysfunction and the psychopathological
disruption of brain signalling potentially relevant for schizophrenia.
6.1.1

The results reflect gene; immune; and gene x immune interactions

With the underlying premise that genetic vulnerability combined with an immune
stimulus will lead to disease development or worse disease outcomes, the results can
also be reconsidered as they relate to genotype; immune stimulus; and the genotype x
immune stimulation interaction. A general overview of all findings from the present
study is presented in (Table 6.1-1).
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Table 6.1-1 Overview of thesis findings
Group wise
comparison

Nrg1 no ic
vs
WT no ic
(A)

WT ic
vs
WT no ic
(B)

Plasma

Nrg1 ic
vs
Nrg1 no ic
(C)
↑IL-6

Nrg1 ic
vs
WT ic
(D)
↑IL-6

cytokines

↑G-CSF

↑G-CSF

↑IL-5
↑KC
↓IL-6 (p)

Prefrontal

↑IL-6Rα (p+m)

cortex

↑ErbB2 (m)
↑Akt1 (m)
↑Pten(m)
↑SOCS3 (m)
↓sgp130 (p)

Hippocampus

↓sgp130 (p)

↑G-CSF (p)

↓G-CSF(p)

↓pAkt (p)
↓Jak1 (m)
Proposed
influence

Genotype

Immune

Genotype x

Genotype x

stimulation

immune

immune

ic = immune challenged, no ic = without immune challenge, p = protein measurement,
m = mRNA expression level measurement. Only changes with significant p values from
t-test analysis shown.

Changes shown in the unchallenged Nrg1 Het mice, when compared with unchallenged
WT mice could be considered to result from the genetic mutation. From this
perspective, with Akt1 and SOCS3 mRNA higher in the PFC, yet lower pAkt levels in
the hippocampus, the PI3K/Akt signalling pathway is implicated as a potential aberrant
pathway effecting later changes revealed in conjunction with the immune stimulus
(Table 6.1-1: A). Since all three molecules are related to the PI3K/Akt signalling
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pathway, it may be considered that these brain regions could be primed to respond
differently to any stimulus that will influence the activity of this pathway in the
presence of this Nrg1 mutation.
When WT mice are stimulated with the melanoma challenge, the immune response
demonstrated compared to un-stimulated WT can be taken to represent a normal
immune response under these experimental conditions (Table 6.1-1: B). The increase in
IL-5 and KC in the plasma confirms an effective peripheral immune response to the
B16F0 melanoma challenge. The reduction in sgp130 and the increase in G-CSF in the
hippocampus validate that the peripheral immune stimulus is able to alter cytokines in
the brain without the influence of a genetic mutation.
Further evidence was provided to suggest that genotype plays a significant role in the
immune response to a peripheral immune challenge in both the periphery and the brain.
If it is assumed from the baseline results that the Nrg1 Het mutation has primed the
PI3K/Akt pathway for an altered response, the decrease in IL-6 in the PFC and the
decrease in sgp130 in the hippocampus could both potentially result from, or contribute
to, aberrant signalling (Table 6.1-1: C). Interestingly the sgp130 receptor was reduced in
both WT and Nrg1 Het mice subject to an immune stimulus when compared to
unchallenged WT and Nrg1 Het mice respectively. In this case the lower levels seen in
the Nrg1 Het mice may be consistent with a normal immune response, or may represent
a similar alteration but occur as a result of a completely different mechanism. The
PI3K/Akt pathway also has the potential to influence both IL-6 and G-CSF production
in the periphery, however as no pathway molecules were measured in peripheral cells
any interaction is purely speculation. The differences between immune challenged and
the unchallenged Nrg1 Het mice therefore represent an irregular immune response in the
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context of the gene mutation, providing strong evidence for the pathological potential of
a gene x immune interaction in this model.
The final comparison considered was between the immune challenged Nrg1 Het and
immune challenged WT mice where the differences point to potentially divergent
outcomes of the genotype x immune challenge. The brain outcomes vary noticeably
between the expected response to an immune stimulus shown in the WT mice and the
immune response in the Nrg1 Het mice subject to the immune challenge (Table 6.1-1:
D). In particular, additional support can be found for aberrant PI3K/Akt signalling with
higher mRNA expression levels of the PI3K/Akt inhibitory molecule, Pten in the PFC.
The hippocampus on the other hand, provides the first evidence for involvement of a
potential second signalling pathway with reduced levels of Jak1 mRNA expression. It is
possible, that the reduced level of Jak1 expression is a direct consequence of the lower
levels of G-CSF in the hippocampus. Alternatively, as G-CSF preferentially utilises the
PI3K/Akt pathway in the brain and Jak1 can directly interact with PI3K/Akt, the
possibility remains that lower expression of Jak1 is related to the PI3K/Akt pathway
alterations thought to exist in this model. Altogether, these data confirm a critical
pathological potential of a Nrg1 mutation to prime the peripheral immune and the
neuroimmune system for changes relevant to the development of schizophrenia.
6.1.2

Potential interactions with neurotransmitters: Relevance of changes in
CNS cytokine levels in response to a peripheral immune stimulus to the
study of schizophrenia

Although alterations in IL-6 and G-CSF in the PFC and the hippocampus of Nrg1 Het
mice with an immune stimulus may not appear directly linked to schizophrenia, there
are several lines of evidence to show that these changes could have impacts on
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neurotransmission, relevant to the disease. Not only Nrg1, but also IL-6 and G-CSF
have been shown to influence schizophrenia-relevant neurotransmitter systems,
including dopamine, glutamate, GABA and serotonin.
IL-6 is a critical neuronal survival factor during development and adulthood, however
IL-6 and schizophrenia relevant neurotransmission interactions are also demonstrated
(Bauer et al., 2007; Dunn, 2006; McAfoose and Baune, 2009). In particular, low IL-6
concentration in dopaminergic neuronal cell cultures had protective effects while
increasing doses of IL-6 resulted in neurotoxicity (Li et al., 2009c) The effect of IL-6 on
glutamatergic neurons appears to demonstrate a ‘U’ shaped curve in vitro; with both
high and low doses proving neurotoxic while a moderate level of IL-6 had
neuroprotective effects (Wang et al., 2009b) Further, age related loss of GABAergic
interneurons can be prevented by targeted deletion of IL-6 while an overexpression of
IL-6 in mice resulted in degeneration of these interneurons (Dugan et al., 2009;
Samland et al., 2003). These existing findings, together with the increased levels of
plasma IL-6 yet reduced levels of IL-6 protein found in the PFC of Nrg1 mice show it is
possible dopamingergic, glutamatergic and GABAergic neurons are affected by a
peripheral immune stimulus. Any potential effects may be dependent on age, type of
immune stimulus (innate, adaptive, humoral or cellular, peripheral or central, acute or
chronic) and the intensity of response; however the likelihood of an interaction is high.
G-CSF has been extensively studied for the neuroprotective functions (Li et al., 2009d;
Schneider et al., 2005a, 2005b). G-CSF knockout mice, show reduced NMDA-R
density in the dendritic layers of the hippocampus (CA3 and dentate gyrus) with
enhanced GABAa receptor binding density in the same areas of the hippocampus and
the dentate gyrus (Diederich et al., 2009a). This would suggest a potential reduction in
Peta Snikeris

156

excitatory signalling in these areas of the hippocampus, consistent with the
glutamatergic hypofunction hypothesis of schizophrenia (Olney and Farber, 1995). The
higher levels of G-CSF found in the hippocampus of WT mice subject to the immune
stimulus are therefore potentially representative of a functional protective mechanism in
line with previous literature. On the other hand, the reduced level of G-CSF found in the
hippocampus of Nrg1 Het mice with the immune stimulus might reflect a lack of
neuroprotection, resulting in reduced excitatory neurotransmission as shown in the GCSF knockout mice, consistent with the glutamatergic hypothesis of schizophrenia.
6.1.3

Method overview, limitations and experimental recommendations

To test our hypothesis, male Nrg1 Het mice were challenged with a 9 day stimulus from
B16F0 melanoma cells injected in the flank. The first consideration was the peripheral
immune response, measuring circulating immune cells and cytokine levels following the
immune stimulus using flow cytometry techniques. Tumour growth in the periphery
was monitored and the tumour excised for measurement of size. In addition, markers of
angiogenesis and of innate immune cell infiltration were investigated using fluorescence
microscopy and real time reverse transcription quantitative PCR (RT-qPCR).
Central levels of those cytokines altered in the periphery were considered next, with the
investigation conducted in the PFC and the hippocampus and extended to include the
cytokine receptors. Western blotting, RT-qPCR and flow cytometry methods were used
for these studies. The central response was studied in the PFC and the hippocampus,
two brain regions considered relevant in schizophrenia. Finally we conducted a
preliminary exploration of potential common signalling pathway molecules using RTqPCR and flow cytometry methods.
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These exploratory studies were conducted with male Nrg1 Het mice only as sex is
known to influence schizophrenia susceptibility in the general population and in relation
to genetic risk (Goldstein et al., 2013; van der Werf et al., 2014; Zhang et al., 2012).
Sex has also been shown to influence schizophrenia-like traits in the Nrg1 Het mouse
model used (Chesworth et al., 2012). Thus additional studies in female mice would
provide further insight into the sex differences in this mouse model and inform future
human patient studies on the need for adequate male and female subject numbers to
ensure accurate interpretation of results.
Measurement of cytokines used a multiplex Luminex assay for 32 cytokines combined
may have resulted in a loss of sensitivity for some of the included cytokines. In
schizophrenia patients changes in cytokines such as TNFα and IL-2 were shown
previously (Borovcanin et al., 2012; Miller et al., 2011). While the Luminex assay had
these cytokines included, they were below the limit of detection in the assay used.
Although it has been shown that such multiplex kits show good correlation with other
measurement methods such as ELISA, it is possible for the quantitative results to differ
between methods where different capture and reporting beads are used (Elshal and
McCoy, 2006). Therefore, validation of all findings using individual ELISA kits should
be performed, and these or individual Luminex assays may yield more unequivocal
results for additional cytokines. While these validation studies could not be performed
in the course of present studies owing to technical difficulties resulting in an inability to
obtain further tissue, they represent a productive avenue for follow-up studies. Due to
the exploratory nature of this project, statistical results were chosen to be reported
without correction for multiple testing, which represents a potential limitation in the
analysis and interpretation of results.
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Tumour growth was monitored before excision and measurement of size, angiogenesis
markers and innate immune cell infiltration. As the tumour and tumour
microenvironment were not the focus of these studies, only limited measurements were
taken and no differences found. This does not rule out the possibility of changes in the
tumour microenvironment and more detailed studies may elucidate differences. For
example, utilising a slower growing tumour, or injecting a smaller number of tumour
cells would allow monitoring over a longer period and may reveal differences in growth
rate. Additionally, a cross breeding program of Nrg1 Het mice with mice that
spontaneously develop tumours may provide a more realistic setting to determine
genetic influences on tumour growth and immune response.
Cytokines found altered in the periphery were then investigated in the PFC and the
hippocampus, with obligate cytokine receptors included in these studies. As discussed
in chapter 3 and relevant to all subsequent chapters, the small physical size of the PFC
in mice and the limitations this presented in the amount of tissue available resulted in
the pooling of PFC samples. Although initially representing 8 animals, the result of
pooling is statistical analysis on only 3-4 samples. For technical reasons, no more
animals could be added to this analysis. In this case the results are therefore rather
descriptive, hence the analysis and interpretation of the resulting data must be
considered with care. Future studies to account for tissue limitation could increase the
sample number and pooling samples to analyse multiple protein and mRNA analytes.
Alternatively, focussing future studies on single analytes such as IL-6 alone could better
utilise the limited tissue obtained. Repeat studies should be conducted to confirm the
data presented herein on the PFC.
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Similarly, the findings in the hippocampus for these studies may mask additional
alterations since hippocampal dissections were randomly allocated to experimental
protocols. Brain lateralisation variances have been demonstrated in the hippocampus
and future studies could dissect the hippocampi specifically into left and right as well as
dorsal and ventral segments to overcome this limitation. Additionally, histological
examination of the hippocampal sub regions could be performed to reveal details
concealed by the random assignment of hippocampal dissections.
In addition, the limitation presented by tissue availability in the PFC and in the brain
overall resulted in the requirement to change from luminex assays, which need a large
input of total protein for analyte analysis and work best with liquid rather than solid
tissue, to western blotting which uses far less total protein input to obtain valid results
for the number of follow-up analytes investigated. Repeat studies, focussing on a
limited number of analytes and using either ELISA or western blot for both the
peripheral and the brain measurements will need to be performed. Additionally,
increased sample numbers in follow up studies may also give explicit insights into
potential correlations between the peripheral and central analytes and their changes due
to immune stimulation.
The final signalling molecule study presented mRNA expression comparison data. The
use of a commercially available mRNA expression assay designed for high analyte
throughput with low sample numbers in this exploratory study means that all mRNA
expression findings should be confirmed with higher sample numbers, repeat
experiments, and those in conjunction with protein and functional phosphorylation
analysis, which were, however, beyond the scope of this study.
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As noted above, animal models, including our Nrg1 mutant mice, only partially reflect
human schizophrenia symptomatology or pathogenesis, and there are limitations
affecting the validity and full interpretation of some results. However, the present
studies were a fundamental step in identifying neuroimmune interactions that may
contribute to the translation of a genetic vulnerability conferred by Nrg1 into immune
system dysfunction and psychopathological disruptions in brain signalling, particularly
with a focus on the IL-6 system.
6.1.4

Future directions: Investigations of the interaction of peripheral
immune stimuli; the central cytokine alterations; and, schizophrenia
relevant neurotransmission

Nrg1 is a candidate gene for schizophrenia development. The present study has shown
that a Nrg1 mutation also represents a vulnerability factor for an individual’s
neuroimmune system, allowing an altered response to an immune stimulus. The altered
CNS immune response in Nrg1 Het mice is further hypothesised to facilitate disruption
of already aberrant neurotransmitter systems, which could impact on onset, symptom
progression or severity in schizophrenia. It is therefore important to continue providing
new evidence of the role for genetic vulnerability and immune system interactions in
schizophrenia pathology.
In order to further the present findings, Nrg1 Het mice could be subjected to a range of
peripheral immune stimuli, including a repeat of this melanoma stimulus at different
intensity and time frames, and acute or long term challenges with LPS and the viral
mimic polyinosinic-polycytidylic acid (PolyIC). In addition, direct injection of IL-6, GCSF or a combination of both could be employed in both Nrg1 Het and WT mice to
look for similar responses in the brain. Following any of the stimuli above, IL-6, G-CSF
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and the PI3K/Akt pathway analytes could be further examined for mRNA expression
changes, protein level alterations, and functional impairments.
Additional to the cytokine, mRNA and protein measurements performed in this study,
neurotransmitter receptor density assays for dopamine, glutamate and GABA could be
performed. Microdialysis techniques could be employed to measure real time
neurotransmitter and cytokine release in freely moving mice to determine the direct
effects of a peripheral immune challenge in vivo both in the periphery and the brain. The
schizophrenia relevance of these could be confirmed with the administration of antipsychotic drugs to see if the alterations are ameliorated. At the same time,
schizophrenia-relevant behavioural and cognitive testing will be required, including
open field testing for hyper locomotion; and pre-pulse inhibition, to shed light on the
pathophysiological impact of the respective immune stimulation. Such future studies
can confirm the validity of this gene x immune model and elucidate the detail of the
links between alterations of cytokine levels, neurotransmitter signalling, and reflections
in pathological behaviour.
6.1.5

Final conclusion

The results of the present study show a clear interaction between a genetic mutation and
an immune stimulus relevant to schizophrenia, with a particular focus on IL-6 and GCSF. The results demonstrated in our Nrg1 Het mice are similar to findings in human
studies for peripheral cytokine changes in schizophrenia patients, and in particular are
consistent with findings in humans carrying a similar Nrg1 genetic mutation. We could
therefore establish the Nrg1 Het mice as a valuable model to study gene x immune
interactions as potentially relevant to psychopathology. Future studies based on these
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current findings will provide further insight into the role of peripheral and central
cytokine changes in schizophrenia development, progression and treatment.
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APPENDIX A

GeNorm qBase plus software generated results for selection of reference genes to use in
brain tissue based RT-qPCR (high resolution figures are unavailable from this
software).
A1) geNorm qBase plus software generated graph (geNorm M): Average stability of
remaining reference targets
This graph demonstrates the increasing expression stability of each tested reference
gene ranked from left to right across the graph. The genes on the far right-hand side of
the graph are the most stably expressed: i.e. Ap3d1 followed by Fbxw2
A2) geNorm qBase plus software generated graph (geNorm V).
This graph is generated to depict the optimal number of reference genes to use in
subsequent experiments. The software uses a “pairwise variation, V(n/n+1)” calculation
to determine the optimal number of reference genes. An appropriate number of
reference genes is reached with V(n/n+1) is below 0.15.
In this experiment it can be seen that the two most stably expressed genes demonstrate a
V(n/n+1) less than 0.075 with limited gain from adding additional reference genes,
therefore two genes were used: Ap3d1 and Fbxw2
A3) the geNorm qBase plus software generated written report is included as a “screen
capture” to demonstrate the analysis of the noted graphs.

A1)

A2)

A3)

APPENDIX B

Figure representing western blot results for each protein measured, showing one
representative animal from each group in each of the brain regions as well as
competitive binding assay for G-CSF.
a) gp130 (Sections 3.2.5c, 3.3.4 and Figure 3.3-4
b) G-CSFR (Sections 4.2.5c, 4.3.2 and Figure 4.3-2
c) IL-6Rα (Sections 3.2.5c, 3.3.2 and Figure 3.3-3)
d) G-CSF (Sections 4.2.5c, 4.3.1 and Figure 4.3-1
e) IL-6 (Sections 3.2.5c, 3.3.1 and Figure 3.3-2)

Prefrontal Cortex
1

2

3

4

Hippocampus
1
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3

4

gp130

~130kDa

G-CSFR

~110kDa

IL-6Rα

~73kDa

G-CSF

~50kDa

IL-6 Dimer

~46kDa

IL-6

~29kDa

Actin

~44kDa

1 = WT unchallenged, 2 = Nrg1 unchallenged, 3 = WT immune challenged, 4 = Nrg1
immune challenged

Results of competition binging assay to determine G-CSF in western blot (4.2.5c)
Size
(kDa)
B
A
150
100
75
50
37

25
20
15

(A) is G-CSF (K-15): sc-49679 (Santa Cruz) at 1:250 o/n at 4 degrees with BSA block
(1 hour) and (B) is is G-CSF (K-15): sc-49679 pre-incubated for 1 hour before use with
the G-CSF blocking peptide: sc-49679 P (Santa Cruz), 5x more concentrated than
antibody.

